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GENERAL ABSTRACT 
Inflammatory bowel disease (IBD) is an idiopathic group of chronic disorders characterised 
by inflammation of the small intestine and colon. In Australia, more than 85,000 people 
live with IBD and by the year 2022 it is expected that this number will have surpassed 
100,000. The two major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). 
Both diseases are characterised by a series of relapses and remissions where the 
inflammation in the gastrointestinal tract becomes so severe that patients need 
hospitalisation or even surgery.  
A major complication of chronic inflammation (colitis), either by recurrent CD or UC is 
the development of colitis-associated colorectal cancer (CAC). Crohn and Rosenberg first 
reported the ulcerative colitis case associated with colorectal cancer development in 1925, 
thereafter many studies have been published linking gut inflammation as an important 
predisposing factor for the development of colorectal cancer. However, the understanding 
of specific underlying mechanism of how chronic inflammation is connected to the 
initiation and progression of colon cancer is yet to be established.  
Although the exact aetiology of IBD has yet to be elucidated, a defective innate immune 
system has been proposed as a primary mechanism in colitis. As an important arm of the 
innate immune system inflammasomes particularly the well characterised NLRP3, is 
involved in gut homeostasis and inflammatory pathologies. However, the role of NLRP3 
in these processes is not well understood.  
Investigations on the role of NLRP3 in colitis is still controversial and inconclusive with 
some studies showing a protective role while other studies demonstrate a detrimental effect 
of NLRP3 activation. The reason for the discrepancies observed in the Nlrp3-/- chemically 
induced colitis mouse model phenotype could be due to differences in length and 
concentration of chemical treatment or baseline differences in the composition of the 
intestinal microbiota in experimental mice. Thus, the overall aim of the PhD project was to 
address the above issues and define the role of NLRP3 in the development of colitis.  
This doctoral research thesis consists of seven chapters. Chapter 1 is an overall introduction 
to the rationale of the research, hypothesis and aims of the research project. Chapter 2 is a 
review article that critique the literature and summarises the role of NLRP3 in intestinal 
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inflammation and CAC. Chapter 2a is a detailed description of the Winnie mouse model 
and methodology of generation and genetic confirmation of the novel mouse model Winnie 
x Nlrp3-/-. 
Chapter 3 is a review article on background of current experimental NLRP3 inhibitors that 
have been investigated in IBD experimental models and the potential mechanism of action 
of these inhibitors. Chapter 4 is a research article that describes the experiments and data 
generated that detail the effect of MCC950, a specific small molecule inhibitor of NLRP3 
inflammasome on colonic inflammation in spontaneous colitis Winnie mice. 
Chapter 5 details research experiments and data generated that characterise clinical 
parameters, histopathology, biochemical and cytokine profile of the novel mouse model 
Winnie x Nlrp3-/- mouse model. In chapter 6, I further explored the molecular mechanisms 
that lead to CAC by investigating the hyperactive molecular pathways by means of 
analysing the protein and gene expression, metabolomics and microbiota changes in the 
CAC mouse model Winnie x Nlrp3-/-. Finally, chapter 7 is a comprehensive discussion of 
all the results obtained from the research objectives and includes potential directions for 
future work arising from this research thesis. 
Current treatment regimen for IBD utilise anti-inflammatory drugs, immune system 
suppressors and antibiotics or a combination of these. However, these therapeutics lead to 
several adverse effects, remission or significant non-responsiveness leading to colectomy 
which is an emergency surgery with a high rate of morbidity. Thus, there is an urgent need 
to develop potent drugs with novel mechanisms of action. Given the evidence that aberrant 
NLRP3 activation is involved in the progression of IBD, targeting the activation pathway 
is a promising strategy for the development of novel effective therapeutics for IBD. 
Therefore, I reviewed past literature and discussed all the experimental NLRP3 inhibitors 
that has been investigated in IBD experimental animal models. The most salient finding of 
the review article was that all experiments were conducted in chemically induced colitis 
models with inhibitors that were nonspecific to the NLRP3 inflammasome and therefore 
was unable to specifically define its role towards IBD.  
Therefore, I investigated the therapeutic effect of a NLRP3 inhibitor, MCC950 in a 
spontaneous chronic colitis mouse model Winnie. Extensive studies in Winnie have proven 
it to be an appropriate murine model to study IBD and its pathogenesis. MCC950 is a 
potent, highly specific small molecule inhibitor of both canonical and noncanonical 
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activation of NLRP3 inflammasome and has been evaluated in a multitude of NLRP3 
driven inflammatory diseases. However, the effect of MCC950 on colitis has not yet been 
reported. To my knowledge this is the first time a specific NLRP3 inhibitor has been 
applied to colitis and I was able to determine the contribution of anti-inflammatory effects 
resulting exclusively from inhibition of canonical and non-canonical NLRP3 
inflammasome activation in colitis. Mice were orally administered with 40 mg/kg of 
MCC950 for three weeks at chronic stage of colitis. The treatment significantly ameliorated 
colitis with improved body weight gain, colon length, ratio of colon weight to body weight, 
and disease activity index. Histopathological scores of MCC950 treated Winnie mice were 
significantly reduced suggesting not only attenuation of ongoing colitis but also delay of 
disease onset. MCC950 significantly suppressed IL-1β and IL-18 cytokine expression at 
both mRNA and protein levels in Winnie colons. Additionally, MCC950 also effectively 
suppressed the release of proinflammatory cytokines (IL1-α, IL17, TNF-α and IFN-γ) and 
chemokine (MIP1a) in mucosal explants. Moreover, MCC950 treatment resulted in a 
significant decrease of IL-1β release and activation of caspase-1 in Winnie explants and in 
vitro macrophage cells isolated from these mice. Taken together, the results illustrate the 
efficacy of MCC950 in the treatment of murine ulcerative colitis and provides a potential 
avenue for a novel therapeutic agent for human inflammatory bowel diseases.  
With the successful discovery of the therapeutic potential of the specific NLRP3 inhibitor 
MCC950, I hypothesised that the absence of NLRP3 inflammasome in the spontaneous 
colitis mouse model Winnie would ameliorate colitis. To conduct this work, I generated a 
novel mouse model by knocking out the Nlrp3 gene in Winnie, with a defined microbiota, 
to elucidate the functional role of NLRP3 inflammasome in colitis. 
Interestingly, detailed phenotypical analysis of Winnie x Nlrp3-/- colon at 12 and 16 weeks 
showed spontaneous multiple colonic tumours. Winnie x Nlrp3-/- mice had significantly 
shorter colons, and a higher ratio of colon weight to length and colon weight to body weight 
compared to control groups indicating the severity of colitis and tumorigenesis. 
Histopathology of Winnie x Nlrp3-/- colon revealed severe crypt distortion and goblet cell 
depletion with high-grade dysplasia and invasive carcinoma regions. Analyses of colonic 
tissue homogenates by biochemical assays showed increased activity of myeloperoxidase, 
Nitric Oxide and serum C-reactive protein consistent with human CAC. RNA was extracted 
from colonic tissue segments converted to cDNA and analysed for proinflammatory and 
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cancer biomarker gene expression using PCR microarray. Upregulated biomarkers Bcl2, 
Sod2, Pparγ, Myc, Birc5 and Cdk2 were confirmed by individual qPCR.  Colonic organ 
cultures were performed, and the supernatants were assayed via Bio-Plex and results 
identified differential expression of proinflammatory cytokines, chemokines and cancer 
biomarkers. Detailed immunohistochemistry revealed high-grade dysplasia and 
adenocarcinoma regions with increased expression of DNA damage biomarkers anti-
Oxoguanine 8, anti-gamma H2A.x and oxidative stress biomarkers anti-NQ01, anti3-
Nitrotyrosine. Immunofluorescence for Ki-67, VEGF and Survivin biomarkers showed an 
increased expression indicating cell proliferation, angiogenesis, and anti-apoptotic activity 
respectively, validating Winnie x Nlrp3-/- as a CAC model. Protein analysis of colonic 
tumours and Western blot results showed upregulation of Wnt/β-catenin and PI3K/ AKT 
pathways as the potential molecular mechanism of CAC. Faecal microbiota analysis 
revealed significant increase in colitogenic members such as Akkermensia muciniphila in 
the phylogenetic architecture in Winnie x Nlrp3-/- mice while metabolomics profiling 
revealed upregulation of key metabolites and significant decrease of beneficial short chain 
fatty acids. These results provided confirmation that NLRP3 is a negative regulator of 
tumorigenesis during CAC. 
In summary, the study has generated new data and knowledge that defines the NLRP3 
inflammasome as a double-edged sword in colitis and CAC. Specific chemical inhibition 
of an over active NLRP3 inflammasome in chronic colitis attenuated severity of the disease 
whereas genetic ablation of NLRP3 gene in the same colitis model lead to CAC. This 
highlights the critical function of NLRP3 inflammasome as an innate immunity guardian 
in the maintenance of gut homeostasis. Finally, the results stress the importance of 
evaluating the pharmacokinetics and long-term effect of novel NLRP3 inhibitors designed 
for chronic inflammatory diseases in clinically relevant experimental models before 
progressing to human clinical trials. 
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1.1 NLRP3 inflammasome in Intestinal Inflammatory Diseases  
Inflammatory bowel disease (IBD) is a group of life long gastrointestinal 
disorders characterised by inflammation of the small intestine and colon. IBD is a global 
disease, with over 1 million patients in the USA and 2.5 million in Europe (Kaplan, 2015). 
IBD is an emerging disease in newly industrialized countries in Asia, South America and 
Middle East with rising incidence in every continent, with Australia having one of the 
highest prevalence with more than 85,000 IBD patients and by the year 2022 it is expected 
that this number will have surpassed 100,000  (Wilson et al., 2010, Loftus, 2004).  In 2013, 
the annual economic and financial cost associated with managing IBD in Australia was 
estimated at 3.1 billion (Australia, 2013).  
The two major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). Both 
diseases are characterised by a series of relapses and remissions. CD is a transmural, 
granulomatous condition commonly involving the ileum and the colon. In contrast, UC 
specifically involves the colon and rectum of the intestine and manifests as superficial 
inflammation confined to the mucosal and submucosal layers of the intestinal wall 
(Blumberg and Strober, 2001, Monteleone and Neurath, 2012 ). Overlapping symptoms of 
CD and UC are chronic relapsing flares associated with rectal bleeding, abdominal pain 
and diarrhoea (Monteleone and Neurath, 2012 , Strober, 2013).  
A major complication of chronic inflammation, either by recurrent CD or UC is the 
development of colitis-associated colorectal cancer (CAC) (Triantafillidis et al., 2009, 
Parian and Lazarev, 2015). Crohn and Rosenberg first reported the ulcerative colitis case 
associated with colorectal cancer development in 1925 (Crohn and Rosenberg, 1925b), 
thereafter studies have shown gut inflammation as an important predisposing factor for the 
development of colorectal cancer (Karin and Greten, 2005, Dupaul-Chicoine et al., 2010). 
The cumulative risk of ulcerative colitis associated cancer is estimated to be at 1.6 % at 10 
years, 8.3 % at 20 years and 18.4 % at 30 years (Eaden et al., 2001). However, the precise 
mechanism by which chronic colitis develop in to colorectal cancer is yet to be established.  
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Although the exact aetiology of colitis has yet to be elucidated, recent studies identify a 
defective innate immunity as the primary mechanism in chronic mucosal inflammation in 
IBD (Xavier and Podolsky, 2007, Xu et al., 2014, Marks and Segal, 2008). The innate 
immune response to cell stress or infection depends on the activation of  receptors called 
pattern recognition receptors (PRRs) (Halle et al., 2008). The two main types of receptors 
are, Toll-like receptors (TLRs) and Nod-like receptors (NLRs) (Schroder and Tschopp, 
2010, Martinon et al., 2009). Activation of these receptors initiate an immune response 
which involves activation of the inflammasome complex and a cascade of pro-
inflammatory cytokines and an adaptive immune response (Ranson and Eri, 2013).  
Among the NLR activated inflammasomes, NLRP3 is the best characterized and is closely 
associated with inflammatory diseases (Duewell et al., 2010, Rajamaki et al., 2010). The 
NLRP3 inflammasome is a multimolecular platform constituting of NLRP3 protein 
encoded by the NLRP3 gene and an adaptor protein ASC (known as the apoptosis-
associated speck-like protein containing a CARD) and procaspase-1. Activation of the 
NLRP3 inflammasome leads to activation of  caspase-1 and the consequent cleavage and 
secretion of IL-1β and IL-18 (Martinon et al., 2002) proinflammatory cytokines (Figure 
1.1).  
These proinflammatory cytokines are associated with increased colitis (Villani et al., 2009, 
Schoultz et al., 2009) and colorectal cancer (Allen et al., 2010) development. Genetic 
association studies show that polymorphisms in the IL-1β gene cluster significantly 
increases the risk of developing a variety of cancers, including gastric cancer (Barber et al., 
2000, El-Omar et al., 2001). IL-1β levels are significantly altered in patients suffering from 
either acute or chronic gastrointestinal inflammation and have been implicated in tumour 
angiogenesis, progression, and metastasis (Bioque et al., 1995, Casini-Raggi et al., 1995). 
Studies on IL-18 polymorphisms have confirmed its association with the increased 
susceptibility to CD (Tamura et al., 2002). In addition, in sites of active intestinal 
inflammation in CD, IL-18 (Monteleone et al., 1999) and IL-1β (Papadakis and Targan, 
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Figure 1.1: Schematic illustration of the Canonical activation pathway of NLRP3 inflammasome. 
Many studies have assessed the role of NLRP3 inflammasome on intestinal inflammation 
in Dextran Sodium Sulphate (DSS) colitis mouse models deficient in NLRP3. Some studies 
indicate that Nlrp3-/- mice exhibited severe inflammation following oral DSS treatment 
(Zaki et al., 2010a, Dupaul-Chicoine et al., 2010, Allen et al., 2010, Hirota et al., 2011). 
Controversially, competing studies have reported that the loss of NLRP3 was protective in 
the DSS mouse model of colitis (Bauer et al., 2010, Elinav et al., 2011). Therefore, there is 
a crucial need to resolve the role of NLRP3 in colitis.  
The contrasting data published regarding the role of NLRP3 in the above experimental 
models could be due to the different chemical methods used in colitis induction and 
alteration in the gut microbiota between different animal facilities. Thus, in the current 
work, I characterize and explore the role of NLRP3 mediation in a spontaneous colitis 
mouse model with a defined microbiota.   
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Studies in Winnie investigating IBD pathogenic mechanisms have proven that Winnie 
spontaneous colitis closely resemble human ulcerative colitis, making these mice a valuable 
tool in IBD research and treatment. Thus, we used this model to investigate the therapeutic 
potential of MCC950, a specific NLRP3 inhibitor in ameliorating colitis.  
The Winnie mouse model is remarkable in that colitis results from an intestinal epithelial 
defect whilst the underlying immune system is normal and does not display major 
disturbances to immunity as seen in many other mouse models of IBD. Therefore, it will 
be easier to interpret pathological changes specifically resulting from genetic deletion of 
Nlrp3 and hence was chosen to be used in developing the Winnie x Nlrp3-/- model for the 
research study. 
The project will give a comprehensive understanding of the role of NLRP3 inflammasome 
in colonic inflammation in IBD. This has potential implication not only in IBD 
pathogenesis and treatment but also in the understanding the role of NLRP3 inflammasome 
in colitis associated colorectal cancer.  
1.3 Hypothesis 
Inactivation of the NLRP3 inflammasome will ameliorate colitis in the spontaneous colitis 
mouse model. 
1.4 Aims  
Aim 1: To investigate the potency and mechanism of specific small molecule NLRP3 
inflammasome inhibitor, MCC950 in ameliorating colonic inflammation in 
spontaneous colitis mouse model. 
The exact cause of IBD is not known and there is no golden treatment for IBD. Current 
experimental NLRP3 inhibitors have shown to decrease symptoms of colitis in mouse 
models however they are not exclusive inhibitor of NLRP3 inflammasome. A recently 
developed small molecule is proving to be an exclusive and highly potent NLRP3 inhibitor 
and has shown success in attenuating the severity of an inflammatory disease model of 
multiple sclerosis (Coll et al., 2015).  However, the mechanism of the inhibitory pathway 
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is yet to be elucidated. In this aim, I investigate for the first time the potency and specific 
NLRP3 inhibitory action of MCC950 to ameliorate colitis and investigate the mechanistic 
pathway. 
Aim 2: To assess the role of NLRP3 inflammasome in colitis by analysing clinical, 
histopathological, molecular and immunological parameters of Winnie x Nlrp3-/- 
colon. 
This aim was designed to address the controversial role of NLRP3 in experimental colitis 
by investigating the phenotype of a novel murine model deficient in NLRP3 in the 
spontaneous colitis mouse model Winnie. To my knowledge this is the first study of 
genetic ablation of Nlrp3 in a spontaneous colitis mouse model resembling human UC and 
warrants extensive investigation.  
Aim 3: To investigate the influence of NLRP3 inflammasome on gut microbiome and 
metabolomics and its interrelatedness to colitis associated colorectal cancer in mouse 
model. 
An imbalance or dysbiosis in the microbiome is associated with spontaneous colitis and 
increased susceptibility to CAC. Mouse studies deficient in immune genes have provided 
evidence that specific immune regulatory proteins associated with CAC influence the gut 
microbiome in a manner consistent with disease penetrance. 
The role NLRP3 plays in dysbiosis during colitis and CAC has been examined in Nlrp3-/-
mice with contradictory results. The reason for discrepant results is not clear but could be 
due to differences in the composition of the intestinal microbiome. Here, we used the CAC 
mouse model generated in Aim 2 to analyse the microbiota and metabolites and define the 
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NLRP3 inflammasome in colitis and colitis-associated colorectal cancer 
2.1 Abstract 
A low level of inflammation is an integral part of the balance between the immune system 
and the microbiota in the high antigen environment of the gastrointestinal tract and 
maintains homeostasis. A failure of this balance can lead to chronic intestinal inflammation 
and increase the chances to develop colorectal cancer significantly. The underlying 
mechanisms that link inflammation and carcinogenesis are not clear but the molecular 
platforms of the inflammasomes have been implicated. Inflammasomes are molecule 
complexes that are assembled in response to microbial components or cellular danger 
signals and facilitate the production of bioactive pro-inflammatory cytokines. One 
inflammasome, NLRP3, has been analysed extensively in its contribution to colitis and has 
been shown to be associated with the development of colitis associated colorectal cancer. 
This review will summarise the role of NLRP3 in intestinal inflammation, discuss some of 
the triggers of inflammation in the gastrointestinal tract such as diet and introduce some 
opportunities to use this inflammasome as therapeutic target for the treatment of colitis and 
colitis-associated colorectal cancer. 
2.2 Introduction  
Colorectal cancer (CRC) is the third most common malignancy worldwide (Ferlay et al., 
2015) and presents with a high mortality rate (Siegel et al., 2016) due to rapid cancer 
progression with late diagnosis at an advanced tumour stage (Siegel et al., 2014). An 
inflammation-associated form of CRC, colitis-associated CAC has been recognised as a 
complication of inflammatory bowel disease (IBD) (Parian and Lazarev, 2015, 
Triantafillidis et al., 2009). These chronic inflammatory, idiopathic disorders are 
characterised by significant inflammation of small intestine and colon and are becoming 
more prevalent and more severe due to global adoption of western diet, the increasing use 
of nonsteroidal anti-inflammatory medications and an ageing population (Taleban et al., 
2015). Furthermore, the increasing incidence and prevalence of IBD in children makes it 
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an important paediatric chronic disease (Nasiri et al., 2017) with an increased risk of 
developing CAC (Peneau et al., 2013).  
The two primary types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). CD 
commonly affects the small intestine or colon, however it can affect all parts of the 
gastrointestinal tract from the oesophagus to the anus involving all layers of the intestinal 
wall. Complications characteristic for CD are strictures, fistulae and fissures. UC is 
characterised with inflammation that is limited to the mucosa of the colon and presents with 
bleeding ulcers and that can result in the perforation of the colon (Cosnes et al., 2011, 
Mulder et al., 2014). 
2.3 Innate immunity, Inflammatory Bowel Disease and Cancer  
Crohn and Rosenberg first reported an ulcerative colitis case associated with colorectal 
cancer development in 1925 (Crohn and Rosenberg, 1925a). Subsequently, many studies 
have been published indicating gut inflammation as an important factor predisposing the 
development of colorectal cancer (Dupaul-Chicoine et al., 2010, Karin and Greten, 2005). 
The cumulative risk of UC-associated cancer is estimated to be at 1.6% at 10 years, 8.3% 
at 20 years and 18.4% at 30 years (Eaden et al., 2001) correlating CAC directly to the extent 
and duration of colitis. Nevertheless, the exact mechanism of how chronic inflammation is 
connected to the development of colitis-associated colorectal cancer (CAC) has yet to be 
established. 
Chronic inflammation in IBD progresses to CAC with constant overproduction of pro-
inflammatory cytokines such as IL-1β, IL-6, TNF-α (Becker et al., 2004, Popivanova et al., 
2008), chemokines and DNA damaging reactive oxygen and nitrogen species. These 
inflammatory effector molecules promote aberrant intestinal epithelial cell proliferation, 
survival and angiogenesis and lead to epithelial dysplasia and ultimately to a formation of 
invasive tumours (Grivennikov, 2013). Therefore, understanding and modulating the 
mechanisms of chronic mucosal inflammation will be the key to preventing the progression 
to CAC (Foersch and Neurath, 2014).  
Although the exact aetiology of chronic intestinal inflammation is not yet known, recent 
studies support the hypothesis of a defective innate immune response as the primary 
mechanism in chronic mucosal inflammation (Asquith and Powrie, 2010). The innate 
immune response controls the intestinal microbiota and provides initial resistance to 
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invading pathogens whilst maintaining homeostasis (Ignacio et al., 2016). Beyond 
anatomical barriers such as the skin and mucosa, various cellular components of the innate 
immune system such as epithelial cells, macrophages, dendritic cells (DC) and neutrophils 
are in the intestinal wall and intestinal lymphoid organs including Peyer’s Patches and 
mesenteric lymph nodes. These cell populations keep the microbial occupants of the 
intestines under surveillance with the help of extracellular and cytosolic pattern recognition 
receptors (PRRs).  
The PRRs comprise the pro-inflammatory membrane-bound Toll-like receptors (TLR) and 
the cytosolic sensory protein complexes consisting of NOD-like receptors (NLR), the RNA 
sensing retinoic acid-inducible gene-1 receptors (RLR) and the pyrin and HIN domain 
(PYHIN) receptor family which includes the AIM2-like receptor (ALR) and C-type lectins 
(Ranson et al., 2017). These receptors recognise pathogen-associated molecular patterns 
(PAMPs) or host derived danger-associated molecular patterns (DAMPs). Receptor 
engagement causes cellular activation of various effector mechanisms ranging from 
microbicidal molecules and phagocytosis to activation of large multiprotein complexes 
called inflammasomes. 
2.4 Biology of inflammasomes  
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Inflammasomes have emerged as a central feature in innate immunity (Martinon et al., 
2002) and are involved in pathogen clearance, maintain tissue homeostasis and stimulate 
an adaptive immune response that removes tumour cells. These large cytosolic protein 
complexes can be divided in the NLR, the PYHIN or the ALR family (Figure.2.1) and 
comprise inflammatory caspases which undergo autocatalytic activation and initiate 
inflammatory signalling cascades that activate protease caspase-1 and releases pro-
inflammatory cytokines IL-1β and IL-18 (Latz et al., 2013, Ranson and Eri, 2013). 
This sequence of activating events is culminating in the initiation of pyroptosis, a 
Gasdermin-D-mediated form of inflammatory programmed cell death (Man et al., 2017). 
The functionally most completely characterised family member of the NLR is the NOD-
like receptor family, pyrin domain containing protein 3 (NLRP3) (Table 2.1).  
Table 2.1: NLR subfamilies and their functions 
Family Subtypes Role in immunity References 
NOD 6 subtypes    
Defence against bacterial and viral infection. NLRC3 
is associated with Colitis, CAC and CRC. NLRC4 has 
been correlated with melanoma 
(Janowski et al., 2013, 
Karki et al., 2016, 
Kobayashi et al., 2005, 
Loving et al., 2009, 
Viala et al., 2004, Zhang 
et al., 2014b) 
IPAF 2 subtypes    
NAIP–NLRC4 together prevent against bacterial 
infection 
(Janowski et al., 2013, 
Zhao and Shao, 2015) 
NLRP 
14 
subtypes     
Associated with defence against various bacterial and 
viral infection. NLRP3, 6 and 12 have been associated 
with colitis and CAC. NLRP3 is associated with 
various manifestations of metabolic syndrome 
(Allen et al., 2010, 
Anand et al., 2012, 
Chavarria-Smith and 
Vance, 2015, Janowski 
et al., 2013, Vladimer et 
al., 2012) 
The association of inflammasomes with intestinal inflammation and CAC has been 
demonstrated with expression analysis of human colon cancer samples which shows lower 
expression levels for NLRP and AIM2 family members (Liu et al., 2015, Ranson and Eri, 
2013). Genetic ablation of these inflammasomes in the DSS/AOM CAC murine model 
suggested that they act to suppress intestinal inflammation associated tumorigenesis 
essentially through inhibiting cellular proliferation and driving cell death (Allen et al., 
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2010, Chen and Nunez, 2011, Karki et al., 2017, Normand et al., 2011, Wilson et al., 2015, 
Zaki et al., 2011c). Mice deficient in inflammasome components such as apoptosis 
associated speck-like protein containing a caspase activation and recruitment domain 
(ASC), caspase-1 and caspase-11, IL-18 or IL-18r, exhibit increased colitis and 
tumorigenesis compared to wild-type (WT) mice in the azoxymethane dextran sulphate 
sodium (AOM-DSS) model (Dupaul-Chicoine et al., 2010, Salcedo et al., 2010, Williams 
et al., 2015, Zaki et al., 2010b). These studies highlight the importance of inflammasome 
pathways in the modulation of colitis and the suppression of CAC. 
2.5 Mechanism of action: NLRP3 in the innate immune response 
Polymorphisms of the Nlrp3 gene are associated with poor survival in CAC patients and 
the specific role of NLRP3 in the processes leading to tumorigenesis is not well understood 
(Ungerbäck et al., 2012). Therefore, we will discuss the current literature on the specific 
contribution of NLRP3 to the modulation of the intestinal microbiota and intestinal 
pathologies of colitis and CAC.  
The NLRP3 inflammasome is a multiprotein platform comprising the NLRP3 protein, the 
adaptor protein ASC and pro-caspase-1. The NLRP3 protein itself contains a nucleotide-
binding and oligomerization domain (NBD or N ACHT), carboxy-terminal leucine-rich 
repeat (LRR) at the C-terminus and a PYD (Leemans et al., 2011). The inflammasome 
assembly is inhibited by the LRR domain. This activity is disabled by the activating signal 
either from PAMPS or DAMPS, whereas the NBD is required for homo or hetero-
oligomerization that leads to the activation of caspase-1 from the inactive zymogen pro-
caspase-1 and the subsequent auto-cleavage and secretion of the pro-inflammatory 
cytokines IL-1β and IL-18 (Martinon et al., 2002, Schroder and Tschopp, 2010). 
Triggers for activation of NLRP3 inflammasome include a diversified array of unrelated 
molecular structures (PAMPs) such as microbial cell wall components including 
lipopolysaccharide (LPS) and muramyl dipeptide (MDP), nucleic acids, pore-forming 
toxins, DAMPs, ATP and crystalline substances such as uric acid, oxidised mitochondrial 
DNA. As the NLRP3 inflammasome assembles in response to these molecules, it has been 
proposed that it responds to a common cellular distress signal, instead of a direct interaction 
with cognate ligands (Halle et al., 2008, Mariathasan et al., 2006, Martinon et al., 2006, 
Shimada et al., 2012) (Figure 2.2).  
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Three key mechanistic pathways have been suggested for triggering the activation of 
NLRP3 inflammasome. Firstly, pore formation and potassium efflux (Petrilli et al., 2007), 
secondly, lysosomal destabilisation (Okada et al., 2014) and thirdly, mitochondrial reactive 
oxygen species (mROS) generation (Gurung et al., 2015). Importantly, the presence of ROS 
has been implicated in the activation of the NLRP3 inflammasome and has been linked to 
cancer promotion (Fang et al., 2009). 
Canonical activation of NLRP3 occurs in two steps via both transcriptional and post-
transcriptional processes. The first signal (Signal 1) is provided predominantly in a PAMPs-
dependent manner. A frequently used model is the lipopolysaccharide (LPS)-induced 
activation of the TLR4/NF-κB pathway. This step is termed “priming” and causes a 
transcriptional up-regulation of the transcription of Nlrp3 mRNA and for pro-il-1β and -il-
18 (Latz et al., 2013) (Figure 2.2). 
 
 
Figure 2.2: Canonical and non-canonical activation of NLRP3.  
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In a second step, intracellular sensing of specific ligands (DAMPs) leads to the recruitment 
and oligomerization of the key adaptor protein, ASC, which, through its caspase activation 
and recruitment domain (CARD) facilitates the subsequent recruitment and activation of 
caspase-1. In a final activating step this protease catalyses the proteolytic cleavage of 
inactive pro-IL-1β or pro-IL-18 proteins into secreted bioactive cytokines which initiate a 
plethora of potent inflammatory responses. Furthermore, activation of caspase-11 induces 
Gasdermin-D-mediated pyroptosis, a form of cell death frequently observed during 
invasion by gram-negative and gram-positive pathogens (Figure 2.2).  
In addition to canonical inflammasomes comprising NLRP3, ASC and caspase-1, recent 
studies have identified an alternative non-canonical NLRP3 inflammasome which consists 
of caspase-11 (caspase-4 and caspase-5 in human) and not caspase-1. The non-canonical 
pathway is seen in infections with gram-negative bacteria, where caspase-11 binds directly 
to cytosolic LPS. This promotes inflammasome-independent pyroptosis and the assembly 
of the NLRP3 inflammasome and activation of caspase-1 to cleave pro-IL-1β and pro-IL-
18 into secreted bioactive cytokines (Kayagaki et al., 2011, Rathinam et al., 2012b) (Fig. 
2). 
IL-1β and IL-18 are important pro-inflammatory mediators of the mucosal inflammatory 
response. The presence of IL-1β can induce various cellular activities, including the 
proliferation, differentiation and apoptosis of both immune and non-immune cells (Huber 
et al., 2012, Vela et al., 2002). Additionally, IL-1β can co-stimulate IL-6 production which 
acts as a growth factor for B cell proliferation and initiate the release of other pro-
inflammatory cytokines such as TNF-α, IL-23 and IL-6 that can polarise the adaptive 
immune response to a Th2 or a Th17 response depending on the antigenic environment 
(Dinarello, 2009). 
The importance of IL-1β in the pathogenesis of colitis has been well established (Ning et 
al., 2015). In addition, numerous studies have revealed that secretion of IL-1β is elevated 
in the sera of patients with IBD (Sartor, 1994) and mice subjected to DSS-induced colitis 
(Bauer et al., 2010). Importantly inhibition of IL-1β has shown to alleviate DSS induced 
colitis (Siegmund et al., 2001b).  
Other studies have indicated that in contrast to IL-1β, IL-18 plays a major role in 
suppressing colitis and CAC. Polymorphisms of the il-18 gene have confirmed a strong 
association of this cytokine with an increased susceptibility to CD (Tamura et al., 2002). 
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This suggests that IL-18 signalling provides protection against a development of intestinal 
inflammation. Mice deficient for IL-18 and IL-18 receptor were hyper-susceptible to DSS-
induced colitis, which was associated with higher mortality rates and more severe 
histopathological changes (Takagi et al., 2003). In a similar study, Il-18-/- and Il-18r-/- mice 
also developed severe DSS-induced colitis with high lethality and more histopathological 
abnormalities and were more susceptible to AOM/DSS-induced colon tumorigenesis as 
compared to WT mice, suggesting an essential and protective role of IL-18 signalling in 
colorectal cancer (Salcedo et al., 2010). MyD88 KO mice, which are defective in both IL-
1β and IL-18 production and the downstream signalling of their respective receptors, 
showed increased colonic epithelial proliferation and colorectal tumorigenesis (Salcedo et 
al., 2010). 
The explanation proposed was that the increase in tumorigenesis was caused by a decrease 
in DNA damage response genes causing insufficient response to DNA damage. 
Additionally, IL-18 is a key mediator in epithelial regeneration by the upregulation of 
adhesion molecules (Stuyt et al., 2003) during the early stages of colitis (Allen et al., 2010, 
Hirota et al., 2011, Nowarski et al., 2015, Zaki et al., 2010a). Besides its indirect tumour-
suppressive role in CAC, IL-18 has been associated with a T helper 1-skewed immune-
stimulatory, anti-tumorigenic response through its ability to induce IFN-γ (Okamura et al., 
1995) and its effects on enhancing the cytosolic activity of cytotoxic T cells and NK cell 
response (Chaix et al., 2008, Novick et al., 2013, Takeda et al., 1998). Furthermore, high 
levels of IL-18 have been detected in lamina propria mononuclear cells (LPMCs) and colon 
epithelial cells of patients with Crohn’s disease (Monteleone et al., 1999, Pizarro et al., 
1999). 
In an experimental T cell-mediated colitis model administration of a recombinant IL-18 
antisense-expressing adenoviruses was able to reduce IL-18 and suppress IFN-γ thus 
ameliorating colitis in vivo (Wirtz et al., 2002). The connection between IL-18 and IFN-γ 
was supported by an analysis of LPMCs from Il-18-/- mice which featured an exacerbated 
form of DSS colitis and produced a significantly higher amount of IFN-γ (Takagi et al., 
2003). Furthermore, the in murine colitis models neutralisation of IL-18 has shown to 
ameliorate intestinal inflammation (Siegmund et al., 2001a, Sivakumar et al., 2002) and 
may therefore an interesting candidate for a targeted immunotherapy of human intestinal 
inflammatory diseases. These experiments have highlighted the dual role of IL-18 in 
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intestinal homeostasis and colitis. Early in the mucosal immune response, its expression by 
IECs and LPMCs indicates a protective, local role through epithelial regeneration and 
proliferation in response to injury. In chronic inflammation its excessive production can 
enhance inflammation, which potentially promotes tumorigenesis and tumour growth 
(Reuter and Pizarro, 2004). 
2.6 The role of NLRP3 in colitis and colitis‑associated cancer: lessons 
from mouse models 
NLRP3 inflammasome and its activation in intestinal pathologies have been investigated 
predominantly using mouse models of chemically induced intestinal inflammation and 
CAC specifically the 2,4,6-trinitrobenzene sulphonic acid (TNBS) and the dextran sulphate 
sodium (DSS) models of inflammation, and the azoxymethane (AOM or AOM/DSS) model 
of CAC induction respectively (Table 2.2).  
Table 2.2: Examples of colitis and CAC mouse models  
Mouse Model Trigger Role of NLRP3 Reference 
Nlrp3-/- DSS/TNBS Protective (Zaki et al., 2010a) 
Nlrp3-/- DSS Protective (Allen et al., 2010) 
Nlrp3-/- DSS Protective (Hirota et al., 2011) 
Nlrp3-/- DSS Harmful (Bauer et al., 2010) 
Nlrp3-/- DSS Harmful (Elinav et al., 2011) 
Nlrp3-/- Oxazolone Protective (Itani et al., 2016) 
Nlrp3R258Wx Rag1-/- Spontaneous Protective (Yao et al., 2017b) 
Nlrp3-/- AOM/DSS Protective 
(Zaki et al., 2010b, 
Allen et al., 2010) 
Nlrp3-/- AOM/DSS None (Hu et al., 2011) 
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In murine of TNBS models the chemical compound is administered intrarectally and 
mediates a T cell-mediated immune response, similar to chronic colonic inflammation as 
described in CD (Wirtz and Neurath, 2007). In the DSS colitis model, DSS is dissolved in 
the drinking water and is ingested. The chemical causes significant damage to the epithelial 
barrier by causing acute colonic crypt destruction and mucosal ulceration. The 
compromised epithelial barrier is invaded by gut microflora which enters to the lamina 
propria resulting in massive infiltration of inflammatory cells and up-regulation of pro-
inflammatory cytokines comparable to human ulcerative colitis (Chassaing et al., 2014, Ni 
et al., 1996). Administering DSS in weekly cycles alternating it with water results in a 
condition that is similar to clinically observed conditions of active and remission phases of 
UC. Finally, AOM a potent genotoxic carcinogen that causes DNA damage in epithelial 
cells is used in combination with repeated DSS administration. The resulting chronic 
inflammation promotes the development of colorectal cancer in cells carrying mutations 
generated by AOM (Tanaka et al., 2003).  
The role of NLRP3 in colitis and CAC is still controversial with some studies showing a 
protective role while other studies demonstrate a detrimental effect of NLRP3 activation 
(Table 2.2). Studies of individual inflammasome components in colitis models before the 
inflammasome was identified as complex molecular platform questioned the role of 
caspase-1 (Dupaul-Chicoine et al., 2010, Siegmund et al., 2001b). The phenotype of 
Caspase-1-/- DSS colitis mice showed reduced acute and chronic colitis (Siegmund et al., 
2001b). Both Caspase-1-/- and Asc-/- mice showed an increased susceptibility to DSS colitis 
and disease severity was linked to reduced IL-18 production. Conversely, the 
administration of exogenous IL-18 completely reversed severity of colitis (Dupaul-
Chicoine et al., 2010). Intestinal epithelial cells rather than lamina propria cells were shown 
to be the source of IL-18 that was needed for early induction of tissue repair and epithelial 
cell regeneration. 
The discrepancy in the above studies was explained by the novel discovery of two 
confounding aspects of the Caspase-1-/- mouse model. First, Caspase-1-/- mice additionally 
lacked caspase-11 (Kayagaki et al., 2011). Therefore, all results based on previous studies 
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The second controversy revolves around the fact that the Caspase-1-/- Caspase-11129mt/129mt 
mice harbour colitogenic microbiota that have shown to enhance the severity of DSS colitis 
(Elinav et al., 2011). A recent study characterised the intrinsic functions of caspase-1 in 
vivo. The study generated Caspase-1-/- and Caspase-11-/- mice on a pure C57BL/6N genetic 
background with a non-dysbiotic intestinal microbiota. Using these gut microbiota it could 
be shown that canonical caspase-1 activation, not caspase-11, is responsible for 
exacerbating DSS-induced colitis (Blazejewski et al., 2017). 
The protective role of NLRP3 in colitis was suggested by experiments that showed 
enhanced colitis in Nlrp3-/- mice mediated by a loss of epithelial barrier integrity and 
reduction of IL-18 (Zaki et al., 2010a), defective antimicrobial mechanism leading to 
bacterial dysbiosis and increased susceptibility to DSS- and TNBS-induced colitis (Hirota 
et al., 2011). 
The role of the NLRP3 inflammasome in the pathogenesis of UC was analysed in an 
oxazolone-induced murine colitis model. Intrarectal delivery of oxazolone (OXA) created 
a relevant UC pathogenesis model mediated by Th2 cytokines. In this model a reduction of 
mature IL-1β and IL-18 production induced a higher severity of colitis in OXA-treated 
Nlrp3-/- mice when compared to WT mice. Conversely this increase in severity could be 
prevented by exogenous administration of IL-1β or IL-18. This study shows that NLRP3 
inflammasome-derived IL-1β and IL-18 may play a protective role against OXA-induced 
colitis (Itani et al., 2016). 
Controversially, competing studies showed that DSS induced colitis was attenuated in 
Nlrp3-/- mice potentially mediated by a local reduction of pro-inflammatory cytokines IL-
1β, TNF-α and IFN-γ (Bauer et al., 2010). Exposure to DSS and concurrent treatment with 
the caspase-1 inhibitor Pralnacasan ameliorated colitis (Bauer et al., 2007). An attenuation 
of colitis in NLRP3-deficient mice has been confirmed by others supporting the function 
of NLRP3 as a negative regulator of the inflammatory process (Elinav et al., 2011). 
Genetic models of Nlrp3-/-, Caspase-1-/- and Asc-/- mice exposed to AOM/DSS have an 
increased tumour burden (Allen et al., 2010). Using bone marrow chimaeras, it was 
demonstrated that tumorigenesis suppressive signalling by NLRP3 was in the 
hematopoietic and not in the epithelial compartment. This correlated colitis-associated 
tumours with a defective production of IL-18 during the initiation of inflammation in the 
AOM/DSS model.  
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Consequently, the role of NLRP3 in CAC has mainly been reported as a negative regulator 
in colitis-associated tumorigenesis (Allen et al., 2010, Zaki et al., 2010b). 
Consistent with a protective role of NLRP3 in tumorigenesis Nlrp3-/- mice were highly 
susceptible to AOM/DSS induced inflammation and the treatment caused increased 
tumours in the colon. The mechanism proposed was that NLRP3-dependent IL-18 secretion 
is required for STAT1 activation and IFN-γ induction leading to decreased immune tumour 
surveillance in the absence of IL-18. This phenotype was reduced with administration of 
recombinant IL-18 (Zaki et al., 2010b).  
The ability of NLRP3 to release bioactive IL-18 is a potential mechanism explaining the 
protective role of this cytokine against CAC development. However, another study found 
no difference in CAC between NLRP3-deficient and WT mice in a AOM/DSS model (Hu 
et al., 2011). The reason for these discrepancies observed in the Nlrp3-/- colitis or CAC 
model phenotype is not clear but could be due to differences in length and concentration of 
DSS treatment or to baseline differences in the composition of the intestinal microbiota in 
experimental mouse colitis. 
Human and murine studies suggest that bacterial dysbiosis promotes inflammation in 
human and mouse colitis and CAC models (Kitajima et al., 2001, Richard et al., 2018). 
Studies in mice deficient in inflammasome genes have provided evidence that specific 
inflammasomes like NLRP6 and NLRP3 are major regulators of commensal microbiota. A 
study in Nlrp3-/- mice suggested that the NLRP6/ASC inflammasome acts as a crucial 
regulator of the gut microbiota (Elinav et al., 2011). Another study that observed a 
significant increase in bacterial counts in stool, colon, mesenteric lymph node and liver in 
DSS colitis of Nlrp3-/- mice compared to DSS colitis in wild-type mice demonstrated that 
NLRP3 plays a role in controlling commensal overgrowth and bacteraemia (Zaki et al., 
2010a). 
How NLRP3 regulates the microbial composition in the intestines is not clear. This 
question was addressed by comparing faecal microbiota of Nlrp3-/- deficient mice to their 
WT littermates (Hirota et al., 2011). Only Nlrp3-/- mice were shown to carry a specific 
bacterial composition with potentially pathogenic members of the family 
Enterobacteriaceae including the species Citrobacter, Proteus and Shigella (Hirota et al., 
2011). Furthermore, the unique genera Mycobacterium, Collinsella, Clostridium and 
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Ralstonia were identified which were not detectable in WT littermates. Additionally, it 
could be shown that colon crypt secretions obtained from Nlrp3-/- mice ex vivo had 
decreased bactericidal activity against E. coli. The significant difference in composition of 
the intestinal microbiota in the Nlrp3-/- mice could explain the increased susceptibility to 
DSS- and TNBS-induced colitis (Hirota et al., 2011).  
Further studies have demonstrated that the distinct commensal bacterial species Proteus 
mirabilis induces a robust Il-1β secretion via NLRP3 inflammasome activation in newly 
recruited intestinal Ly6Chigh monocytes during DSS colitis. This could be linked to an 
increased severity of disease (Seo et al., 2015). However, the molecular pathways by which 
intestinal bacterial populations in NLRP3 inflammasome-deficient mice promote intestinal 
inflammation are still elusive. It has been speculated that this could be due to their ability 
to upregulate the generation of pro-inflammatory chemokines and cytokines such as CCL5 
(Elinav et al., 2011), IL-6 and TNF-α (Hu et al., 2013). 
Nlrp3-/- mice show a more severe colitis when compared to WT mice after infection with 
the intestinal pathogen Citrobacter rodentium (Song-Zhao et al., 2013). This could be due 
to a lack of downstream cytokines IL-1β and IL-18 in the gene-deficient mice and allows 
the conclusion that activation of the NLRP3 inflammasome is necessary for an attenuation 
of Citrobacter rodentium driven intestinal inflammation. 
In contrast to gene-deficient models, the Nlrp3R258W mouse model displays an enhanced 
NLRP3 inflammasome signalling. These mice develop an auto-inflammatory response in 
the skin (Meng et al., 2009). In the intestine they maintain homeostasis and remain strongly 
resistant to experimental colitis and subsequently, colorectal cancer. This due to a distinct 
microbiota in Nlrp3R258W mice with an increased presence of bacterial species such as 
Clostridium XIVa and Lactobacillus murinus and also a significant reduction of colitogenic 
bacteria such as Akkermensia muciniphila which promote the local differentiation of Tregs, 
that contribute to homeostasis in the gut (Yao et al., 2017b). Further work needs to be done 
to elucidate the signalling pathways by which resident bacteria stimulate the NLRP3 
inflammasome to induce colitis in IBD. 
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2.7 Diet, microbiota and the activation of NLRP3: bowel cancer as an end 
stage of inflammation    
Environmental factors, together with the individual genetic makeup and the innate immune 
response play role in development of IBD (Marion-Letellier et al., 2016). Two central 
environmental factors are diet and the composition of symbiotic microorganisms that live 
in our gastrointestinal tract, the so-called microbiome. Microbiota composition has been 
shown to modulate metabolism-associated conditions like obesity and inflammatory 
diseases of the bowel like IBD and associated cancers such as CAC and CRC (Requena et 
al., 2018).  
A healthy diet helps to maintain a balanced and healthy microbiota and consequently, 
immune homeostasis in the gut. Unbalanced consumption of nutrients can lead to a 
dysbiosis of the microbiota and inflammation (Geuking et al., 2014, Marion-Letellier et al., 
2016). Chronic insults from dietary metabolites activate NLRP3 and IL-1β production and 
thus progress disease pathogenesis (Camell et al., 2015). Consequently, diet has been 
identified as an important driver of the development a large percentage (50–90%) of 
tumours of the bowel (Kasdagly et al., 2014). For example, diet rich in fat increases the 
amount of bile acid which consists to 58% of deoxycholic acid (DCA). DCA has been 
found to disrupt epithelial integrity due to Cathepsin B activation of NLRP3 and leads to 
barrier disruption observed in DSS-induced colitis. In mice deficient for NLRP3 or caspase- 
1 DSS-induced colitis could not be established which underlines the role of NLPR3 in the 
development of colitis in a high fat environment (Zhao et al., 2016). Another chronic insult 
by the ingested diet is the presence of dietary cholesterol in the intestines. In an AOM-
treated mouse model this has been associated with a hyperactivity of NLRP3 resulting in 
an increase in IL-1β (Du et al., 2016). In general, saturated lipids, ceramide (Vandanmagsar 
et al., 2011) and uric acid can act as DAMPs that induce unwanted NLRP3 activation by 
initiating the production of ROS (Camell et al., 2015). 
On the other hand, some metabolites like omega-fatty acids prevent activation of NLRP3 
and thus have an anti-inflammatory effect (Yan et al., 2013). These examples allow an 
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Under normal physiological conditions the symbiotic microbiota support the host by 
breaking down complex polysaccharides in dietary fibre into short chain fatty acids (SCFA) 
with less than six carbon atoms (Nieuwdorp et al., 2014). The predominant forms are 
acetate (C2), propionate (C3) and butyrate (C4). SCFA are the major products of bacterial 
fermentation and important as energy source for colonic epithelial cells (Huycke and 
Gaskins, 2004). SCFA induce a favourable intestinal environment in a variety of ways and 
high fibre diet boosts bacterial species which produce SCFA (Desai et al., 2016, Kelly et 
al., 2015). The presence of dietary fibre and SCFA also protects in DSS directly through 
activation of NLRP3 possibly in colonic epithelial cells (Macia et al., 2015). While the 
molecular pathways of this interaction are still elusive it demonstrates the important role of 
diet in intestinal homeostasis. 
Furthermore, butyrate is one of the main SCFA induces functional Tregs via intrinsic up-
regulation of the Foxp3 gene (Furusawa et al., 2013). The extra thymic differentiation of 
Tregs in the periphery is enhanced via the conserved non-coding sequence 1 (CNS-1)-
dependent pathway in the presence of butyrate and propionate (Arpaia et al., 2013). 
Butyrate activates the intestinal butyrate GPR109A receptor which drives the 
differentiation of Tregs and modulates immune responses by upregulation of the production 
of IL-10, suppressing colonic inflammation and carcinogenesis in a mouse model of 
intestinal inflammation associated with CAC (Singh et al., 2014). Increased Treg initiate an 
anti-inflammatory response and act as antagonist to NLRP3 thus maintaining the 
homeostasis in experimental colitis and CAC (Yao et al., 2017b). 
2.8 Future directions of colitis associated colon cancer therapy by 
intervention with NLRP3 activation 
An improved understanding of the mechanistic interactions between diet and microbiota, 
and inflammasomes such as NLRP3 will reveal new potential therapies that target these 
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Table 2.3: Opportunities for interventions with colitis and CAC 
Potential NLRP3-mediated 




Various dietary molecules which can help to 
reduce only detrimental activity of NLRP3 
Stimulation therapy 
Targeting the various activating mechanism of 
NLRP3 
Inhibitory molecules 
Designing inhibitory small molecules against 
activation, assembly or various subunits of 
NLRP3 
Associated target therapy 
Chemokines, cytokines, signalling cascade and 
immune cells like macrophage’s which support 
in negative activity of NLRP3 
2.8.1 Diet/metabolic immunomodulators 
Metabolite targeted therapy can be used to modulate the hyper activation/blockage of 
NLRP3. Metabolic product induced inflammatory mediators like plasminogen activator 
inhibitor (PA)-1, sphingosine-1-phosphate and ceramide-1-phosphate constitute a link that 
allows modulation of NLRP3 activity. Targeting these mediators results in a therapy of 
colitis. Lipoxygenase is needed to recruit monosodium urate which activates NLRP3 in 
gout. This mechanism needs to be investigated in colitis and CAC models (Amaral et al., 
2012). A further interesting possibility is the inhibition of ceramide synthesis by increasing 
fatty acid oxidation to reduce fatty acid inflammation (Schilling et al., 2013). 
2.8.2 Inhibition of de novo activation of NLRP3  
The cytoskeleton protein α-microtubulin is an activator of NLRP3. This protein supports 
NLRP3 assembly by recruiting ASC from mitochondria. This supporting role of NLRP3 
activation requires an assistance from dynein (Akira et al., 2013). The microtubules have 
to undergo post-translational modification by acetylation by the Mec17 gene product in 
order to activate NLRP3 (Akira et al., 2013). An activation of the enzyme SIRT2 which is 
α-tubulin deacetylase is required by DAMPs in order to activate NLRP3. A targeted therapy 
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2.8.3 Small molecule targeted therapy  
Novel small molecule specific inhibitors such as MCC950, CY-09, BHB has been used to 
pharmacologically target NLRP3 activation and successfully treat a variety of 
inflammatory disorders (Coll et al., 2015, Jiang et al., 2017, Youm et al., 2015). These 
inhibitory molecules target various protein components such as ASC or caspase-1 or inhibit 
production of NLRP3-mediated effector cytokines such as IL-1β (Mangan et al., 2018). At 
present there are no specific NLRP3 inhibitors used in clinical IBD therapy. 
However, a few compounds that show inhibition of NLRP3 activity have emerged as 
potential therapeutics for IBD (Perera et al., 2017). Most of these are nonspecific with 
unknown mechanisms, limiting their progression to clinical usage for long term application 
in chronic IBD but specific NLRP3 inhibitors have shown promise in IBD patient tissues 
and colitis mouse models. A recent study using specific inhibitor MCC950 in the 
spontaneous chronic IBD mouse model Winnie, illustrated the potent therapeutic effect of 
NLRP3 blockade. Established colitis was ameliorated by a 3-week treatment of orally 
administered MCC950 (Perera et al., 2018). Another study used glyburide alleviating 
colitis and preventing disease onset in Il10-/- mice. This drug also inhibited pro-
inflammatory cytokines in mucosal explants from Crohn’s patients (Liu et al., 2016b).  
Furthermore, the benzimidazole-containing synthetic small molecule inhibitor Fc11a-2 
alleviated colitis in a DSS-induced colitis mouse model (Liu et al., 2013). In this study the 
mechanism of action was found to be inhibition of cleavage of pro-caspase-1 following a 
reduction in production of IL-1β and IL-18 suppressing the activation of NLRP3 
inflammasome. Finally, a noncytotoxic, novel acrylate derivative inhibitor INF39 which 
does not block caspase-1.  
Oral administration of INF39 in a TNBS-induced rat colitis model attenuated intestinal 
inflammation (Cocco et al. 2017). The use of small molecule inflammasome inhibitors also 
shows promise when it comes to prevention of CAC. A study on the small molecule 
andrographolide (Andro) shows that it is protective against AOM/DSS induced colon 
carcinogenesis in mice by inducing mitophagy in macrophages which leads to a reversed 
mitochondrial membrane potential collapse that inactivates the NLRP3 inflammasome and 
prevents the development of CAC (Guo et al., 2014).  
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A further example is the small-molecule AMPK activator GL-V9 which resolves colitis 
and is protective against tumorigenesis in colitis-associated colorectal cancer. GL-V9 acts 
by triggering autophagy in cells leading to activation of the NLRP3 inflammasome (Zhao 
et al., 2018). In summary the regulation of chronic inflammation in the intestines through 
pharmacological intervention of small molecule NLRP3 inhibitors in IBD patients could 
be a potential therapeutic option for preventing CAC. 
2.8.4 Combination therapy 
Combination of small molecule therapy along with diet modulators could be tried to 
increase effectiveness. For example, various combinations of diet modulators can be used 
such as 5-aminosalicylic acid together with fish oil. This combination lowered the 
inflammatory score compared to treatment with 5-aminosalicylic acid alone in rats with 
TNBS-induced colitis (Mbodji et al., 2013). In human tissues the combination of glutamine 
and arginine have been shown to reduce TNF-α production in colonic biopsies of colitis 
patients (Lecleire et al., 2008). 
2.9 Conclusion 
There is clear evidence supporting the NLRP3 inflammasome as key player in the 
inflammatory response in colitis (Schoultz et al., 2009, Villani et al., 2009) with ultimate 
implications for CAC development (Allen et al., 2010). However, it is also clear from the 
conflicting evidence outlined in this review that involvement of the NLRP3 inflammasome 
in inflammatory processes leading to tumour development is complex and may be context 
dependent. Therefore, carefully designed follow up experiments are warranted, where 
conditions for the induction of colitis including controlled intestinal microbiota, are 
carefully controlled. Unravelling the role of the NLRP3 inflammasome in intestinal 
inflammation will provide insights for the role of NLRP3 in intestinal epithelial cells and 
the pathways employed by the mucosal immune system to modulate the microbiota and 
integrate with the adaptive immune response to defend the integrity of the gut mucosa. 
Understanding the mechanisms that underpin these interactions also more broadly builds 
on the current strong interest in understanding the immune pathways underpinning chronic 
inflammation in tumorigenesis.  
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Chapter 2a 
 Introduction to Experimental Mouse models           
2a.1 Spontaneous colitis mouse model Winnie 
Experimental mouse models of colitis are usually induced by chemicals such as DSS or 
TNBS or pathogens such as nematodes (Brierley and Linden, 2014). However, these 
models do not resemble chronic intestinal inflammation as seen in human IBD. Thus, 
spontaneous chronic colitis models such as Winnie mice play an important role as 
experimental model for investigating IBD pathogenesis and therapy. 
2a.1.1 Winnie mouse model generation 
Winnie mouse model was derived from a from ENU (N-ethyl-N-nitrosourea) mutagenesis 
targeting a single missense mutation in the mucin 2 gene (Muc2) gene. Winnie and another 
mouse model Eeyore were the first animal models of spontaneous intestinal inflammation 
resulting from a single missense mutation in any gene. The single nucleotide polymorphism 
(SNP) is an alteration from a cysteine to tyrosine in the N-terminal D3 domain of Muc2 of 
Winnie mice (C57BL/6 background).  One significant feature of Winnie mice is that the 
mutation is confined to the intestinal primary epithelial and their underlying immune 
system is normal.   
The gel forming mucin 2 is the major constituent of intestinal mucin responsible for its high 
viscosity and forming a protease-resistant matrix that retains molecules vital to host defence 
(MUC2 and Muc2 in humans and mice, respectively). Muc2 is a glycoprotein 
macromolecule and is secreted by the goblet cells in the epithelial lining and released to 
the colonic mucus.   
In Winnie mice, missense mutation in the Muc2 gene resulted in the development of 
spontaneous colitis in which chronic intestinal inflammation resulted in 100% of the 
Winnie strain as early as within 6 weeks (Heazlewood et al., 2008). Investigations in to 
disease pathogenesis revealed that abnormal Muc2 oligomerisation in endoplasmic 
reticulum (ER) resulted in unfolded-protein response (UPR). UPR caused ER stress in 
intestinal goblet cell resulting in cell defects and premature goblet cell apoptosis eventually 
leading to the development of chronic colitis spontaneously in Winnie (Heazlewood et al., 
2008).   Moreover, aberrant Muc2 biosynthesis leads to depleted mucus barrier increasing 
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intestinal barrier permeability. The epithelial layer in normal conditions is protected by the 
sterile impenetrable inner mucus layer, however in Winnie mice the diminished mucus 
barrier exposed the epithelial layer to increased vulnerability to luminal bacteria, antigens 
and to inflammation-inducing toxins (Randall-Demllo et al., 2016). 
2a.1.2 Winnie Clinical Symptoms 
Winnie colitis closely represents the clinical symptoms representative of human UC 
including perianal bleeding, bloody stools, diarrhea, ulceration and weight loss 
(Heazlewood et al., 2008). Chronic inflammation in Winnie mice was established by 
detection of lipocalin-2 in faecal samples over a  4 week period (Robinson et al., 2016b). 
Another major feature of human UC seen in Winnie colitis is the chronic and relapsing 
nature of the disease.  
Clinical symptoms appear at 6 weeks when animals reach adulthood and shows severe 
colitis at age of 16 weeks. In comparison to age matched C57BL/6 mice the proximal and 
distal colon were thickened, and colon weight was greater in Winnie. The spontaneous 
intestinal inflammation was most severe in the distal colon with age progressive disease 
severity, however this did not lead to growth retardation. Moreover, chronic inflammation 
did not develop spontaneous colonic tumours as seen in Muc2-/- mouse model (Velcich et 
al., 2002). 
Winnie mice have been reported to be prone to developing rectal prolapse associated with 
intestinal inflammation. However, only 25% of the Winnie mice have been reported to 
develop rectal prolapse and although there has been no specific age reported to date, it 
could occur at any time between 9–20 weeks (Rahman et al., 2016). 
2a.1.3 Winnie Histopathology 
Histological evaluation of H&E-stained Winnie colonic sections showed aberrant crypt 
architecture, goblet cell loss, neutrophilic infiltration, crypt abscesses and focal epithelial 
erosions and ulceration particularly in the mid and distal colon. Consistent with 
observations from previously published studies Rahman et al, observed classical signs of 
colonic inflammation in Winnie due to thickening of muscle and mucosal layers, and 
increased CD45-immunoreactivity in the distal colon (Rahman et al., 2015b). 
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2a.1.4 Winnie immune profile  
Extensive studies conducted in the past decade has detailed the immunological nature of 
spontaneous inflammation in Winnie mice. The original immunological description 
showed an increased local production of inflammatory cytokines such as TNF-α, IL-1β and 
IFN-γ in the distal colon explant cultures of Winnie mice. Increased production of TH1 and 
TH2 cytokines (TNF-α, IFN-γ, IL-13) was observed in in vitro MLN-derived leukocytes 
cultures. The pro-inflammatory cytokine IL ̶1β were elevated and increased in the intestines 
of both UC and CD patients and this was also observed with the Winnie colitis model 
(Heazlewood et al., 2008). 
More detailed characterization showed a less secretion of the mucosal immune system 
conditioning factor TSLP (thymic stromal lymphopoietin). TSLP is a regulatory cytokine 
produced by intestinal epithelial cells and its role is suppressing dendritic cell activation, 
which is necessary for regulating immune responses to the normal gut microbiota. The 
decreased production of TSLP in Winnie results in an accumulation of activated intestinal 
lamina propria DC. These activated DCs produces IL-6 and IL-23 with a Th17 favouring 
chemokine milieu. Further investigations showed an elevated expression of Th17 gene 
expression and associated cytokines such as IL-17 and IL-23 identified in Winnie mice 
demonstrates a dominant IL-23/Th17 immune response (Eri et al., 2011). The distal colon 
of Winnie mice featured increased levels of CD11c+ APCs and activated dendritic cells 
DCs (CD11c+ MHC-11hi) which also assists in configuring a Th17-dominated mucosal 
immune response. The above observation may explain why the inflammation is most severe 
in Winnie distal colon that is also seen in human UC. 
In summary, the immune profile of Winnie mice, DCs and macrophages, APCs, initiate an 
innate immune inflammatory response which is followed by adaptive immune responses 
which progress toward a mixed Th1, Th2 and a predominant Th17 mucosal immune 
response resulting in spontaneous colitis in a complex pattern as in human UC. The nature 
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Figure 2a.1: Schematic representation of the initiation of inflammation in Winnie mice.  
Reproduced from R.D. Eri et al (Eri et al., 2011).  
Copyright license for this image is provided in Appendix-3. 
2a.1.5 Winnie intestinal innervation and colonic function 
Enteric neurons and extrinsic nerves innervating the bowel have been suggested to play a 
role in the pathogenesis of IBD (Sharkey and Kroese, 2001). Histological evidence has 
shown an increased number of myenteric ganglion cells in chronic ulcerative colitis 
(Storsteen et al., 1953). The spontaneous chronic colitis in Winnie closely represents human 
IBD and therefore has been investigated to evaluate the intrinsic and extrinsic intestinal 
innervation especially of the distal colon. The distal colon of Winnie mice showed 
decreased density of sensory, cholinergic and noradrenergic fibres innervating the 
myenteric plexus, muscle and mucosa when compared to C57BL/6 mice. The innervation 
changes observed in Winnie mice were similar to changes observed in patients with 
ulcerative colitis (Rahman et al., 2015b). 
In a separate study, the same group looked in to the innervation of the Winnie rectum and 
damage to enteric nervous system (ENS) associated with rectal prolapse. The study 
investigated changes in the myenteric and inhibitory motor neurons and compared changes 
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in the density of sensory afferent, sympathetic, and parasympathetic fibres in the rectum of 
prolapsed and normal Winnie mice. This study validated that Winnie prolapsed mice is 
associated with significant impairment of rectal innervation and muscular hypertrophy of 
the rectum (Rahman et al., 2016).  
Further study by the same group investigated intestinal transit and colonic function of the 
Winnie colon (Robinson et al., 2017). Colonic transit was faster in Winnie mice while 
motility was altered including decreased frequency and increased speed of colonic 
migrating motor complexes and increased occurrence of short and fragmented contractions. 
Many of these changes are similar to disturbed motor functions seen in IBD patients. 
2a.1.6 Winnie intestinal tumorigenesis 
UC is also associated with an increased risk of colorectal cancer. however the underlying 
mechanisms have yet to be defined (Rutter et al., 2004). Randall-Demllo et al hypothesised 
that exacerbation of pre-existing chronic inflammation using colitogenic DSS in Winnie 
mice would induce colorectal tumorigenesis. Winnie mice exposed to three cycles of DSS 
displayed epithelial hyperplasia in the distal colon and crypt abnormalities resembling 
dysplasia. Tumour growth oncogenes Cav1, Ccl5, Myc and Trp53 expression was 
differentially regulated in the distal colon of Winnie mice. However, no incident of colonic 
tumour growth was reported with DSS exacerbation of pre-existing chronic inflammation 
Winnie mice. 
2a.1.7 Winnie Microbiota and Metabolomics 
A recent study analysed the faecal microbial and metabolomic profiles in Winnie mice and 
discussed their relevance to human IBD (Robinson et al., 2016a). Composition of the 
dominant microbiota was found to be disturbed, and prominent differences were evident at 
all levels of the intestinal microbiome in faecal samples from Winnie mice, similar to 
observations in patients with IBD.  In general, the abundance of members from the 
Actinobacteria and Proteobacteria was greater, whereas Bacteroidetes and Tenericutes 
were less present in samples from Winnie mice.  
Analysing the metabolomics of faecal samples from Winnie determined changes in 
metabolites produced by the intestinal bacteria during colonic inflammation. Metabolic 
profile revealed that chronic colitis in Winnie mice associated with increases in CHO 
metabolites and decreases in amino acid metabolites, thereby generating disrupted CHO, 
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fat, and amino acid profiles in faecal samples. These results point to mechanisms of 
oxidative stress and malabsorption of nutrients in the colon, both of which are reported in 
IBD.  
2a.1.8 Winnie a model for anti-colitis therapy 
Winnie mice share similarities with human UC and has been used successfully as 
experimental model for investigating the effect of anti-colitis therapeutics.  A study 
investigated the effect of the thiopurine 6TG on Winnie chronic colitis (Oancea et al., 2013) 
and found that the split dosing of 6TG was able to prevent the adverse thiopurine associated 
drug effect known as sinusoidal obstructive syndrome while preventing spontaneous colitis 
in Winnie mice. 
Another study by the same group investigated the effect of glucocorticoid dexamethasone 
(DEX) in ameliorating ER stress in Winnie mice (Das et al., 2013). Winnie mice ER stress 
is caused by misfolding of the Muc2 mucin resulting in UPR in goblet cells. DEX treatment 
in Winnie mice suppressed ER stress significantly restoring goblet cell Muc2 production 
and ameliorating colitis. Therefore, glucocorticoids are potential drug in IBD, where they 
can   reduce ER stress by promoting correct folding of secreted proteins and enhancing 
removal of misfolded proteins from the ER. 
The Winnie mouse model was used to show the efficacy of IL-23 neutralizing antibodies 
in inflammatory bowel disease (Wang et al., 2015b). The results of the study show that 
neutralizing IL-23 using an anti-p19 antibody significantly downregulating TH17 
proinflammatory cytokine expression and diminishing neutrophil infiltration alleviated 
both emerging and established colitis. Another result of this study supported clinical studies 
showing that IL-17 neutralization is not therapeutic in IBD. 
In another study a novel mouse model was generated by crossing Winnie to understand the 
molecular mechanism underlying the anti-TNFα non-responding UC patient group (De 
Santis et al., 2017). The results demonstrated that IL-1β expression is a major pathway for 
the progression of colitis in TNFα-deficient Winnie colitis. These data also suggest that IL-
1β can be a potential target for clinical intervention of UC patients who fail to respond to 
TNF-α neutralization. 
We recently studied the effect of small molecule NLRP3 specific inhibitor MCC950 in the 
Winnie mouse model (Perera et al., 2018). The results illustrated that the efficacy of 
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MCC950 in the treatment of murine ulcerative colitis and provided avenue for a potential 
novel therapeutic agent for human inflammatory bowel diseases. 
2a.2 Generation of Winnie x Nlrp3-/- mouse model  
The Winnie mice used for this experiment was bred from an established strain at the 
University of Tasmania Cambridge Farm Facility. The Nlrp3-/- mice were imported directly 
to the Cambridge Farm Facility from University of Queensland, St Lucia, Australia.  
In our animal facility, the imported Nlrp3-/- mice were rederived before being introduced 
into barrier housing facilities. Imported mice are always subjected to the rederivation 
procedure when procured from vendors or from other research labs which differ in 
veterinary health surveillance systems.  The rederivation process is a standard procedure 
used to decontaminate certain pathogens prior to introducing them in to the colony (Sztein 
et al., 2011). Rederivation prevents possible outbreaks in the animal facility and 
misinterpretation of study results caused by infected animals.   Rederivation also protects 
the staff and researches from the rare evet of receiving animals carrying a transmissible 
zoonotic disease. 
For rederivation, embryos were harvested at preimplantation stage and were thoroughly 
washed for five times and surgically transferred into a clean Swiss Webster female mouse. 
At weaning, after the surrogate mice were screened negative for unacceptable pathogens, 
the pups were considered as pathogen-free to produce specific pathogen-free (SPF) mice 
suitable for breeding purposes. Based on the Mendelian pattern of inheritance a breeding 
plan was sketched to generate Winnie x Nlrp3-/- mice (Figure 2a.2). The first stage was 
where Nlrp3-/- mice were rederived by crossing with WT strain to produce 100% 
heterozygous Nlrp3+/- mice. Mice were then transported to the PC2 animal facility at the 
Menzies Institute for Medical Research, Hobart. In the second stage, heterozygous Nlrp3+/- 
mice were crossed with heterozygous Nlrp3+/- mice and were expected to produce 25% 
homozygous (Nlrp3-/-), 50% heterozygous (Nlrp3+/-) and 25% wild type (WT). In the third 
step, Winnie homozygous mice were crossed with Nlrp3 homozygous mice, and all pups 
produced were Winnie heterozygous and Nlrp3 heterozygous. Subsequently, in the fourth 
step, Winnie heterozygous and heterozygous Nlrp3 mice were crossed with Winnie 
heterozygous and heterozygous Nlrp3 mice, resulting in the generation of 9 different 
genotypes (Table 2a.1). In this step, the Winnie x Nlrp3-/- experimental mice were 
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generated at 1:16 ratio as per Mendelian inheritance pattern.  Many litters were produced 
until a working population of experimental mice resulted, and these were subsequently 
utilised for experimental purposes whilst maintaining healthy breeding pairs. 
 
Figure 2a.2: Schematic presentation of generation of Winnie x Nlrp3-/- mice. 
2a.3 Genotyping of experimental mouse models 
Genotyping was performed for each batch of pups to determine the respective genotype. 
Optimisations of Winnie and Nlrp3-/- mice were performed until a working protocol was 
developed for the study. Appropriate genotyping assays were then performed and 
homozygous Winnie and Nlrp3-/- mice were identified. 
2a.3.1 Extraction of DNA from mouse ear biopsies 
The DNeasy Blood & Tissue Kit (69504, Qiagen) was used for genomic DNA (gDNA) 
extraction. Mouse-ear clips were lysed overnight using the supplied proteinase K and lysis 
buffer. Lysis was performed at 56°C with constant agitation at 500rpm using an Eppendorf 
ThermoMixer® C (5382000015, Eppendorf). Supernatant was then transferred to spin 
columns and processed according to the manufacturer’s protocol and genomic DNA eluted 
(200μL). Neat DNA concentrations were used for PCR assays. 
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Table 2a.1: Efficient Generation of Winnie x Nlrp3-/- mice. 
Stages Parents Offspring Percentage 
1 Nlrp3-/- WT Nlrp3+/- 100% 





















































2a.3.2 Winnie SNP genotyping assay 
The presence of the Winnie Muc2 mutation was confirmed using a custom-designed 
Winnie SNP PCR assay TaqMan probe where the reporter/quencher for Allele-1 was 
VIC/MGB-FAM, Allele 2- FAM/MGB-NFQ (Life Technologies, Assay ID: AHCSX8U, 
Catalogue No: 4332077, Size: 1500rxn, 40x). TaqMan genotyping master mix (4371355, 
Thermo Fisher Scientific) or TaqMan® GTXpress™ Master Mix (4401892, Thermo Fisher 
Scientific) was used for the PCR assay protocol detailed in Table 2a.2 and run in ABI 
StepOnePlus Real-Time PCR Systems (4376600, Applied Biosystems). The genotype of 
each mouse as identified by allelic discrimination plots seen in Figure 2a.3. Results of 
genotyping were analysed by using appropriate Step One software.  
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 Figure 2a.3: Distribution of allelic discrimination plots of genotypes. 
Allelic discrimination plot of SNP assay shows clusters of blue dots which represent Allele 
2/Allele 2 (Win/Win) homozygous Winnie mutants. Allele 1/Allele 2 (Win/WT) 
heterozygous is represented as a green cluster of dots, and Allele 1/ Allele 1 wild-type (WT) 
is represented as red dots. No template control (NTC) is represented in black. The SNP 
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Table 2a:2: Master Mix Preparation protocol 
Reagents Volume per reaction 
2 x TaqMan Genotyping master mix 5 μl 
20 x working stock of SNP 0.5 μl 
DNase-free H2O 3.5 μl 
DNA Template (10ng/µl) 1 μl 
Total Volume 10 μl 
2a.3.3 Nlrp3 genotyping assay 
Deletion of the Nlrp3 gene was confirmed (Table 2a.3) by traditional PCR with NLRP3 
primers (20 μM) purchased from GeneWorks Pty Ltd. HotStar Taq Master Mix Kit 
(203445, Qiagen) was used with 2μl of genomic DNA in a reaction volume of 20 μl and 
thermal cycling performed according to program in Table 2a.4 using a thermal cycler (PTC-
200, MJ Research).  
The amplicons were run on an 1.2% agarose (A9539, Sigma-Aldrich) gel in 1x TBE 
(T4415, Sigma-Aldrich) and a DNA ladder (BIO-33045, Bioline) was used to identify the 
genotypes, and the size of fragments was 250 base pairs (bp) for wildtype allele and 500 
base pairs for Nlrp3 mutant allele (Figure 2a.4). 
 
 
Figure 2a.4: Agarose Gel for Nlrp3-/- genotyping amplicons.  
Agarose gel electrophoresis was performed, and the amplified fragments were visualised 
on 2% agarose (A9539, Sigma-Aldrich) gel using SYBR safe DNA gel stain (S33102, 
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size band-100-2000 bp. The product size was 250 bp for homozygous Nlrp3 and 500 bp 
for WT.  
Table 2a.3: NLRP3 genotyping primer list 
Primer Sequence 
Mutant AAG TCG TGC TTC ATG T 
WT Common TCA AGC TAA GAG AAC TTT CTG 
WT ACA CTC GTC ATC TTC AGC A 
Table 2a.4: NLRP3 genotyping thermocycle program 
Primer Temperature/Time Cycles 
Mutant 95°c/ 5 min 1x 
WT 
Common 
95°c/ 45 sec 
95°c/ 30 sec 
72°c/ 40sec 
40x 
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NLRP3 Inhibitors as potential therapeutic agents for treatment 
of Inflammatory Bowel Disease 
3.1 Abstract 
Inflammatory bowel disease (IBD) is a group of intestinal disorders characterised by 
chronic relapsing inflammation of the small intestine and colon. IBD manifests as either 
ulcerative colitis or Crohn’s disease and increases the risk of developing colorectal cancer. 
Current treatment regimen for IBD utilise anti-inflammatory drugs, immune system 
suppressors and antibiotics or a combination of these. However, these therapeutics lead to 
several adverse effects, remission or significant non-responsiveness creating an urgent need 
to develop potent drugs with novel mechanisms of action for IBD. The inflammasome is a 
multiprotein complex that assembles to a key innate immune system signalling platform 
and is involved in the pathogenesis of inflammatory and autoimmune diseases. The NLRP3 
inflammasome recognizes microbial and cell stress components and serve as a platform for 
caspase-1 activation and pro-inflammatory cytokine IL-1β, IL-18 maturation. Although the 
exact aetiology of IBD is unknown, uncontrolled NLRP3 Inflammasome activation has 
shown to play a major role in the chronic intestinal inflammation and mature IL-1β and IL-
18 are consistently associated with increased colitis and colitis associated colorectal cancer 
development. In this review, we discuss the experimental NLRP3 inhibitors that have been 
investigated in IBD experimental models. The potential mechanism of action of these 
inhibitors such as inhibiting NF-κB activation and decreasing mitochondrial reactive 
oxygen species are discussed in detail. We further expand on the controversial role of 
NLRP3 in IBD and future issues that might arise from the long-term use of NLRP3 
inhibitors in IBD therapy. 
3.2 Introduction 
Inflammatory bowel disease (IBD) is a group of intestinal disorders characterised by 
inflammation of the small intestine and colon. IBD is an important adolescent chronic 
disease, with 20–30% of patients presenting under 20 years of age (Kelsen and Baldassano, 
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2008). The incidence and prevalence of IBD is highest in the developed countries of North 
America and Europe (Bernstein et al., 2006, Munkholm et al., 1992). Approximately 2.5–
3 million people in Europe suffer from IBD, with a direct healthcare cost of 4.6–5.6 bn 
Euros/year (Burisch et al., 2013). 
The two major clinical types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC) 
(Hanauer, 2006). Both diseases are characterised by chronic series of relapses and 
remissions. Crohn’s disease cause inflammation in all part of the intestinal tissue along the 
length of gastrointestinal tract, whereas ulcerative colitis is limited to the mucosal and 
submucosal layers of the colon and rectum. Common symptoms include diarrhoea with 
blood, abdominal pain, rectal bleeding and weight loss (Ponder and Long, 2013). Chronic 
gut inflammation is an important predisposing factor for the development of colorectal 
cancer (CRC) (Karin and Greten, 2005, Dupaul-Chicoine et al., 2010) with clinical data 
showing  that UC increases cumulative risk of CRC by up to 18-20%, while CD is up to 
8% after 30 years of disease (Rubin et al., 2012, Eaden et al., 2001, Canavan et al., 2006).  
The standard therapy for IBD is reduction of symptoms and underlying inflammation by 
nonspecific anti-inflammatory corticosteroids (Fornaro et al., 2015). However the relief 
from corticosteroids is short lived and treatment disturb general immunity and can cause 
steroid dependency (Faubion et al., 2001). Infliximab is a novel monoclonal antibody 
targeting TNF-α which is efficient in inducing and preventing remission, however it can 
lead to serious side effects such as increased risk of opportunistic infection (Beaugerie et 
al., 2009). Moreover, significant number of patients are unresponsive to Infliximab (Naija 
et al., 2011).  
Failure of current medical therapy and disease severity leads to colectomy which is an 
emergency surgery with a high rate of morbidity (Cima, 2010). To avoid surgery there is a 
need for developing next generation potent agents that target the underlying mechanisms 
driving the inflammation and regulate the long-term control of inflammation and maintain 
intestinal homeostasis. 
IBD is thought to arise from dysfunctional activation of the intestinal mucosal immune 
system in response to commensal bacteria in a genetically susceptible individuals (Bouma 
and Strober, 2003). Although the exact aetiology of IBD has yet to be elucidated, recent 
studies support the hypothesis of a dysfunctional innate immunity as a major mechanism 
in chronic mucosal inflammation in IBD (Maloy and Powrie, 2011).  
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The innate immune response to cell stress or infection depends on the activation of 
receptors belonging to the pattern recognition receptors (PRRs) (Medzhitov and Janeway, 
2002).The two main types of receptors are, Toll-like receptors (TLRs) and Nod-like 
receptors (NLRs) (Schroder and Tschopp, 2010, Martinon et al., 2009). Activation of these 
receptors initiate an immune response which involves activation of the inflammasome 
complex and a cascade of pro-inflammatory cytokines that initiates an adaptive immune 
response (Ranson and Eri, 2013). It is well known that the dysregulation of the 
inflammasome complex positively contributes to chronic inflammation and disease onset 
(Chen and Nunez, 2011, Elinav et al., 2013). Among the NLR activated inflammasomes, 
NOD-like receptor protein 3 (NLRP3) is the best characterized and most associated with 
inflammatory diseases such as atherosclerosis, type 2 diabetes gout, multiple sclerosis, 
Alzheimer’s disease, Parkinson’s disease, and age-related macular degeneration (Duewell 
et al., 2010, Guo et al., 2015a). Several reports have shown that the NLRP3 inflammasome 
plays a pathological role in experimental colitis (Bauer et al., 2012, Bauer et al., 2010).  
The NLRP3 inflammasome is a multimolecular platform constituting of NLRP3 protein 
encoded by the Nlrp3 gene and an adaptor protein ASC (apoptosis-associated speck-like 
protein containing a CARD) and procaspase-1. NLRP3 is expressed mostly in the cytosol 
of myeloid cells, lymphocytes, epithelial cells, and osteoblasts (Kummer et al., 2007).  
NLRP3 inflammasome is activated by a range of pathogen-associated molecular patterns 
(PAMPS) and host derived damage-associated molecular patterns (DAMPS) released 
through cellular stress and damage. The known microbes that are recognized by NLRP3 
includes Candida albicans (Gross et al., 2009), Staphylococcus aureus (McGilligan et al., 
2013), Escherichia coli (Rathinam et al., 2012a), Influenza A virus (Allen et al., 2009). The 
endogenous host derived factors associated with damage are extracellular adenosine 
triphosphate (ATP) (Mariathasan et al., 2006), monosodium urate (MSU) crystals 
(Martinon et al., 2006), β-amyloid plaques (Halle et al., 2008) and islet amyloid polypeptide 
(Masters et al., 2010). Activation of the inflammasome leads to activation of caspase-1 and 
the consequent cleavage and secretion of mature IL-1β, IL-18 (Ranson and Eri, 2013) 
(Martinon et al., 2002) proinflammatory cytokines. 
3.3 NLRP3 inflammasome: Novel Target for IBD 
Many studies have investigated the role of NLRP3 inflammasome on intestinal 
inflammation in mouse models deficient in NLRP3 associated with enhanced susceptibility 
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to Dextran Sulphate Sodium (DSS). DSS a Sulphated Dextran with a high molecular 
weight, compromise the mucosal epithelial barrier function by increasing colonic mucosal 
permeability which leads to luminal antigens and microorganisms entering into the mucosa 
resulting in an overwhelming inflammatory response (Perše and Cerar, 2012). 
Administration of DSS leads to clinical observations similar to human UC, such as weight 
loss, diarrhea and occult blood in stool and anaemia. DSS treatment significantly increases 
expression of Th1 proinflammatory cytokines such as IL-12, IL-10, TNF-α, IL-1β and IFN-
γ in the colon (Yan et al., 2009). Observational changes in the histology of the colonic 
mucosa with DSS treatment is increased inflammatory cell infiltration in to lamina propria 
and submucosa, mucin depletion, cryptitis and crypt abscesses. Acute colitis is induced by 
addition of 2–5% DSS to drinking water for an average of 7 days. Chronic colitis is induced 
by uninterrupted treatment of low concentrations of DSS or cyclical administration of DSS 
and water for up to 28 days. 
Some studies indicate that Nlrp3-/- mice exhibited severe inflammation following oral DSS 
treatment (Dupaul-Chicoine et al., 2010, Zaki et al., 2010a) (Allen et al., 2010). In contrast 
to the above mentioned studies another study reported that the loss of NLRP3 or caspase-1 
was protective in the DSS model of colitis and that in vivo inhibition of caspase-1 attenuated 
DSS-induced inflammation (Bauer et al., 2010). Due to contradictory findings the precise 
role of NLRP3 inflammasome on colitis is yet to be explained and warrants further 
experimental analysis. 
However among the innate immunity inflammasomes, NLRP3 induced proinflammatory 
cytokines IL-1β and IL-18 has been consistently associated with promoting localized 
inflammation in IBD (Villani et al., 2009, Schoultz et al., 2009, McAlindon et al., 1998) 
and their correlation with disease activity (Guimbaud et al., 1998) have been well 
described. IL-1β and IL-18 are the major pro-inflammatory cytokines that promote 
activation of both the innate and adaptive immune responses (Dinarello, 2009, Chung et 
al., 2009). Moreover, IL-1β modulates the functions of dendritic cells, macrophages, 
neutrophils, as well as the differentiation of Th17 cells and can cause T cell mediated 
inflammation (Ziegler and Buckner, 2009, Coccia et al., 2012, Clambey et al., 2012). There 
is a strict correlation between the presence of IL-18 and the severity of inflammation (van 
de Veerdonk et al., 2011, Kanai et al., 2013). Furthermore, IL-18 neutralization (Siegmund 
et al., 2001a, Sivakumar et al., 2002) or chemical caspase-1 inhibitor (Bauer et al., 2007, 
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Loher et al., 2004) can effectively reduce severity in murine colitis. Therefore, inhibition 
of caspase-1 mediated IL-1β and IL-18 secretion may serve as a useful therapeutic option 
for patients with IBD (Coll et al., 2015, Thomas et al., 1991). Thus, targeting NLRP3 
inflammasome complex appears to be a promising therapy option for IBD patients. 
3.4 Promising NLRP3 inhibitors in experimental colitis and their 
mechanisms  
NLRP3 inflammasome activation typically occurs in a two-step process (Sutterwala et al., 
2006, Ozaki et al., 2015). The first priming signal leads to the activation of NF-κB mediated 
up regulation of the precursor proteins, pro-IL-1β, pro-IL-18, and NLRP3 (Franchi et al., 
2012). In the second step, NLRP3 is stimulated by DAMPS and PAMPS which assembles 
NLRP3, ASC, and procaspase-1 components in to the NLRP3 inflammasome. The above 
complex initiates the conversion of procaspase-1 to caspase-1 leading to the production and 
secretion of mature IL-1β and IL-18 (Ozaki et al., 2015). Three different mechanistic 
pathways have been suggested for the above-mentioned conversion process. These are (1) 
pore formation and potassium efflux (Perregaux and Gabel, 1994, Petrilli et al., 2007), (2) 
lysosomal destabilization (Okada et al., 2014) and (3) mitochondrial reactive oxygen 
species (mROS) generation (Heid et al., 2013, Gurung et al., 2015). Given the evidence 
that aberrant NLRP3 activation is involved in the progression of IBD, targeting the 
activation pathway is a promising strategy for the development of novel effective 
therapeutics for IBD.  
Since the discovery of the inflammasome (Martinon et al., 2002) many NLRP3 inhibitors 
have reached clinical trials and implemented as pharmacological agents in various 
inflammatory diseases. Examples include Canakinumab an IL-1β blocker, GSK1070806 
an IL-18 blocker, Glyburide indirect NLRP3 inhibitor, Bay 11-7082 a NLRP3 ATPase 
inhibitor, Parthenolide a caspase-1 inhibitor and AZD9056 a P2X7 antagonists (Ozaki et 
al., 2015). However, these inhibitors are not specific to NLRP3 but disturb the signalling 
pathway or components of the inflammasome. Currently there are no specific NLRP3 
inhibitors used in IBD therapy. Therefore, there is a great interest in the scientific 
community for the research of NLRP3 inhibitors for therapeutic use in IBD. We have 
summarised all the therapeutic agents and the mechanism of action in experimental IBD 
studies in Table 3.1. 
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Alpinetin Flavonoid 
THP-1 cells DSS 
colitis mouse 
model 
Blocking activation of NF-
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(Liu et al., 
2016b) 
Fraxinellone Lactone 
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The most common target of the experimental drugs, is inhibiting the activation of 
transcription factor NF-κB (He et al., 2016a, Sun et al., 2015, Liu et al., 2016b, Wu et al., 
2014). The drug, Alpinetin is a plant flavonoid isolated from Alpinia katsumadai Hayata 
which can effectively inhibit the expression of TNF-α and IL-1β in DSS-induced mouse 
colitis. This study showed that pre-treatment with Alpinetin successfully reduced the levels 
of IL-1β in THP-1 cells, which was through inhibiting the expression of NLRP3 
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inflammasome complex. The mechanism was deduced to work through down-regulation 
of TLR4, NF-κ B and NLRP3 inflammasome (He et al., 2016a).  
Wogonoside is another drug that targets NF-κB activation. This drug is a glucuronide 
metabolite of bioactive flavonoid wogonin with anti-cancer (Chen et al., 2013) and anti-
inflammation-induced angiogenic activities (Chen et al., 2009). Wogonoside has shown to 
ameliorate clinical symptoms and histopathological features of DSS-induced colitis. 
Potential mechanism for Wogonoside is through inhibiting NF-κB activation leading to 
reduced formation of NLRP3 inflammasome and caspase-1 activity and thus suppressing 
IL-1β and IL-18 processing (Sun et al., 2015).  
Another promising target predicts involvement of ROS, as many NLRP3 agonists such as 
ATP and MSU crystals have been shown to promote ROS formation (Petrilli et al., 2007, 
Cruz et al., 2007). The main source of cellular ROS is believed to be the mitochondria, and 
mitochondrial DNA (mt DNA) released by damaged mitochondria has also been shown to 
activate the NLRP3 inflammasome (Zhou et al., 2011). The electron transport chain in the 
mitochondrial inner membrane is critically involved in the generation of energy, where 
oxygen acts as an electron acceptor. When the electron transport chain breaks down, ROS 
can reach toxic levels within cells. Conversely, treatment of macrophages with the ROS 
inhibitors N-acetyl-L-cystine (Klionsky et al., 2012) or (2R,4R)-4- aminopyrrolidine-2,4-
dicarboxylate (Dostert et al., 2008) has been shown to inhibit silica and asbestos-induced 
NLRP3 inflammasome activation. 
MitoQ is a mitochondria-targeted antioxidant derived from ubiquinone, which is the active 
antioxidant component of coenzyme Q. The adsorbed MitoQ in the mitochondrial inner 
membrane acts as an antioxidant and is reduced by the respiratory chain to its active form 
and protects mitochondria from oxidative damage. MitoQ demonstrates a good 
pharmacokinetic profile and has been successfully trialled as a daily oral tablet in 
Parkinson’s disease patients for a year in phase 2 trials (Snow et al., 2010). In vivo and in 
vitro studies have shown MitoQ to have good anti-oxidative, anti-inflammatory and anti-
apoptotic effects in many oxidative damage-related pathologies (Graham et al., 2009). 
MitoQ was investigated as a potential therapeutic agent to treat acute colonic injury in a 
mouse model of DSS-induced colitis (Dashdorj et al., 2013).  Results show that MitoQ was 
able to reduce oxidative stress and restore mitochondrial alterations and thereby decrease 
the excessive activation of the NLRP3 inflammasome leading to significant improvement 
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in clinical and histological changes seen in the DSS induced mouse model of colitis. These 
results suggest that mROS may play an important role in IBD and indicate that MitoQ could 
be a promising candidate for treatment of human IBD. 
The experimental drug Dimethyl fumarate (DMF) dose-dependently attenuated body 
weight loss, colon length shortening and colonic pathological damage including decreased 
myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) activities in Dextran 
Sulphate Sodium (DSS)-induced mouse model (Liu et al., 2016c). Furthermore, protein and 
mRNA levels of pro-inflammatory cytokines, including IL-1β, TNF-α and IL-6 were 
markedly suppressed by DMF. At the same time, decreased activation of caspase-1 was 
detected in DMF-treated mice, indicating that the NLRP3 inflammasome activation was 
suppressed. Nuclear factor-erythroid 2-related factor 2 (NRF2) is a redox-sensitive 
transcription factor that regulates multiple anti-oxidative enzymes (Suzuki et al., 2013). 
NRF2 is indicated in the protection against many inflammatory diseases (Li et al., 
2008).The inhibitory mechanism was attributed to the up regulation of NRF2 which 
decreased mROS generation and mtDNA release.   
MCC950 is a small molecule NLRP3 inhibitor that has gained immense impact in the 
research community in recent times. MCC950 is a proven highly selective and potent 
inhibitor of the NLRP3 inflammasome (Coll et al., 2015). MCC950 block NLRP3-
dependent inflammasome activation at nanomolar concentrations, with no effect on 
NLRC4, NLRP1 or AIM2 inflammasomes. In vivo, MCC950 reduced IL-1β production 
and attenuated the severity of experimental autoimmune encephalomyelitis, a disease 
model of multiple sclerosis which is known to be aggravated by the NLRP3 inflammasome 
(Gris et al., 2010). MCC950 was effective in preventing the neonatal lethality in a mouse 
model of cryopyrin-associated periodic syndromes whereas blockade of IL-1β did not 
prevent lethality. This suggest that inflammasome inhibitors are more potent than the 
inhibition of IL-1β alone in ameliorating inflammatory damage. The study provided a 
detailed pharmacokinetic profile of MCC950 even though the mechanism of action was not 
resolved. This invaluable data has made it possible for this drug to be applied as a 
therapeutic agent in other inflammatory diseases such as myocardial infarction (van Hout 
et al., 2016) and kidney fibrosis (Ludwig-Portugall et al., 2016). MCC950 is an ideal 
candidate to be used as a therapeutic agent for the selective inhibition of NLRP3 in IBD. 
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NIMA-related kinase 7 (NEK7) is a member of the NIMA (never in mitosis gene A) related 
serine-threonine kinase family and is known to be involved in mitotic progression 
downstream of NEK9 (Belham et al., 2003). In a major breakthrough of the NLPR3 
activation process two recent independent studies have concluded that NEK7 is necessary 
for the activation of the NLRP3 complex (He et al., 2016b). NLRP3 inflammasome 
formation is dependent on NEK7 binding directly to the LRR domain of NLRP3 
downstream of the generation of mROS. The NEK7 role as a regulator of NLRP3 activation 
can be a novel promising therapeutic target for managing NLRP3 associated inflammatory 
diseases by targeting NEK7 to specifically inhibit NLRP3 inflammasome.  
3.5 NLRP3 inhibitors: A double edged sword? 
The NLRP3 inhibitors for IBD are still at the initial stage of drug development of biological 
confirmation in cellular and animal models (Table 1). Caution should be exercised when 
these drugs progress on for human clinical trials due to the controversial role of NLRP3 
inflammasome and blockade of IL-1β and IL-18 cytokines in IBD. 
The functions of IL-18 are complex and their possible contribution to chronic inflammation 
in the intestine is unclear (Siegmund, 2010b). Polymorphism in the gene encoding IL-
18RAP has been associated with IBD (Zhernakova et al., 2008) while other studies reported 
that Il-18-/- or Il-18R-/- mice are more susceptible rather than resistant to DSS-induced 
colitis (Takagi et al., 2003, Reuter and Pizarro, 2004). A study on mice deficient for NLRP3 
shows that they are more vulnerable to DSS-induced colitis due to lack of IL-18 and not 
IL-1β (Hirota et al., 2011). Mice deficient in caspase-1 are also more vulnerable to DSS-
induced colitis, and administration of IL-18 initiates mucosal healing in these mice 
(Dupaul-Chicoine et al., 2010). These studies show a protective role for IL-18 possibly due 
to it being continuously expressed in intestinal epithelial cells and its role in maintaining 
the intestinal barrier under homeostatic conditions. Therefore, inhibiting NLRP3 will 
drastically inhibit IL-18 production and this could exacerbate IBD. 
NLRP3 inflammasome has been shown to be responsible for protection against increased 
tumorigenesis (Allen et al., 2010). NLRP3 inflammasomes anti-carcinogenic capability is 
by inhibiting cell proliferation and promoting pyroptotic cell death pathways (Salaro et al., 
2016, Dupaul-Chicoine et al., 2015). Therefore, NLRP3 inflammasome is essential for the 
homeostasis of epithelial barrier function and wound repair processes during IBD. This 
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observation suggests that elevated inflammatory responses and increased destruction of the 
epithelial barrier in the absence of a functional NLRP3 inflammasome drives colitis-
associated tumorigenesis. Therefore, there is a possibility that the usage of NLRP3 
inhibitors in IBD patients could lead to the development of CRC. 
IBD is known to lead to extra-colonic inflammatory manifestations in other tissues such as 
lungs, joints, eyes, skin and liver (Levine and Burakoff, 2011). The physiological function 
of NLRP3 in these systems could be different to NLRP3 role in the intestine. Therefore, it 
is extremely important to evaluate the pharmacokinetics and long-term effect of these novel 
NLRP3 inhibitors designed for IBD before progressing to human clinical trials. 
Majority of the studies of the efficacy of NLRP3 inhibitors detailed in Table 3.1 have used 
DSS induced colitis as the experimental model. DSS was given for up to 7 days to induce 
an acute colitis condition and treatment for less than 30 days. However, IBD is a chronic 
disease with long term use of therapeutic drugs. Therefore, the experimental conditions in 
these studies are not translational to IBD conditions and the efficacy of the inhibitors are 
uncertain. It would be more reliable to design experiments in a spontaneous chronic colitis 
murine model (Eri et al., 2012) that mimics human IBD condition to evaluate the effect of 
novel NLRP3 inhibitors. 
3.6 Conclusion 
Taken together, all the NLRP3 inhibitors showed significant ability to inhibit NLRP3 
inflammasome activation and significantly improved clinical and histological changes in 
the DSS induced mouse model of colitis. All the inhibitors show potential use in the 
treatment of inflammatory bowel diseases. However, NLRP3 function is controversial at 
the moment with protective and harmful effects observed in murine colitis models. 
Therefore, when considering applying NLRP3 inhibitors for long term therapeutic relief 
for a chronic disease such as IBD more research needs to be done to analyse the complete 
structure and physiological function of NLRP3. The next exciting step would be to 
investigate if the protection offered in murine colitis models could be replicated when the 
inhibitors are applied to human IBD clinical trials.  
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Chapter 4 
MCC950, a specific small molecule inhibitor of NLRP3 
inflammasome attenuates colonic inflammation in spontaneous 
colitis mice 
4.1 Abstract 
MCC950 a potent, highly specific small molecule inhibitor of canonical and noncanonical 
activation of NLRP3 inflammasome has been evaluated in a multitude of NLRP3 driven 
inflammatory diseases. However, the effect of MCC950 on colonic inflammation has not 
yet been reported. In the present study we investigated the effect of MCC950 in a 
spontaneous chronic colitis mouse model Winnie, which mimics human ulcerative colitis. 
Oral administration of 40 mg/kg MCC950 commencing at Winnie week seven for three 
weeks significantly improved body weight gain, colon length, colon weight to body weight 
ratio, disease activity index and histopathological scores. MCC950 significantly suppressed 
release of proinflammatory cytokines IL-1β, IL-18, IL1-α, IFN-γ, TNF-α, IL-6, IL17, 
chemokine MIP1a and Nitric Oxide in colonic explants. Moreover, MCC950 resulted in a 
significant decrease of IL-1β release and activation of caspase-1 in colonic explants and 
macrophage cells isolated from Winnie. Complete inhibition with MCC950 in Winnie 
colonic explants shows, for the first time, the contribution of inflammatory effects resulting 
exclusively from canonical and noncanonical NLRP3 inflammasome activation in colitis. 
Taken together, the results illustrate the efficacy of MCC950 in the treatment of murine 
ulcerative colitis and provides avenue for a potential novel therapeutic agent for human 
inflammatory bowel diseases. 
4.2 Introduction 
Inflammatory bowel disease (IBD) is a group of intestinal disorders characterised by 
inflammation of the gastrointestinal tract (Ponder and Long, 2013). The two major types of 
IBD are Crohn’s disease and ulcerative colitis. Crohn’s disease causes inflammation in all 
parts of the intestinal tissue along the length of gastrointestinal tract while ulcerative colitis 
is restricted to the mucosa of the colon and rectum. Both diseases are characterised by a 
series of relapses and remissions and also increases the risk of colon cancer (Terzić et al., 
 
 
Agampodi Promoda Perera 
ROLE OF NLRP3 IN COLITIS AND COLITIS ASSOCIATED COLORECTAL CANCER   47 
 
2010). The aetiology and pathogenesis of IBD is still unclear. Emerging evidence support 
the hypothesis that the dynamic key players are dysbiosis in enteric microbiota, a 
dysfunctional epithelial barrier, and defective innate immunity (Elinav et al., 2013).  
The innate immune response to cell stress or infection depends on  receptors such as Toll-
like receptors (TLRs) and Nod-like receptors (NLRs) (Schroder and Tschopp, 2010, 
Martinon et al., 2009). In particular NLRP3 is one of the best characterized and is associated 
with inflammatory diseases (Duewell et al., 2010, Rajamaki et al., 2010). The NLRP3 
inflammasome is a cytoplasmic multimolecular platform composed of NLRP3 protein 
bound to an adaptor protein, apoptosis-associated speck-like protein containing a CARD 
(ASC) and procaspase-1. Activation of the inflammasome leads to proteolytic activation of 
caspase-1 triggering cleavage and subsequent secretion of proinflammatory cytokines IL-
1β and IL-18 (Martinon et al., 2002). Kayagaki et al., 2011 described a novel non-canonical 
pathway resulting in NLRP3 inflammasome activation. This pathway is via caspase-11, 
which is widely expressed in both hematopoietic and non-hematopoietic cells, including 
macrophages and epithelial cells. Caspase-11 is activated by cytosolic gram-negative 
bacteria leading to pyroptosis and IL-1α and HMGB1 release, and NLRP3 inflammasome 
assembly and  maturation of IL-1β, IL-18 (Kayagaki et al., 2011).  
IL-1β cytokine levels are significantly altered in patients suffering from either acute or 
chronic gastrointestinal inflammation and have been additionally implicated in tumour 
angiogenesis, progression, and metastasis (Bioque et al., 1995, Casini-Raggi et al., 1995). 
Many clinical studies show evidence of increased IL-1β secretion from colonic tissues and 
macrophages of IBD patients, correlating to the severity of disease (Coccia et al., 2012, 
McAlindon et al., 1998, Ligumsky et al., 1990). Preclinical studies imply that IL-18 
contributes the pathogenesis of colitis (Kanai et al., 2013, van de Veerdonk et al., 2011). 
Moreover, IL-18 neutralization (Siegmund et al., 2001a, Sivakumar et al., 2002) or 
pralnacasan inhibition of caspase-1 (Bauer et al., 2007, Loher et al., 2004) effectively 
reduced severity in murine colitis. These clinical findings suggest IL-1β and IL-18 play an 
important role in the pathogenesis of IBD.  
A study by Bauer et al., 2010 found that NLRP3-deficient mice were significantly protected 
from colitis in DSS-induced colitis mouse model (Bauer et al., 2010) suggesting that the 
blockade of NLRP3 inflammasome may serve as a potential target for the development of 
novel therapeutics for patients with colitis. However, current pharmacological modulators 
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of NLRP3 inflammasome tested in experimental colitis are not specific to NLRP3 
inflammasome and do not inactivate both canonical and noncanonical pathways (Perera et 
al., 2017). 
MCC950 is a potent highly specific small molecule inhibitor of both canonical and 
noncanonical activation of NLRP3 inflammasome. In vivo, MCC950 reduced IL-1β 
production and attenuated the severity of experimental autoimmune encephalomyelitis, an 
animal model of multiple sclerosis which is known to be aggravated by the NLRP3 
inflammasome (Coll et al., 2015). Inhibition of NLRP3 by MCC950 effectively rescued 
neonatal lethality in a mouse model of cryopyrin-associated periodic syndrome, a genetic 
disease caused by activating mutation in NLRP3. In agreement with cell profiling, 
MCC950 was not effective against an NLRP1 mutant highlighting the compounds 
specificity in vivo. The study provided a detailed pharmacokinetic profile of MCC950 but 
the mechanism of action was elusive; MCC950 did not affect K+ efflux, Ca2+ flux, NLRP3-
NLRP3 or NLRP3-ASC interactions (Coll et al., 2015). Further work by Primiano et al., 
2016 (Primiano et al., 2016), dismissed other likely targets of MCC950 such as GST Omega 
1-1 (Laliberte et al., 2003), SUR1, SUR2a and SUR2b. Moreover MCC950 did not target 
cellular proteins involved in the activation of NLRP3 inflammasome such as caspase-1, 
SYK, JNK, GPR40, and GPR120 (Primiano et al., 2016). Only very weak off-target activity 
was identified through multiple commercially available screening panels (Eurofins Cerep, 
DiscoverX, Reaction Biology, Carna Biosciences, WuXi AppTec) (Primiano et al., 2016). 
In 2016 two independent studies discovered NEK7, a serine-threonine kinase, as an 
upstream regulator of NLRP3 inflammasome activation (He et al., 2016b, Shi et al., 2016). 
This major discovery of a new inflammasome component, revealed a potential therapeutic 
target for the inhibitory mechanism of sulfonylurea molecules such as MCC950 and 
glyburide. We and others hypothesise that MCC950 and glyburides target of inhibition 
could be the NEK7-NLRP3 interaction (Van Hauwermeiren and Lamkanfi, 2016). 
MCC950 is the most specific and well characterised NLRP3 inhibitor known to date and 
has been tested in a diverse array of NLRP3 engaged inflammatory diseases. MCC950 
shows promising therapeutic potential for reducing crystal-induced kidney fibrosis in mice 
(Ludwig-Portugall et al., 2016), reversing inflammation and blood pressure in a 
hypertension mouse model (Krishnan et al., 2016), in valosin-containing protein associated 
disease (Nalbandian et al., 2017) and decreasing inflammation associated with pathogenic 
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Influenza A Virus (Pinar et al., 2017). Temporal administration of MCC950 was able to 
reduce lung inflammation and cellular influx (Tate et al., 2016). However, MCC950 was 
not effective in reducing angiotensin II induced hypertension (Dinh et al., 2017) and in the 
treatment of acute procedural inflammation in burn-injured mice (Deuis et al., 2017). This 
was however due to the limited role of NLRP3 inflammasome in these disease models.  
Recently MCC950 was recommended as an ideal therapeutic candidate for the selective 
inhibition of NLRP3 in colitis (Perera et al., 2017). Pellegrini et al,.2017 suggested 
MCC950 treatment will define anti-inflammatory effects resulting exclusively from 
inhibition of canonical and noncanonical NLRP3 inflammasome activation in colitis 
(Pellegrini et al., 2017). At present, the majority of available studies on the efficacy of 
NLRP3 inhibitors have used Dextran Sulphate Sodium (DSS) induced acute colitis as the 
experimental model of ulcerative colitis (Perera et al., 2017). The DSS colitis model is very 
established due to its rapidity, reproducibility and controllability. The DSS chemical exerts 
a toxic effect on colonic epithelium leading to a leaky tight junction and bacterial 
translocation (Poritz et al., 2007). Therefore it is reflective more of an acute injury than an 
inflammatory disease (Ni et al., 1996). In addition, DSS induced colitis development does 
not involve the T and B cell immunity which is unlike human ulcerative colitis (Chassaing 
et al., 2014). Due to these limitation in DSS induced colitis there is a great need for 
clinically relevant spontaneous colitis murine models which resembles human disease for 
understanding the inflammatory immune process of ulcerative colitis.  
In this study we have used the spontaneous chronic colitis mouse model Winnie which 
develops spontaneous distal intestinal inflammation as early as 6 weeks of age and 
progresses over time to severe colitis by 16 weeks (Eri et al., 2011, McGuckin et al., 2011). 
Chronic colitis in Winnie is due to a primary epithelial cell defect due to a point mutation 
in the Muc2 mucin gene resulting in aberrant Muc2 biosynthesis leading  to  endoplasmic 
reticulum stress in intestinal goblet cells and reduced secretion of mucus which is very 
similar to active ulcerative colitis in humans (Pullan et al., 1994) (Heazlewood et al., 2008). 
Winnie mice display symptoms of diarrhoea, ulcerations, rectal bleeding and pain at 
different stages of colitis similar to human disease. Extensive studies done in Winnie has 
proven it to be the best available murine model to study human chronic colitis and its 
pathogenesis (Rahman et al., 2015a, Robinson et al., 2017, Robinson et al., 2016a). The 
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aim of this study was to investigate the therapeutic effect of MCC950 on Winnie and the 
results show a significant reduction of colitis.  
4.3 Methods 
Animals 
All animal experiments were approved by the Animal Ethics Committee of the University 
of Tasmania (Ethics approval number: A16166) and conducted in accordance with the 
Australian Code of Practice for Care and Use of Animals for Scientific Purposes (8th 
Edition 2013). Mice were housed in a temperature-controlled environment with a 12-hour 
day/night light cycle. Individual body weights were assessed daily over an initial 
acclimation period of 7 days. All mice had access to radiation-sterilised rodent feed 
(Barastoc Rat and Mouse, Ridley AgProducts, Australia) and autoclaved tap water for 
drinking ad libitum during experiments. All efforts were made to minimize animals' 
suffering and to reduce the number of animals used.  
Explant Culture  
Mice were euthanized by CO2 asphyxiation. The colons were dissected and removed from 
C57BL/6 and Winnie mice (n=5, 12 weeks). The colon was opened, and the faecal matter 
removed and cut in half lengthways, sectioned into distal and proximal tissue and weighed. 
Tissues are washed in PBS (P3813, Sigma-Aldrich) containing 1% penicillin/streptomycin 
(10000 U/ml) (1% P/S) (15140122, Gibco) three times. Equivalent amount of tissue was 
placed in a 24 well cell culture plate in growth media RPMI 1640 (11875085, Gibco) 
supplemented with 10% FCS (16000044), 1% P/S (15140122, Gibco). The tissues were 
stimulated with 10 ng/ml Lipopolysaccharide (LPS) from Escherichia coli serotype EH100 
(ra) TLRgrade (ALX-581-010-L001, Enzo Life Sciences) for 2 hours. The medium was 
removed and replaced with serum-free medium (SFM) containing MCC950 (0.001-10 μM) 
(AG-CR1-3615, Adipogen), glyburide (200 μM) (10238-21-8, Sigma-Aldrich) and 
incubated for 24 hours at 37 0C in a moist atmosphere of 5% CO2. After which the 
supernatants were removed and centrifuged at 12,000 g at 4 0C for 15 min and stored at -
80 0C for cytokine analysis. Tissue was stored in RIPA buffer (R0278, Sigma-Aldrich) with 
protease inhibitor (4693116001, Sigma-Aldrich) to be analysed by Western blot. 
Supernatants were assayed for cytokine levels by ELISA kits according to the 
manufacturer’s instructions IL-1β (DuoSet, R&D Systems), IL-10 (BMS614-2, 
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Invitrogen), TNF-α (KMC3011 Invitrogen) and concentrations were normalized to the 
weight of the explants. 
Isolation of murine macrophages 
Mice were euthanized by CO2 asphyxiation. Peritoneal macrophages (IP) were isolated 
from the peritoneal cavity of C57BL/6 and Winnie mice (n=4, 12 weeks) by injection of 
10 ml of PBS (P3813, Sigma-Aldrich). After 30 seconds of abdominal massaging, 
peritoneal lavage was performed. Collected peritoneal lavage was washed twice in PBS 
(P3813, Sigma-Aldrich) and plated in 6 well plates suspended in RPMI-1640 (11875093, 
Gibco) medium containing 10% FCS (10437-028, Gibco) 1% P/S (15140122, Gibco) for 
two hours. Non-adherent cells were removed by washing the plate twice with PBS (P3813, 
Sigma-Aldrich). The adherent macrophages were analysed in subsequent experiments. 
Bone marrow derived macrophages (BMDM) cells were isolated from tibiae and femurs of 
C57BL/6 mice and Winnie mice (n=4, 12 weeks) and cultured suspended in RPMI-1640 
(Gibco 11875093) medium containing 10% FCS (Gibco, 10437-028), 1% P/S (15140122, 
Gibco)  and 10 ng/ml human macrophage colony stimulating factor (M-CSF) (130-094-
129, Miltenyi Biotec). Culture medium was exchanged every 3 days. Under these 
conditions, an adherent macrophage monolayer was obtained at 7-8 days. Cells were 
harvested and seeded on 6-well plates. After culturing for 6 hours without M-CSF (130-
094-129, Miltenyi Biotec), the cells were used for the experiments as BMDM. 
For the isolation of Mesenteric lymph node (MLN) macrophages the peritoneal cavity of 
Winnie (n=4, 12 weeks) was opened and the gut was taken out so that the MLN were 
visible. The MLN were excised and placed in chilled PBS (P3813, Sigma-Aldrich). To 
generate a single cell suspension, the MLN were placed on a sterile 70 μm nylon mesh cell 
strainer (22-363-548, Fisher brand) and was mechanically disrupted into the mesh using 
the base of a plunger from a 1 cc syringe. Cells were washed in PBS (P3813, Sigma-
Aldrich) containing 1% FCS (10437-028, Gibco). Cell suspension was decanted through a 
second 70 μm cell strainer (22-363-548, Fisher brand) to remove any remaining cellular 
aggregates or tissue debris. Cells were subjected to gentle centrifugation at 500 g for 5 min. 
Supernatant was decanted and cells re-suspended and cultured in RPMI-1640 medium 
(11875093, Gibco) containing 10% FCS (10437-028, Gibco) and 1% P/S (10437-028, 
Gibco) till an adherent macrophage monolayer was obtained.  
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Single cell LPMC (lamina propria mononuclear cell) suspensions were prepared from 12-
week-old Winnie n=12 mice. The colons were dissected carefully and washed with ice-
cold PBS (P3813, Sigma-Aldrich) and cut in to small pieces. Fragments were placed in 
Hanks’ balanced salt solution (H9269, Sigma-Aldrich) containing 5 mM EDTA (E6758, 
Sigma-Aldrich) and 1 mM DTT (10197777001, Sigma-Aldrich) 37 °C for 40 mins with 
gentle shaking to remove the epithelial layer. The colon segments were then digested in 
PBS (P3813, Sigma-Aldrich) containing 0.5 mg/mL collagenase (C2139, Sigma-Aldrich), 
0.5mg/mL DNaseI (11284932001, Roche) and 3 mg/mL Dispase II (D4693, Sigma-
Aldrich) at 37°C, at slow rotation, for 1.5 hours. Supernatants were collected by filtering 
through a 70 μm cell strainer (22-363-548, Fisher brand). Filtered cells were layered on a 
40/80 Percoll gradient (P4937) and centrifuged at 1000 ×g for 20 min. The separated 
LPMCs were washed twice, and re-suspended and cultured in RPMI-1640 medium (Gibco 
11875093) containing 10% FCS (10437-028, Gibco) and 1% P/S (10437-028, Gibco). 
Cell viability assay 
Cell viability of BMDMs was measured using alamarBlue® reagent (A50101, 
ThermoFisher Scientific). Briefly, 1 × 105 of BMDMs were seeded into each well of a 96-
well plate. The following day, the overnight medium was replaced with serum-free media 
for 12 hours. Cells were then stimulated with different concentrations of MCC950 (AG-
CR1-3615, Adipogen) (0.001, 0.01, 0.1, 1 μM) for 24 h. 10 μl of alamarBlue® reagent was 
added directly to cells in each well and incubated for 4 h at 37 °C. Then, absorbance at 570 
nm was measured. Experiments were repeated three times.  
Inflammasome activation assays 
We seeded BMDMs, IP and MLN macrophages at 5 × 105/ml and LPMCs at 1x105/ml in 
96-well plates. The following day, the overnight medium was replaced, and cells were 
stimulated with 10 ng/ml LPS from Escherichia coli serotype EH100 (ra) TLRgrade (ALX-
581-010-L001, Enzo Life Sciences) for 3 hours. The medium was removed and replaced 
with SFM containing MCC950 (AG-CR1-3615, Adipogen) (0.01 μM), glyburide (10238-
21-8, Sigma-Aldrich) (200 μM), Cells were then stimulated with the following 
inflammasome activators: 5 mM adenosine 5′-triphosphate disodium salt hydrate (ATP) 
(A2382, Sigma-Aldrich) (1 hour), and 10 μM Nigericin (tlrl-nig, Invivogen) (1 hour). 
Supernatants were removed and analysed using ELISA kits according to the manufacturer’s 
instructions IL-1β (DuoSet, R&D Systems), TNF-α (KMC3011, Invitrogen). 
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Western blotting 
Cell lysates were prepared by direct lysis in 50 μl of 2× Laemmli sample buffer (1610737, 
Biorad). The protein content of supernatants was concentrated using StrataClean resin 
(400714, Agilent Technologies) according to the manufacturer’s instructions. The protein 
samples were resolved on 4-20% mini-protean precast SDS-PAGE gels (4561093, Biorad) 
and transferred onto polyvinylidene difluoride membrane (1620177, Biorad) using transfer 
buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol, pH 8.3) in a wet-transfer 
system. Membranes were blocked in 5% (wt/vol) dried milk in TBS-T (50 mM Tris/HCL, 
pH 7.6, 150 mM NaCl and 0.1% (vol/vol) Tween-20) for 1 hour at room temperature. 
Membranes were incubated with primary antibody diluted in 5% (wt/vol) dried milk in 
TBS-T and then with the appropriate horseradish peroxidase (HRP)-conjugated secondary 
antibody (sc-2030, Santa Cruz Biotechnology) diluted in 5% (wt/vol) dried milk in TBS-T 
for 1 hour. Membranes were developed using SuperSignal West Pico chemiluminescent 
substrate (34580, Thermo Fisher Scientific). Membranes were stripped using Restore 
PLUS Western blot stripping buffer (46430, Thermo Fisher Scientific) before being re-
probed. 
Primary antibodies used were ASC antibody (1 in 1,000) (AL177, Enzo Life Sciences); β-
actin; mouse caspase-1 p10 (sc-514, Santa Cruz Biotechnology) (1:1,000), mouse IL-1β 
(NB600-633, Novus Biologicals) (1:1,000) and NLRP3 antibody (1:1,000) (NBP2-
12446SS, Novus Biologicals). Secondary HRP-conjugated antibodies used were, anti-
rabbit IgG and (1:5000) (sc-2030, Santa Cruz Biotechnology). 
Densitometry analysis of Western blot images were performed in Multi Gauge analysis 
software Ver2.0 (FujiFilm). 
In vivo oral administration of MCC950  
Seven-week-old Winnie mice (homozygous Muc2 mutant; C57BL6/J background) n=20 of 
both sexes average weight 18 g were obtained from the University of Tasmania animal 
breeding facility. Mice were randomly divided into two groups. MCC950 used in in vivo 
experiment was a gift from Avril Robertson. MCC950 treatment group: (n=10) and control 
group (n=10). Treatment group mice were fed 1 g of freshly made chow mash (chow 
powder blended with water) mixed with 40 mg/kg MCC950 daily. Control mice received 
the formulation vehicle PBS in 1 g chow mash. The mice were single-caged throughout the 
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experiment to ascertain the defined daily intake of MCC950 from prepared chow mash. 
Mice were sacrificed on day 21. 
Clinical scoring and histological analysis 
Bodyweight, stool consistency and the presence of gross blood in stool and at the anus were 
observed every day. Stool was collected from individual mice and tested for the presence 
of blood using Hemoccult II slides (Beckman Coulter Inc., California, USA). The disease 
activity index (DAI) was calculated by assigning well-established and validated scores 
(Lean et al., 2015). Briefly, the following parameters were used for calculation: a) Stool 
consistency (0 points = normal, 1points = soft but formed, 2 points =loose stool, 3 points= 
watery stool; b) blood in stool (0 points=no bleeding, 1 point= Hemoccult +, 2 points= 
visual blood, 3 points=gross bleeding). At day 21 following treatment, animals were 
sacrificed by CO2 asphyxiation. The colon from the caecum to the anus was removed. The 
length of the colon from ileocaecal junction to the rectum was recorded. The colon was 
subsequently opened along its longitudinal axis and the luminal contents were removed 
prior to weighing the organ. The colon was bisected longitudinally and one half was 
prepared using the Swiss roll technique (Cooper et al., 2000), whereas the remaining 
colonic tissue was dissected and snap-frozen for molecular analyses. Swiss rolls underwent 
24 h fixation in 10% (v/v) neutral-buffered formalin (HT501128, Sigma-Aldrich). Swiss 
rolls were subsequently transferred to 70% ethanol prior to progressive dehydration, 
clearing and infiltration with HistoPrep paraffin wax (SH75-1250, Fisher Scientific). They 
were then embedded in wax and 5 μm sections were cut using a rotary microtome. Sections 
were stained with haematoxylin (HHS16, Sigma-Aldrich) and eosin Y (HT110280, Sigma-
Aldrich). Slides stained with H&E were evaluated for inflammatory features. Histological 
inflammation was graded in a blinded fashion by RF and APP based on criteria (Randall-
Demllo et al., 2016). Briefly, frequency of lamina propria neutrophils graded 0-2, frequency 
of crypt abscesses graded 0-2, crypt architectural distortion was graded 0-2, extent of 
surface damage graded 0-2, goblet cell depletion graded 0-2. The inflammation score for 
each individual region (distal, middle and proximal colon) was derived from the sum of the 
score for each of the aforementioned criteria.  
Cytokine measurements 
Serum was collected from blood drawn by cardiac puncture at the end of the treatment. 
Explants from the proximal and distal colons of treatment and control groups (n = 3) were 
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cultured overnight in RPMI 1640 (11875093, Sigma-Aldrich). Culture supernatants were 
measured for Nitrite by the Griess reaction method (G4410, Sigma-Aldrich) as an index of 
Nitric Oxide generation. 
Cytokine concentrations in neat culture supernatants and serum were determined using 
mouse Bio-Plex mouse cytokine 23-plex panel kit (#M60009RDPD, Bio-Rad) and 
analysed using Bio-Plex 200 system (171000205, Bio-Rad) and Bio-Plex Manager 
software. IL-18 was determined by 5 times diluted supernatant measured by a mouse IL-
18 ELISA kit (7625, R&D Systems). The most significantly altered cytokines are presented 
as pg per g of tissue. 
RNA extraction and RT-PCR 
Colonic tissue was homogenised using Omni Mixer Homogenizer (3410B05, Thomas 
Scientific) and RNA extracted using the RNeasy Mini spin column kit (74104, Qiagen) 
according to the manufacturer’s instructions. Integrity and concentration of extracted RNA 
was assessed using Eppendorf Biophotometer (D30, Eppendorf). Complementary DNA 
(cDNA) was synthesised from RNA samples using the iScript gDNA clear cDNA synthesis 
kit (1725034, Bio-Rad) using reaction conditions suggested by the manufacturer. 100 ng 
of cDNA from each sample was added to a PCR reaction including TaqMan Fast Advanced 
Master Mix (4444557, Applied Biosystems) and a single gene-specific TaqMan 
probe/primer set. IL-1β (Assay ID: Mm00434228_m1, Thermo Fisher Scientific) and IL-
18 (Assay ID: Mm00434226_m1, Thermo Fisher Scientific). 
Thermal cycling was performed using a StepOnePlus Real-Time PCR Systems (4376600, 
Applied Biosystems). Gene expression was quantified using the comparative (ΔΔCT) 
method where the threshold cycle (CT) for each gene was normalised to reference gene 
Gapdh (Assay ID: Mm99999915_g1, Thermo Fisher Scientific). Relative gene expression 
in the MCC950 treated animals was presented as 2-ΔCT. 
NEK7 phosphorylation state analysis by Phos-tag SDS-PAGE 
We seeded J774A.1 (TIB-67, ATCC) at 1 × 105/ml in 6-well plates.  The following day, 
the overnight medium was replaced, and cells were stimulated with 100 ng/ml LPS (ALX-
581-010-L001, Enzo Life Sciences) for 3 hours. The medium was removed and replaced 
with SFM containing MCC950 (AG-CR1-3615, Adipogen) (1 μM) and glyburide (10238-
21-8, Sigma-Aldrich) (200 μM) for 30 min or no treatment with SFM. Cells were then 
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stimulated with 5 mM ATP (A2382, Sigma-Aldrich) for 30 min. Supernatants were 
removed and analysed using ELISA kits according to the manufacturer’s instructions IL-
1β (DY401, DuoSet, R&D Systems). Cell lysates from three wells were pooled in 200 ul 
of RIPA buffer (R0278 Sigma-Aldrich) with protease inhibitor (4693116001, Sigma-
Aldrich). Contaminants were removed in protein samples by TCA precipitation. Samples 
mixed in 2× Laemmli sample buffer (1610737, Biorad) and run in Phos-tag SDS-PAGE 
(192-17401, Wako Chemicals) for the separation of phosphorylated proteins according to 
their degree of phosphorylation. Membranes were developed using SuperSignal West Pico 
chemiluminescent substrate (34580, Thermo Fisher Scientific). Membranes were stripped 
using Restore PLUS Western blot stripping buffer (46430, Thermo Fisher Scientific) before 
being re-probed. Primary antibodies used were NEK7 antibody (Ab109433, Abcam) (1 in 
1,000). Secondary HRP-conjugated antibodies used were, anti-rabbit IgG and (1:5000) (sc-
2030, Santa Cruz Biological). 
Statistical analysis  
Data are presented as average values ± SEM from multiple individual experiments each 
carried out in triplicate measurements in a representative experiment. Change in body 
weight percentage over time was compared using repeated-measures analysis of variance 
(ANOVA). The statistical significance of the normalised mRNA expression was tested by 
one sample t-test. Differences in histological scores between anatomical regions were 
tested post-ANOVA using Tukey’s multiple pairwise comparisons test. Statistical analyses 
were done using a nonparametric an unpaired two-tailed t-test, for two groups study. The 
data were evaluated with one-way analysis of variance (ANOVA) for 3 groups study and 
confirmed using Tukey’s test for multiple comparisons using Prism software (GraphPad). 
Data were considered significant when P ≤ 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***) or P ≤ 
0.0001 (****). 
4.4 Results 
4.4.1 MCC950 inhibits the activation of NLRP3 inflammasome in mouse macrophages 
IL-1β is processed from the inactive cytoplasmic precursor pro-IL-1β which has to be 
cleaved by caspase-1 to produce the mature active form. We examined the ability of 
MCC950 to inhibit the activation of pro-IL-1β by inhibiting the activation of NLRP3 
inflammasome. For our initial experiment we used a concentration of 0.01 µM of MCC950 
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which is close to 0.0075 µM, the half-maximal inhibitory concentration (IC50) of MCC950 
in bone marrow derived macrophages (BMDM) of C57BL/6 mice. We isolated BMDM, 
Intraperitoneal (IP), mesenteric lymph node (MLN) and lamina propria mononuclear cell 
(LPMC) murine macrophages from Winnie and C57BL/6 mice. We could not isolate 
enough MLN and LPMC from C57BL/6 for inflammasome activation experiments.  
The results showed IL-1β release was markedly increased in the macrophages of Winnie 
mice compared with C57BL/6 upon LPS treatment. Cells were then pre-treated with 
MCC950 or glyburide and then stimulated with the NLRP3 agonists ATP or the ionophore 
nigericin. Treating cells with 0.01 µM of MCC950 and 200 µM glyburide significantly 
inhibited the release of IL-1β in BMDMs (Figure 4.1a), IPs (Figure 4.1b) and MLNs 
(Figure 4.1c). Complete inhibition of IL-1β was observed in LPMCs treated with MCC950 
at 1 µM and stimulated with specific NLRP3 stimulants ATP and Nigericin (Figure 4.1d). 
LPS-dependent TNF-α secretion was not impaired by MCC950 in BMDMs (Figure 4.1e), 
which demonstrates that the inhibition of IL-1β secretion was specific. To investigate the 
potential cytotoxicity effect of MCC950, we performed the alamarBlue® cell viability 
assay. The results show that the there is no cytotoxic effects on Winnie BMDM cells against 
MCC950 at 0.001 µM-1 µM (Figure S1). 
The amount of active caspase-1 p10 was reduced in supernatants from MCC950-treated 
Winnie and Wild type BMDMs (Figure 4.1f), suggesting that MCC950 inhibits the 
activation of caspase-1 by NLRP3. Correspondingly, the processing of IL-1β was inhibited 
by MCC950. Similarly, treatment with glyburide inhibited caspase-1 activation and IL-1β 
processing. Western blot densitometry analysis revealed that expression of the 
inflammasome complex proteins such as NLRP3 and ASC was not significantly changed 
during treatment with MCC950 (Figure S2(f)). 
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Figure 4.1:  The effect of MCC950 on NLRP3 inflammasome activation in murine macrophages. 
Production of IL-1β (a) C57BL/6 and Winnie BMDMs (b) C57BL/6 and Winnie IP Macrophages 
(c) Winnie MLNs (d) Winnie LPMCs. Unprimed (UN), primed with 10 ng/ml LPS and treated with 
MCC950 (MCC) (a-c-0.01 µM, d-1 µM ) and Glyburide (Gly) (200 µM) and stimulated with ATP 
and Nigericin as measured by ELISA. (e) Production of TNF-α for Winnie BMDM supernatants 
treated with MCC950 0.01 µM and glyburide 200 µM and stimulated with ATP and Nigericin as 
measured by ELISA. Data are expressed as the mean ± sem of three independent experiments 
carried out in duplicates. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA with Tukey’s 
post-hoc test). (f) Western blots of cell lysates and supernatants from C57BL/6 and Winnie BMDMs 
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primed with 10ng/ml LPS and treated with MCC950 (0.01 µM) or glyburide (200 µM) and 
stimulated with ATP. These results are representative of three independent experiments. 
4.4.2 MCC950 inhibits the activation of NLRP3 inflammasome in colonic explants 
To further explore the effect of MCC950 on NLRP3 inflammasome activation in colitis, 
we investigated the release of IL-1β in treated Winnie colonic tissue explants by ELISA. 
Non-treated Winnie distal colon produces 12, 307 pg/g which is comparatively higher than 
the 7623.5 pg/g released by proximal colon tissue. MCC950 exhibited a concentration-
dependent inhibition of IL-1β secretion from LPS treated Winnie proximal and distal colon 
explant tissue (Figure 4.2a). Treating colon explant with 10µM concentration of MCC950 
was able to significantly reduce the release of IL-1β in proximal colon to 48.6% P<0.001 
and the distal colon to 56.2% P< 0.01 (Figure 4.2b). LPS-dependent tumour necrosis factor-
α (TNF-α) secretion was not impaired by 1 µM MCC950 and 200 µM glyburide (Figure 4. 
2c) which demonstrates that the inhibition of IL-1β secretion was specific. The Western 
blot analysis showed that 1 µM MCC950 and 200 µM glyburide significantly inhibited the 
activation of caspase-1 in to the cleaved form caspase-1 p10. Correspondingly, 1 µM 
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Figure 4.2: MCC950 inhibits NLRP3 inflammasome activation in colonic explants. (a) Production 
of IL-1β from Winnie proximal and distal colons stimulated with 10ng/ml LPS and treated with 
MCC950 (MCC) (0.001-10 µM) and Glyburide (Gly) 200 µM as measured by ELISA. 
(b)Percentage of IL-1β release of Winnie proximal and distal colons stimulated with LPS no 
treatment compared to treated with MCC950 (10 µM) as measured by ELISA. (c) Production of 
TNF-α for proximal and distal colonic explant supernatants treated with MCC950 (1 µM) and 
glyburide 200 µM as measured by ELISA. Data are expressed as the mean±SEM of five 
independent experiments carried out in duplicates. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way 
ANOVA with Tukey’s post-hoc test). (d) Western blots of tissue lysates and Supernatants from 
proximal and distal colons stimulated with 10ng/ml LPS and treated with MCC950 (1 µM) or 
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4.4.3 Oral administration of MCC950 attenuates colonic inflammation in Winnie 
The macrophage cell in vitro data and colon explant data suggested that MCC950 
effectively inhibited NLRP3 inflammasome assembly and may be key to controlling colitis. 
To assess this, we examined the effect of MCC950 (40 mg/kg) in seven-week-old Winnie 
mice, administered orally for three weeks, in a spontaneous colitis mouse model Winnie. 
Throughout the experiment, mice were monitored for the clinical symptoms of colitis. 
Macroscopic observation of the 10-week control Winnie colon at experimental termination 
showed the colons to be visibly inflamed with shortening and thickening of colon wall with 
enlarged mesenteric lymph nodes when compared to MCC950 treated 10-week Winnie in 
(Figure 4.3a). The mean colon length of the MCC950 treated group 8.390±0.1080 was 
significantly (P<0.01) longer than the mean colon length of the control group 7.870 ± 
0.01212 (Figure 4.3b).  
MCC950 40 mg/kg prevented the shortening of the colon which is positively related to the 
severity of colitis. Wet colon weight, an indicator of intestinal oedema and inflammation, 
was presented as the ratio of colon weight over body weight (g/g). The untreated colitis 
group showed the highest relative weight 0.02152±0.00096. MCC950 treatment 
significantly (P<0.05) reduced the mean to 0.01902±0.00060 (Figure 4.3C). 
To determine the therapeutic potential of MCC950 on colitis we characterised the control 
and treatment group by clinical parameters such as percentage of body weight gain and 
disease activity index (DAI) which is an average score of stool consistency, and blood in 
stool. As shown in Figure 4.3d in contrast to the control mice which gained 10.59% body 
weight over 21 days, MCC950 treated mice showed an average of 15.07% body weight 
increase. However, the body weight increase was not statistically significant between the 
control and treatment groups.  MCC950 40 mg/kg significantly improved the DAI as early 
as the 9th day of treatment showing the highest significance at day 21 P<0.001 (Figure 
4.4a). The increase in body weight correlated with a significant decrease in DAI for the 
MCC950 treated group. The relationship between these two clinical parameters was 
significant at P<0.0001 with a spearman’s correlation of r=0.9342. 
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Figure 4.3: Effect of MCC950 on Winnie. Winnie at 10 weeks were weighed on the day of 
termination. Lengths of the freshly removed colons from each group were measured from ileocecal 
junction to rectum. The weight of the colons after removing luminal content was recorded. (a) 
Macroscopic appearances and (b) Colon Length for each group. (c) Ratio of colon weight over body 
weight. Data are expressed as the mean±SEM (n=10 per group) *P < 0.05, **P < 0.01 (two-tailed 
Student’s t test). (d) Body weight of mice was measured every 3 days and presented as a percentage 
of their initial weight. Data are represented as means ± SEM (n=10 per group) repeated-measures 
analysis of variance (ANOVA). 
 
Histological analysis showed infiltration of neutrophils (Figure 4.4c), severe surface 
epithelial damage (Figure 4.4d), crypt abscesses (Figure 4.4e), distortion of crypt 
architecture (Figure 4.4e), and complete loss of crypts (Figure 4.4e), particularly in the 
distal colon of colitis mice compared to MCC950 treated mice (Figure 4.4f-h). The results 
of standard pathological examination of mouse colon reflected in a histological score 
showed much improvement in pathological changes in mice treated with 40 mg/kg of 
MCC950 which was statistically significant for distal colon at a P<0.001. The comparative 
histological score of the mid colon was lower in the MCC950 group, however it was not 
statistically significant. These data reveal that MCC950 improves clinical and histological 
changes in the colon associated with spontaneous colitis. 
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Figure 4.4: MCC950 treatment improves colitis in 10-week-old Winnie. (a) Disease activity index. 
(b) Comparison of summed inflammation scores between control and treatment Winnie mice. PC, 
proximal colon, MC, middle colon, DC, Distal Colon. Data are represented as means ± SEM (n=10 
per group) *P < 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA with Tukey’s post-hoc test).  
(c-e) Representative Winnie control proximal, middle and distal colon sections stained with 
hematoxylin and eosin at 100x and 400x. (c) Lamina propria inflammatory cell infiltrates (black 
arrow) (d) epithelial surface damage (red arrow), goblet cell loss (black arrow) (e) Crypt abscesses 
with neutrophils in the lumen and nearly intact epithelium (red arrow) or damaged epithelium and 
complete crypt loss (blue arrow) and crypt architectural distortion (black arrow). (f-h) 
Representative MCC950 treated Winnie proximal, middle and distal colon sections stained with 
hematoxylin and eosin at 100x and 400x.   
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4.4.4 Oral administration of MCC950 suppresses colonic IL-1β and IL-18 expression 
in Winnie 
 
Figure 4.5: MCC950 suppressed NLRP3 activated proinflammatory cytokine levels in colon 
explant of Winnie mice. Protein levels of cytokines (a) IL-1β (b) IL-18 in C57BL/6, Winnie and 
MCC950 treated Winnie proximal and distal colon explant supernatants as determined by Bio-plex. 
Data presented as means ± SEM (n=3 per group) *P < 0.05, **P < 0.01 (two-tailed Student’s t test). 
The mean values of fold change in mRNA expression levels for (c) IL-1β (d) IL-18 in MCC950 
treated Winnie proximal and distal colon tissue are shown relative to the untreated Winnie proximal 
and distal control samples respectively. Both control and treated values were normalised to those 
of the internal control GAPDH, with treated values representing the fold change relative to that 
of controls, which was converted to 1. Data are expressed as the mean±SEM (n=4 per group) *P 
< 0.05, **P < 0.01 ***P < 0.001 (one sample t test). 
To determine the effect of MCC950 on IL-1β and IL-18 cytokine production in colitis mice, 
cytokine expression in colonic tissue at both mRNA and protein levels in both groups were 
measured. MCC950 treatment was able to significantly (P<0.05) suppress IL-1β cytokine 
in proximal and distal colon compared to control group colons (Figure 4.5a). The 
suppression of Il-18 was at a significant level at proximal colon P<0.01 and distal colon at 
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P<0.05 (Figure 4.5b). Total RNA of colons was extracted and analysed for cytokine mRNA 
expression using quantitative real time PCR method. MCC950 treatment was able to 
significantly suppress IL-1β mRNA relative expression in proximal colon to 0.5277 
(P<0.01) and distal colon to 0.1749 (P<0.01) (Figure 4.5c) and IL-18 mRNA relative 
expression in proximal colon to 0.3016 (P<0.001) and distal colon to 0.4606 (P<0.01) 
(Figure 4.5d).  
4.4.5 Oral administration of MCC950 reduces colonic proinflammatory cytokines  
While the mucosal explants isolated from Winnie colon control group actively secreted 
multiple proinflammatory cytokines (IL1-α, IFN-γ, TNF-α, IL-17 and IL-6), chemokine 
(MIP1a) and Nitric Oxide during 24-hour culture, MCC950 treatment effectively 
suppressed their release (Figure 4.6). 
IL1-α was highly suppressed in MCC950 treated proximal and distal colons (P<0.01) 
(Figure 4.6a). IFN-γ was suppressed in MCC950 treated proximal colon, however it was 
not statistically significant. IFN-γ was strikingly suppressed in the distal colon (P<0.001) 
(Figure 4.6b). TNF-α was suppressed in MCC950 treated proximal colon however it was 
not statistically significant. In the distal colon TNF-α was significantly suppressed 
(P<0.001) (Figure 4.6c). MIP1a also known as the CCL3 chemokine was suppressed in 
MCC950 treated proximal colon however it was not statistically significant. In the distal 
colon MIP1a was effectively suppressed (P<0.01) (Figure 4.6d). IL-17 was highly 
suppressed in MCC950 treated proximal and distal colons (P<0.05) (Figure 4.6e). IL-6 was 
also highly suppressed in MCC950 treated proximal and distal colons (P<0.01) (Figure 
4.6f). Interestingly MCC950 had no effect in blood plasma proinflammatory cytokines 
(IL1-β, IL1-α, TNF-α, IFN-γ, IL-17 and IL-6) and chemokine (MIP1-a) levels when 
compared to control group at the termination day at 24 hours after final treatment (Figure 
4.6g). Nitrite was measured as an index of Nitric Oxide generation and was highly 
suppressed in MCC950 treated proximal and distal colons (P<0.01) (Figure 4.6h). 
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Figure 4.6: MCC950 suppressed proinflammatory cytokine and chemokine production in colon 
tissues but not in blood serum. Protein levels of cytokines including (a) IL1α (b) MIP1a (c) IL17 
(d) IFN-γ (e) TNF-α in explant supernatants (f) IL-1β, IL-1α, MIP1a, IL17, IFN-γ, and TNF-α in 
blood serum were determined by Bio-plex. Data are presented as means±SEM (n=3) *P < 0.05, **P 
< 0.01, ***P < 0.001 (two-tailed Student’s t test). 
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4.4.6 MCC950 and Glyburide do not target NEK7-NLRP3 interaction  
 
Figure 4.7: J774A.1 cells were primed with 100 ng/ml LPS and inhibited with 1 µM MCC950 or 
200 µM Glyburide then stimulated with 5 mM ATP. (a)The phosphorylation state of NEK7 was 
analysed using Phos-tag SDS-PAGE. These results are representative of three independent 
experiments. (b) ELISA analysis of IL-1β in the culture supernatant of J774A.1 cells treated as in 
(a). Data are expressed as the mean ± sem of three independent experiments carried out in 
duplicates. ***P < 0.001 (one-way ANOVA with Tukey’s post-hoc test). 
NEK7 undergoes phosphorylation during the interaction with NLRP3 component and the level of 
phosphorylation correlates to the activation of the inflammasome (Shi et al., 2016). To examine 
the possibility of MCC950 and glyburide targeting the NEK7-NLRP3 interaction, we 
assessed the phosphorylation component of NEK7. We primed the murine macrophage cell 
line J744A.1 with LPS and applied the inhibitors and activated the NLRP3 inflammasome with 
ATP and analysed the level of NEK7 phosphorylation using Phos-tag SDS-PAGE. The Phos-
tag SDS-PAGE blot analysis showed that the level of phosphorylated NEK7 band was the same 
size for MCC950 and glyburide and the untreated sample (Fig. 4.7a). This result concludes that 
both the inhibitors did not react by inhibiting the NEK7-NLRP3 interaction. The IL-1β levels were 
suppressed by the inhibitors, recognizing that the inhibitors were effective (Fig. 4.7b).  
4.5 Discussion 
The study describes for the first time the oral administration of MCC950 in the spontaneous 
colitis murine model Winnie. The most salient finding of the study is that MCC950 
decreased the severity of chronic colitis in Winnie mice by specific inhibition of NLRP3 
inflammasome activation. In addition, MCC950 treatment significantly decreased the 
expression of proinflammatory cytokines IL-1β and IL-18 at mRNA and protein level and 
the associated release of proinflammatory cytokines and chemokine in Winnie colonic 
 
 
Agampodi Promoda Perera 
ROLE OF NLRP3 IN COLITIS AND COLITIS ASSOCIATED COLORECTAL CANCER   68 
 
tissue. Moreover, MCC950 resulted in a significant decrease of IL-1β and active caspase-
1 in Winnie explants and in vitro macrophage cells isolated from Winnie mice. Our data 
shows that the NLRP3 inflammasome plays a negative role in the chronic phase of 
ulcerative colitis in Winnie. The results collectively suggest that MCC950 acts as an 
effective therapeutic compound for the treatment of murine ulcerative colitis. 
The results show that IL-1β is released more in the Winnie distal colon when compared to 
the proximal colon. This explains why MCC950 is more effective in the distal colon and 
shows more improvement with MCC950. We further analyzed the Winnie explant IL-1β 
ELISA data treated at 10 µM, as this high dose will ensure complete efficacy in NLRP3 
inflammasome inhibition even in the presence of explant serum. The results show that the 
NLRP3 specific inhibitor MCC950 at 10 µM inhibited the release of IL-1β in proximal 
colon by 51.4% and the distal colon by 43.7 %. This is an important finding as this indicates 
the percentage of canonical and non-canonical NLRP3 inflammasome contribution to the 
overall IL-1β in the spontaneous colitis colon of Winnie mice. High NLRP3 expression has 
been found in the ulcerated colonic tissue and in the colon of mice with acute and chronic 
colitis (Villani et al., 2009). Accumulating evidence support a pro-inflammatory 
contribution of NLRP3 to colitis pathology (Allen et al., 2010, Liu et al., 2013). It is 
reported that blockage of IL-1β (Thomas et al., 1991) or neutralization of IL-18 (Sivakumar 
et al., 2002, Ten Hove et al., 2001) reduces intestinal inflammation. These findings support 
the detrimental role of the NLRP3 inflammasome in the development of spontaneous colitis 
in Winnie which is supported by both DSS model (Bauer et al., 2010) and Il-10-/- model of 
colitis (Zhang et al., 2014a). The explant results show that selective inhibition of the 
NLRP3-inflammasome with MCC950 dose dependently reduces activated IL-1β secretion 
from colon tissue simulating a clinically feasible treatment regimen. 
A study by Bauer et al., 2010 has proved that the mechanism of NLRP3/ASC/caspase-1 
mediated activation of proinflammatory IL1-β and IL-18 is essential for experimental 
colitis (Bauer et al., 2010). The Western blot results of the in vitro experiments showed that 
treatment with MCC950 significantly reduced the active caspase-1 p10 and IL-1β in 
BMDMs and colon explants suggesting that MCC950 inhibits the activation of NLRP3 
inflammasome in the colitis model. Similarly, treatment with glyburide inhibited caspase-
1 activation and IL-1β processing as seen in protein quantification assays.  
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For the in vitro experiments we chose to use primary macrophages because NLRP3 and 
ASC complex is mainly expressed in these innate immunity cells (Kummer et al., 2007) 
and they have a vigorous inflammasome activation and IL-1β production. The primary 
macrophage cells isolated from Winnie had a higher secretion of IL-1β in comparison to 
C57BL/6 indicating active colitis in Winnie. Similarly it is seen in murine DSS models 
(Arai et al., 1998) and human colitis patients (Ligumsky et al., 1990) where active colitis 
and its severity has been correlated to high levels of IL-1β secreted by activated 
macrophages. Intestinal inflammation is associated with infiltration of macrophages into 
the colon lamina propria where a variety of inflammatory cytokines are produced in 
response to intestinal microbes. A very recent research in gut microbiota has shown that 
NLRP3 is absent in the epithelium but present in the deeper residing lamina propria 
mononuclear cells (Yao et al., 2017a). The in vitro results on LPMCs show complete 
inhibition of IL-1β by 1 µM of MCC950, which explains how MCC950 attenuated colonic 
inflammation in the in vivo spontaneous colitis model Winnie. 
For in vitro experiments apart from MCC950 we have also used glyburide, another specific 
inhibitor of NLRP3 inflammasome (Lamkanfi et al., 2009).  A recent study investigated 
the effect of glyburide in Il-10-/- spontaneous Crohn’s disease mouse model (Liu et al., 
2016a). Very similar to the results with MCC950 in Winnie mice, glyburide effectively 
suppressed NLRP3 inflammasome activation in Il-10-/- mice, leading to attenuation and 
prevention of colitis. Moreover, glyburide also effectively inhibited the release of 
proinflammatory cytokines and chemokines in a similar manner to MCC950 effect in the 
Winnie model. Our in vitro results with glyburide show that it is effective in inhibiting 
NLRP3 inflammasome in a spontaneous ulcerative colitis mouse model. Further in vivo 
studies should be conducted to evaluate the potency of glyburide in the Winnie. However 
in comparison to glyburide, MCCC950 has superior pharmacological characteristics such 
as higher potency (7.5 nM) , oral bioavailability (68%), temporal application and no known 
side effects (Coll et al., 2015). Current experimental NLRP3 inhibitors of colitis are applied 
parenterally (Guo et al., 2014, He et al., 2016a), however in our study we have shown 
effective oral administration with MCC950 which is more clinically desirable than 
parenteral application. 
 In the study MCC950 treatment significantly improved clinical parameters of body weight 
gain, colon length, bloody stool and stool consistency. Similarly, histopathological findings 
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supported that MCC950 protected Winnie mice from surface epithelial erosion, 
inflammatory cell infiltration, loss of goblet cells and disruption of crypt architecture. 
These findings indicate oral administration of specific NLRP3 inhibitor MCC950 at 
40mg/kg decreased the severity of spontaneous chronic colitis in Winnie mice. 
Ulcerative colitis is characterized by a disturbed balance between regulatory and effector 
cells which mainly implicates effector T cells (Th1 and Th2), regulatory T cells (Tregs) and 
Th17 cells (Marquez-Flores et al., 2016). The intestinal inflammation is characterized by a 
Th1- and Th17-mediated responses with enhanced expression of TNF-α, IFN-γ, IL-1β, IL-
12, IL-6, IL-10 and IL-17 (Kmiec et al., 2017). In this regard, Winnie 10-week colon 
explants showed prominently significant increase in IL-1β, IL1-α, IL-18, TNF-α, IFN-γ, 
and MIP1-a when compared to C57BL/6 (Figure 4.6a-f). This establishes the experimental 
model 10-week-old Winnie, as a clinically relevant model of chronic ulcerative colitis. 
Importantly the results demonstrated that MCC950 treatment significantly reduced IL-1β, 
IL-1α, IL-17, IL-6, IFN-γ, TNF-α and MIP1-a in the colitis colon (Figure 4.6a-f). Similarly 
treatment with MCC950 has been reported to have reduced proinflammatory cytokines and 
chemokines in other inflammatory diseases such as Influenza A virus infection (Tate et al., 
2016), in renal inflammation (Krishnan et al., 2016) and a dermal inflammation model 
(Primiano et al., 2016). MIP1-a (CCL3), is a chemokine that attracts proinflammatory 
cytokine production and is particularly alleviated in Winnie distal colon. However, after 
oral treatment with MCC950 the MIP1-a levels were significantly lowered. Increased 
generation of Nitric Oxide leads to excessive production of reactive nitrogen species 
resulting in infiltration of inflammatory cells and intestinal damage (Sánchez-Fidalgo et al., 
2010). MCC950 treatment significantly reduced nitrite which is an index for Nitric Oxide 
production significantly in Winnie proximal and distal colon. 
From these results we can conclude that MCC950 inhibition of NLRP3 inflammasome has 
indirectly suppressed the activation of infiltrating macrophages by inhibiting the release of 
pro-inflammatory cytokines, chemokine immunomodulators and Nitric Oxide that 
contributed to the chronic inflammatory process in the Winnie colon. MCC950 is absorbed 
into the blood stream and is cleared within a window of time. Initially it will be efficacious 
in the reduction of IL-1β, however proinflammatory cytokines measured in blood plasma 
taken after 24 hours of treatment did not show any effect on systemic cytokines. This 
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suggest that MCC950 did not have a prolonged adverse systemic effect but its potency on 
reducing proinflammatory cytokines was significant at the colonic tissue. 
We investigated the possibility of MCC950 and glyburide target to be the NEK7-NLRP3 
interaction.  Shi et al has shown that NEK7 phosphorylation enhances its binding to NLRP3 
and promotes inflammasome activation (Shi et al., 2016). Our results showed no difference in the 
level of phosphorylated NEK7 between the untreated and MCC950 or glyburide treated samples. 
However, the IL-1β levels were suppressed by the inhibitors conceding that they successfully 
blocked the activation of NLRP3 activation. This result suggest that the inhibitory target is not 
NEK7-NLRP3 but is downstream of this interaction. 
The role of NLRP3 inflammasome in colitis is controversial. Genetic ablation of genes of 
NLRP3 components are predisposed to colitis and colorectal cancer (Allen et al., 2010). 
However, hyper activation of NLRP3 inflammasome leads to colitis (Neudecker et al., 
2017). This stresses the need for careful investigation of temporal therapeutic strategies in 
different disease phases in clinically relevant age appropriate experimental models. The 
findings from Tate et al on MCC950 treatment for influenza A virus shows that blockade 
of NLRP3 is detrimental at early stage of disease while protective at late stage of disease 
(Tate et al., 2016). Interestingly the results show that MCC950 is therapeutic in ulcerative 
colitis at chronic phase of the disease. Further studies are needed to look at emerging colitis 
to choose the optimal clinical treatment point of MCC950 for ulcerative colitis. 
4.6 Conclusion 
In conclusion, the results collectively suggest that the small molecule MCC950 paves the 
way for a novel therapeutic strategy in ulcerative colitis. The results show, for the first time, 
the contribution of anti-inflammatory effects resulting exclusively from inhibition of 
canonical and non-canonical NLRP3 inflammasome activation in colitis. Moreover, the 
ability of MCC950 to suppress both translational and transcriptional IL-1β and IL-18 of 
canonical and noncanonical NLRP3 inflammasome in the colon may be promising in 
inflammatory intestinal diseases other than ulcerative colitis. Nevertheless, the detailed 
mechanism of the pharmacological target of how MCC950 inhibits the activation of 
NLRP3 inflammasome needs to be explored in a future study.  
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4.7 Supplementary data  
SUPPLEMENTARY FIGURE S1. AlamarBlue® Cell viability assay results. 
Data represents the mean viability ± SEM from duplicate determinations and representative 
of three independent experiments.  

























SUPPLEMENTARY FIGURE S2. Western blot densitometry analysis graph of IL-1β, 
caspase-1, ASC, NLRP3 density analysis relative to β-Actin The densitometry data are 
expressed as the mean ± SEM of n=3 experiments. *P < 0.05 (Two-way ANOVA with 
Bonferroni post-test). Uncropped Western blot images (b-f), represents full-length Western 
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SUPPLEMENTARY FIGURE S3. Uncropped Western blot images (a-e). This figure 
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SUPPLEMENTARY FIGURE S4. Uncropped Western blot images (a-c). This figure 
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Chapter 5 
  Clinical, histopathological and cytokine assessment of 
Winnie x Nlrp3-/- mouse colon          
5.1 Introduction 
Nlrp3-/- mice has been used extensively to study the function of NLRP3 in the intestine 
through experimental colitis (DSS) and CAC (AOM/DSS) disease models. However, to 
date the results have been controversial with reports of both protective and deleterious 
effects (Zambetti and Mortellaro, 2014). The conflicting data in the above experimental 
models could be due to the different chemical methods used in colitis induction and 
alteration in the gut microbiota between different animal facilities. This study aimed to 
address the above experimental errors and examine intestinal immune pathways in carefully 
controlled spontaneous colitis mice deficient in the Nlrp3 gene. The novel mouse model 
Winnie x Nlrp3-/- was generated to ascertain the functional role of NLRP3 inflammasome 
in spontaneous colitis. Please refer to section 2a.2 for detailed methodology of the 
generation of Winnie x Nlrp3-/-. 
Genetically modified Nlrp3 mouse models are used for studying the role of the NLRP3 
inflammasome in immune responses in many inflammatory diseases such as Muckle-Wells 
syndrome, colitis, metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease, 
gout, atherosclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s (Guo et al., 
2015a).  
Nlrp3R258W mice carry a gain of function mutation in the gene coding for NLRP3 and were 
used to study diseases such as Muckle-Wells syndrome and familial cold autoinflammatory 
diseases caused by an excessive secretion of IL-1β (Hoffman et al., 2001, Martinon et al., 
2009). However, Nlrp3R258W mice with enhanced inflammasome signalling do not display 
an inflammatory pathology of the intestine. A recent study has shown that this is due to an 
excess of local IL-1β production, but not IL-18, that reshapes intestinal microbiota to 
induce local Tregs, to maintain intestinal homeostasis (Yao et al., 2017b).  
Genetic Nlrp3 deficiency in Nlrp3-/- mice attributes to a long-life span and has been shown 
to protect these mice from age related increases in inflammation (Youm et al., 2013). 
Another study comparing WT and Nlrp3-/- littermates discovered 10 bacterial genera 
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clearly enriched in the faecal microbiota of Nlrp3-deficient animals (Hirota et al., 2011). 
Additionally, we and others have found the colon phenotype of Nlrp3-/- mice to be healthy 
and similar to WT mice with base levels of inflammatory markers (Youm et al., 2013, 
Zambetti and Mortellaro, 2014).  
The Winnie mice phenotype has been extensively studied based on clinical, histological, 
molecular and immunological aspects, and it is a well-established spontaneous chronic 
colitis model (Heazlewood et al., 2008, Eri et al., 2011, McGuckin et al., 2011). The 
involvement of both the adaptive and innate immune system is well showcased in Winnie 
mice colitis. Winnie mice develop spontaneous colitis without chemical induction and 
mimic human UC and hence the best option to explore the role of the NLRP3 function in 
colitis. 
In this chapter, primary level assessment of Winnie x Nlrp3-/- mouse colon pertaining to 
clinical parameters, changes in the histopathology, biochemical analysis, and cytokine 
profile are outlined (Figure 5.1). The Winnie x Nlrp3-/- parameters were evaluated at age 
12 weeks and 16 weeks in comparison to C57BL/6J (WT), Winnie and Nlrp3-/- control 
mouse models at 12 weeks. Both Winnie and Nlrp3-/- mouse models were generated from 
a C57BL/6J background.  
Figure 5.1: Schematic representation of phenotype analysis. 
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All animal experiments were approved by the Animal Ethics Committee of the University 
of Tasmania (Ethics approval number: A14095) and conducted in accordance with the 
Australian Code of Practice for Care and Use of Animals for Scientific Purposes (8th 
Edition 2013). Mice were housed in a temperature-controlled environment with a 12-hour 
day/night light cycle. Individual body weights were assessed daily over an initial 
acclimatisation period of 7 days. All mice had access to radiation-sterilised rodent feed 
(Barastoc Rat and Mouse, Ridley AgProducts, Australia) and autoclaved tap water for 
drinking ad libitum during experiments. All efforts were made to minimize animals’ 
suffering and to reduce the number of animals used. Please refer to section 2a.2 for detailed 
methodology of the generation of Winnie x Nlrp3-/-. 
Clinical analysis and histological scoring  
At week 12 and week 16 animals of all four groups were sacrificed by CO2 asphyxiation. 
The colon from the caecum to the anus was removed. The length of the colon from ileo-
caecal junction to the rectum was recorded. The colon was subsequently opened along its 
longitudinal axis and the luminal contents were removed prior to weighing the organ. The 
colon was bisected longitudinally, and one half was prepared using the Swiss roll technique, 
whereas the remaining colonic tissue was dissected and snap-frozen for molecular analyses. 
Swiss rolls underwent 24 h fixation in 10% (v/v) neutral-buffered formalin (HT501128, 
Sigma-Aldrich). Swiss rolls were subsequently transferred to 70% ethanol prior to 
progressive dehydration, clearing and infiltration with HistoPrep paraffin wax (SH75-1250, 
Fisher Scientific). They were then embedded in wax and 5 μm sections were cut using a 
rotary microtome. Sections were stained with haematoxylin (HHS16, Sigma-Aldrich) and 
eosin Y (HT110280, Sigma-Aldrich). Slides stained with H&E were evaluated for 
inflammatory features, hyperplasia, low and high-grade dysplasia and invasive carcinoma 
(Table 5.1). Histological scoring was performed in a blinded fashion by the Launceston 
General Senior Pathologist based on criteria detailed in Table 5.2. The histological score 
for each individual region (distal, middle and proximal colon) was derived from the sum of 
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Cytokine and Biochemical measurements 
Serum was collected from blood drawn by cardiac puncture at the end of the treatment. 
Explants from the proximal and distal colons of treatment and control groups (n = 3) were 
cultured overnight in RPMI 1640 (11875093, Sigma-Aldrich). Cytokine concentrations in 
neat culture supernatants and serum were determined using mouse Bio-Plex mouse 
cytokine 23-plex panel kit (#M60009RDPD, Bio-Rad) and analysed using Bio-Plex 200 
system (171000205, Bio-Rad) and Bio-Plex Manager software. IL-18 was determined by 
5 times diluted supernatant measured by a mouse IL-18 ELISA kit (7625, R&D Systems). 
The most significantly altered cytokines are presented as pg per mg of tissue. Tissue 
homogenates were measured for myeloperoxidase activity using the colorimetric activity 
assay kit (ab105136, Abcam) according to manufacturer’s instructions. Tissue 
homogenates were measured for inducible Nitric Oxide synthase activity using the 
inducible Nitric Oxide synthase fluorometric activity assay kit (ab211084, Abcam) 
according to manufacturer’s instructions. Data presented as fold changes compared to WT 
group. Blood serum was measured for C reactive protein using the kit Mouse C-Reactive 
Protein/CRP Quantikine ELISA Kit (MCRP00, R&D Systems) according to 
manufacturer’s instructions. 
Immunohistochemistry  
Slides were dewaxed and exposed to heat-induced epitope retrieval (4 min at 121 ℃) in a 
10 mmol/L sodium citrate buffer (C9999, Sigma-Aldrich) pH 6.0 in a decloaking chamber 
(DC2012, Biocare Medical). Slides were cooled to room temperature and washed in 0.1 
mol/L TBS (50 mM Tris/HCL, pH 7.6, 150 mM NaCl) for 2 min per wash. Endogenous 
peroxidase activity was blocked by incubating slides in 3% H2O2 (H1009, Sigma-Aldrich) 
in Methanol (322415, Sigma-Aldrich) for 20 min, followed by 3 × 2 min washes (twice 
with dH2O, followed by one wash with TBS). Background sniper (BS966, Biocare 
Medical) was applied to the slides for 20 min and washed off with 3 × 2 min washes with 
TBS. Slides were incubated with either anti-Oxoguanine 8 antibody (ab64548, Abcam), at 
a 1:300 dilution, Anti-gamma H2A.X (ab11174, Abcam) at a 1:300 dilution, Anti-NQO1 
antibody (ab28947, Abcam) at a 1:300 dilution, Anti-3-Nitrotyrosine antibody (ab61392, 
Abcam) at a dilution of 1:300 was incubated with the slides for overnight. Excess primary 
antibody was removed with 3 × 2 min washes with TBS prior to application of HRP-
conjugated anti-rabbit (M3R531, Biocare Medical) or anti-mouse secondary antibody 
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(MHRP520, Biocare Medical)  for 30 min. Slides were thoroughly rinsed with TBS for 3 
× 2 min washes before the addition of a diaminobenzidine (DAB) chromogen solution 
(DB801, Biocare Medical) for 4 min. Tissue was subsequently counterstained with 
haematoxylin (HHS16, Sigma-Aldrich), dehydrated and mounted with DPX (06522, 
Sigma-Aldrich). Slides were examined through a microscope (IX71, Olympus) and images 
captured using the attached microscope camera (DP21, Olympus).  
Statistical analysis  
The statistical tests were clarified in related text or legends, all tests are two-sided unless 
otherwise specifically explained. 
5.3 Results 
5.3.1 Assessment of clinical parameters 
Body Weight  
As part of the clinical assessments, all mice of the four strains (WT, Nlrp3-/-, Winnie, 
Winnie x Nlrp3-/-) aged 12 weeks and 16 weeks of either sex were utilised for this study. 
The body weight of mice (n=10 per group) from all four genotypes were noted prior to 
sacrifice and the averaged body weight was calculated (WT 21.31 g, Nlrp3-/- 23g, Winnie 
18.7g, Winnie x Nlrp3-/- 12wk 17.9g and Winnie x Nlrp3-/- 16wk 18.4g). All strains were 
then compared to WT strain (Figure 5.2). It was noted that the Winnie x Nlrp3-/- mice at 12 
weeks exhibit significantly less (P-value <0.001) body weight relative to WT control. 
Figure 5.2: Mean Body weight (g) of the four experimental mouse strains. The data are 
representative of n=10 per group and are shown as the means±SEM. *P<0.05, (One-way ANOVA 
Dunn’s Multiple comparison test).  
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Colon length  
Colons from WT, Winnie, Nlrp3-/-, and Winnie x Nlrp3-/- (n=12 per group), were retrieved 
and length was measured from the ileo-caecal junction up to the proximal rectum. 
Macroscopic observation of Winnie and Winnie x Nlrp3 -/- colons showed the colons to be 
visibly inflamed with shortening and thickening of colon wall with enlarged mesenteric 
lymph nodes when compared to WT and Nlrp3-/- controls (Figure 5.3A).  
Figure 5.3: A. Colon images of the four experimental mouse strains from the cecum–colon junction 
to the anus end of a loosely stretched colon with a straight ruler. B. The data are representative of 
n=12 per group and are shown as the means±SEM. *P<0.05, **P<0.01 (One-way ANOVA Dunn’s 
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The mean colon length between the four genotypes were the following: WT–7.89 cm, 
Winnie –7.07 cm, Nlrp3-/- – 7.86 cm, Winnie x Nlrp3-/- 12 week –7.04 cm and Winnie x 
Nlrp3-/- 16 week 18.4g-7.19 cm. The colon length was compared to WT control and results 
showed statistically significant shortening between Winnie at P-value <0.01, Winnie x 
Nlrp3-/- 12 week at P-value <0.01 and Winnie x Nlrp3-/- 16 week at a P-value <0.05. The 
mean colon length Nlrp3 -/- showed increase colon lengthening, however it failed to achieve 
a statistical significance (Figure 5.3B). 
Colon weight/Body weight  
The wet colon was cut opened longitudinally; faecal contents were removed and weighed 
for all four experimental mice strains. Wet colon weight, an indicator of intestinal oedema 
and inflammation, was presented as the ratio of colon weight over body weight (g/g). The 
ratio was significantly increased for Winnie at P-value <0.01, Winnie x Nlrp3-/- 12 week 
and Winnie x Nlrp3-/- 16 week at a P-value <0.001when compare to WT control. Nlrp3-/- 
showed no significant change in the mean ratio of colon weight over body weight relative 
to WT control (Figure 5.4). 
Figure 5.4: The mean colon weight/body weight ratio of the four experimental mouse strains. The 
data are representative of n=10 per group and are shown as the means±SEM. **P<0.01, ***P<0.001 
(One-way ANOVA Dunn’s Multiple comparison test)  
Tumours per colon 
Macroscopic assessment of open colon of WT and Nlrp3-/- showed healthy appearance with 
no sign of polyps. Winnie open colon appeared to have mucosal oedema and thickening of 
colon wall as seen described in previous studies (Heazlewood et al., 2008). We next 
examined the impact of the deficiency of NLRP3 activation on colon polyps, a 
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measurement of precancerous growth.  We assessed the macroscopic polyp counts of the   
Winnie x Nlrp3 -/- mice at week 12 and week 16 (Figure 5.5 A). Winnie x Nlrp3-/- mice at 
week 12 had severe mucosal oedema and precancerous polyps throughout the length of the 
colon and enlargement of mesenteric lymph nodes while at week 16 mucosal oedema had 
subsided with well-formed solid tumours throughout the length of the colon. Winnie x 
Nlrp3-/- mice at week 16 had a significantly higher (P-value <0.01) tumour load when 
compare to Winnie x Nlrp3-/- mice at week 12 (Figure 5.5 B).  
 
Figure 5.5: A. Representative images of the open colon of the four experimental strains at 
respective ages. B. The mean of macroscopic tumour counts for Winnie x Nlrp3 -/- 12wk and Winnie 
x Nlrp3 -/- 16wk mice strains. The data are representative of n=10 per group and are shown as the 
means±SEM. ***P<0.001 (Two-tailed Student’s t test) 
Survival analysis 
The survival rates for the four experimental phenotypes were observed for period of 150 
days. During this period WT and Nlrp3-/- had 100% survival. Winnie mice with chronic 
severe colitis are prone to develop rectal prolapse and it is reported to occur at any time 
between 9–20 weeks (Rahman et al., 2016). Winnie prolapsed mice are monitored closely 
and when body weight loss is > 15% were immediately and humanely euthanized. In the 
assessment we observed 70% survival rate of the Winnie strain. The novel model Winnie 
x Nlrp3-/- had a dramatic increase in the number of moribund with a survival rate of only 
30% at the end of 150 days (Figure 5.6). These mice developed rectal prolapses at higher 
and early time point (6 weeks) than the Winnie strains and was humanely euthanized. 
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Figure 5.6:  Kaplan-Meier survival analysis of Winnie and Winnie x Nlrp3-/- mice during an 
observation period of 150 days (n=20, per group). Survival rate, **P < 0.01 (Logrank (Mantel–
Cox) test) 
5.3.2 Histopathological assessment  
Histopathological assessments were performed by me and a senior pathologist in a blinded 
fashion for H&E stained colon tissue sections of all four experimental strains using the 
grading system outlined in Table 5.2. The colon tissue section slides were examined and 
scored for histological hallmarks of inflammation, hyperplasia, low grade dysplasia, high 
grade dysplasia and invasive carcinoma.  The WT mice colon and the Nlrp3-/- mice colon, 
when examined, did not indicate any inflammation or tumorigenesis and appeared to be 
normal which reflected in a histological score of zero. Thus, these two strains were 
subsequently excluded from the figure and statistical analysis.  
Separate histopathological scorings for proximal (PC), mid (MC) and the distal (DC) 
colon regions were performed to determine whether spatial differences in pathology could 
be observed. The examination of H&E stained tissue sections revealed Winnie x Nlrp3-/- 
colon at 12 weeks had increased inflammation, hyperplasia, high grade dysplasia and 
invasive carcinoma at a non-significant increase in the proximal colon (PC) and mid colon 
(MC) and highly significant increase in the distal colon (DC) (P-value < 0.001) relative to 
Winnie PC, MC and DC (Figure 5.7). Winnie x Nlrp3-/- colon at 16 weeks had more 
dramatic statistically significant (P-value < 0.001) increase in inflammation, hyperplasia, 
high grade dysplasia and invasive carcinoma in the MC and DC (P-value < 0.001) relative 
to Winnie MC and DC and non-significant increase in PC relative to Winnie PC (Figure 
5.7).   
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Figure 5.7: Histological score distribution in Wild-type, Nlrp3-/-, Winnie and Winnie x Nlrp3-/- 12 
wk. and 16wk colonic tissue. H&E stained colon tissue sections were graded using a scoring system 
for CAC.  Combined scores from the proximal colon (PC), mid colon (MC) and distal colon (DC) 
segments are represented in the figure. The data are representative of n=12 per, group and are shown 
as the means±SEM. ***P<0.001 (Two-way ANOVA Bonferroni post-test) 
This could be explained by the increase in polyp load at week 16 and associated 
significant increase in colon hyperplasia, dysplasia, in area involved with tumour 
pathology. Histopathological scoring for CAC markers agrees with significantly 
increased disease progression. 
 The PC of Winnie mice at 12 weeks exhibited increased infiltration of neutrophils, 
inflamed oedema, severe superficial epithelial damage and changes in crypt architecture, 
and mild hyperplasia indicative of active intestinal inflammation (Figure 5.8c). The 
inflammatory markers were significantly increased in distal colon of Winnie (Figure 5.8c). 
However, no incident of dysplasia or adenocarcinoma is reported in Winnie mice up to at 
12 twelve months of age and similarly we did not observe these histological pathologies in 
the experimental Winnie mice. 
100% of Winnie x Nlrp3-/- mice colonic mucosa displayed hyperplasia (Figure 5.1.0. b, c) 
and dysplasia (Figures 5.1.1, 5.1.2). Winnie x Nlrp3-/- mice showed hyper chromatism, 
complex glands sections, fibrinogen deposition (Figure 5.1.2.a) and flat dysplasia and 
individual gland dysplasia (Figure 5.1.3.b). Winnie x Nlrp3-/- colon displayed extensive 
ulceration sections and fibrinogen deposition which identify with precancerous lesions as 
seen in (Figure 5.1.0 a, b). We hypothesized that these structural abnormalities will lead to 
invasive carcinoma with progression of CAC. As predicted twenty percent of Winnie x 
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Nlrp3-/- at 12 week showed invasive carcinoma while this increased to forty percent at 16 
weeks. (Table 5.1).  








C57BL/6J (12 week) 
 
10/10 (100%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 
Nlrp3-/- (12 week) 
 
10/10 (100%) 0/10 (0%) 0/10 (0%) 0/10 (0%) 
Winnie (12 week) 
 
2/10 (20%) 8/10 (80%) 0/10 (0%) 0/10 (0%) 
Winnie x Nlrp3-/-  
(12 week) 
0/10 (0%) 10/10 (100%) 10/10 (100%) 2/10 (20%) 
Winnie x Nlrp3-/-  
(16 week) 
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Figure 5.8: Comparative proximal colon histology from all genotypes. Representative H&E 
sections of proximal colon displaying colitis associated atypia in the proximal colon between a. 
Wild-type, b. Nlrp3-/-, c. Winnie and d. Winnie x Nlrp3-/- 12 week. and e. 16-week mice. 
Magnification 100x and 400x. 
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Figure 5.9: Comparative distal colon histology from all genotypes. Representative H&E sections 
of distal colon presenting the differences in colitis associated atypia in the distal colon between a. 
Wild-type, b. Nlrp3-/-, c. Winnie and d. Winnie x Nlrp3-/- 12 week. and e. 16-week mice. 
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Figure 5.10: Histology of advanced colon cancer in Winnie x Nlrp3-/-. a. High grade early invasive 
carcinoma b. Ulceration and hyperplasia and invasive carcinoma c. Invasive carcinoma observed 
in colons of Winnie x Nlrp3-/-. Magnification is 100x and 400x. 
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Figure 5.11: Representative images showing of H&E staining showing a. high grade dysplastic 
adenomatous polyp b. dysplasia and adenomatous polyploid in colons of Winnie x Nlrp3-/-.  
Magnification 100x. and 400x. 
 
Figure 5.12: Representative images showing of H&E staining showing a. High grade dysplasia, 
hyper chromatism and complex glands b. dysplasia in colons of Winnie x Nlrp3-/-.  Magnification 
100x. and 400x. 
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Figure 5.13: Representative images showing of H&E staining showing a. Flat dysplasia and 
complex glands b. Individual gland dysplasia, hyper chromatism and crypt abscess in colons of 
Winnie x Nlrp3-/-. Magnification 100x. and 400x. 
5.3.3 Biochemical Analysis 
Inducible Nitric Oxide synthase activity 
 
Figure 5.14: Nitric Oxide Synthase activity A. Proximal Colon B. Distal Colon presented as fold 
change as compared to the respective WT. The data are representative of three independent 
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The results show an increased fold change of iNOS concentration of the Winnie PC and 
DC relative to the WT control with a statistical significance of p<0.001. The novel CAC 
models Winnie x Nlrp3-/- at weeks 12 and 16 showed considerable increase of fold change 
in iNOS relative to WT at a statistical significance of p<0.001 (Figure 5.1.4). 
Myeloperoxidase activity  
 
Figure 5.15: Myeloperoxidase activity A. Proximal Colon B. Distal Colon presented as fold change 
as compare to the respective WT. The data are representative of three independent experiments and 
are shown as the means±SEM. ***P<0.001 (One-way ANOVA Dunn’s Multiple comparison test) 
Colonic tissue of the four experimental groups were analysed for the concentration of MPO 
and compared to the WT control (Figure 5.1.5). The fold change of MPO concentration of 
the Winnie PC and DC relative to the WT control was respectively with a statistical 
significance of p<0.001. The novel CAC models Winnie x Nlrp3-/- at weeks 12 and 16 
showed considerable increase of fold change in MPO relative to WT at a statistical 
significance of p<0.001. 
Immunohistochemical analysis of DNA damage and oxidative stress markers 
To investigate the oxidative stress associated DNA damage in the experimental models I 
looked at the protein expression of 8-Oxoguanine by colonic tissue immunohistochemistry 
(IHC). The highest expression was observed in the CAC model Winnie x Nlrp3-/- with 
medium expression in the colitis model Winnie and very little expression in WT control 
colonic tissue (Figure 5.17 a-c). 
IHC was performed with the primary antibody anti- γH2A.X to look at the protein 
expression of γH2A.X in WT, Winnie and Winnie x Nlrp3-/- mouse colonic tissue. The 
highest expression was observed in the CAC model Winnie x Nlrp3-/- with medium 
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expression in the colitis model Winnie and very little expression in WT control colonic 
tissue (Figure 5.17 d-f). 
To analyse the oxidative stress in the colon tissue, IHC was performed for NQO1 
expression in WT, Winnie and Winnie x Nlrp3-/- mouse colonic tissue. The highest 
expression was observed in the CAC model Winnie x Nlrp3-/- with medium expression in 
the colitis model Winnie and very little expression in WT control colonic tissue. (Figure 
5.17 g-I). 
Additionally, I investigated another oxidative marker prominent in CAC, 3- nitrotyrosine 
in WT, Winnie and Winnie x Nlrp3-/- mouse colonic tissue. I observed highest expression 
in the CAC model Winnie x Nlrp3-/- with medium expression in the colitis model Winnie 
and very little to no expression in WT control colonic tissue (Figure 5.17 j-l). 
C Reactive Protein 
The serum CRP levels were analysed for all the colons of the experimental mouse models 
and the results showed a base level of 9.328 µg/ml in the WT control, elevated 
concentration of 16.81 µg/ml in Winnie and in Winnie x Nlrp3-/- 12 weeks at 18.88 µg/ml 
increasing to 24.66 µg/ml by 16 weeks. 
Figure 5.16: C Reactive Protein activity in serum. The data are representative of three independent 
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Figure 5.17: Immunohistochemical staining results for proteins 8-Oxoguanine (a, b, c), H2A.X 
(d, e, f) NQO1 (g, h, i) and 3-Nitrotyrosine (j, k. l) in 12-week-old Wild Type, Winnie and Winnie 
x Nlrp3-/- mouse colonic tissue 
5.3.4 Cytokine Profile 
We investigated the cytokine profile of Nlrp3-/-, Winnie and Winnie x Nlrp3-/- at 6wks, 12 
weeks and 16 weeks and compared the levels to expression in WT. We did not observe 
differential production of cytokines between Nlrp3-/- and WT.  
Instead, production of the NLRP3 inflammasome-associated cytokine IL-1β , IL-18 and 
IL-1α and inflammasome-independent cytokines IL-6, IL-17, GM-CSF, IL-12,IL-10 and 
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IFN- ( Figure 5.1.8) and the chemokines KC, MCP-1 (also known as CCL2) and MIP-1α 
(also known as CCL3) was elevated in colon tissue of Winnie and Winnie x Nlrp3-/- 
compared to WT mice (Figure 5.1.9). We further confirmed these results and found 
statistically significant increased levels of circulating IL-1β, IL-6, TNF-α, IL-17 and G-
CSF in the sera of Winnie x Nlrp3-/- compared to Winnie (Figure 5.2.0). 
 
Figure 5.18: The indicated cytokines in the culture supernatants of colon tissues from mice. The 
data are representative of three independent experiments and are shown as the means±SEM. 
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 The cytokines and chemokines showed an increase associated with age in Winnie x Nlrp3-
/- at 6wks and 12 weeks however, a decrease in proinflammatory cytokine levels was 
observed in the Winnie x Nlrp3-/- at week 16. 
Figure 5.19: The indicated chemokines in the culture supernatants of colon tissues from mice. The 
data are representative of three independent experiments and are shown as the means±SEM. 
*P<0.05, **P<0.01, ***P<0.001 (One-way ANOVA Dunnett’s Multiple comparison test) 
 
Figure 5.20: The indicated cytokines and chemokines in the blood serum from mice. The data are 
representative of three independent experiments and are shown as the means±SEM. *P<0.05, 
**P<0.01, ***P<0.001 (One-way ANOVA Dunnett’s Multiple comparison test) 
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5.4 Discussion 
Macroscopic observations of the colon of Winnie x Nlrp3-/- revealed all mice had 
noticeably inflamed and thickened colonic wall, enlargement of mesenteric lymph nodes, 
shortened colon length and formation of intestinal tumours compared to the Winnie control. 
This was a very interesting finding as no tumours are reported in Winnie mice up to twelve 
months of age (Randall-Demllo et al., 2016). Collectively, the macroscopic results 
indicated that a functional NLRP3 inflammasome is critical for protection against colitis 
associated dysplasia and tumorigenesis in the gut. 
Examinations of colon histopathology from the novel model Winnie x Nlrp3-/- revealed all 
mice had increased mucosal inflammation, hyperplasia, dysplasia and polyps compared to 
Winnie controls. Thus, the deletion the Nlrp3 gene in a colitis model has exacerbated colitis 
to colitis associated colon cancer phenotype through the classical sequence of no 
dysplasia progressing to indefinite dysplasia, low-grade dysplasia, high-grade dysplasia 
and eventually to submucosal invasion by the carcinoma. The mucosal tumours were 
assessed on established criteria such as structural and cellular atypia, alterations in tubular 
arrangement, abnormal epithelial cell proliferation and accordingly classified to low-grade 
or high-grade dysplasia or well-differentiated adenocarcinoma. The polyps were not focal 
but throughout the colon length as observed in CAC. The histopathological analysis 
revealed that many of the polyps were adenocarcinomas with a few advancing to invasive 
carcinomas. Macroscopic analysis of Winnie x Nlrp3-/- mice showed no distant metastases 
in other organs however, this was not experimentally analysed. 
The histopathology of Winnie x Nlrp3-/- indicates that a functional NLRP3 inflammasome 
is critical for protection against tumorigenesis in a colitis disease state. Other studies 
support our findings however they have investigated in chemically induced DSS/AOM 
models (Zaki et al., 2011c, Allen et al., 2010). The novel model Winnie x Nlrp3-/- shows 
biological features like colitis associated colorectal dysplasia–invasive carcinoma sequence 
observed in human CAC and in future will be a useful experimental model for anti CAC 
therapeutic agents. 
A hall mark of UC colonic inflammation is the infiltration and enhanced activity of 
phagocytic leukocytes leading to a production of excessive reactive oxygen species (ROS) 
and reactive nitrogen species (RON).  These free radicals lead to oxidative/nitrosative stress 
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and cellular DNA damage which induces epigenetic mutations in genes related to cell 
proliferation, cell survival and stress induced pathways in colonic epithelial cells promoting 
tumorigenesis (Roessner et al., 2008, Waldner and Neurath, 2015). Inhibition of ROS and 
RON has been shown to effectively decrease DNA damage and delay (Hussain et al., 2003, 
Shaked et al., 2012). 
The enzyme inducible nitric oxide synthase (iNOS) is highly expressed in inflammatory 
reactions. It is regulated by the transcription factor NF-κB, a known promoter of CAC. It 
is responsible for the generation of nitric oxide and is associated with the pathogenesis of 
CRC (Sawa and Ohshima, 2006). An increased expression of iNOS is associated with the 
mutagenesis of the tumour suppressor protein p53 and was found at an increased level in 
the colons of UC patients (Hussain et al., 2000). Analysis of human biopsies 
of colitis and CAC showed elevated iNOS protein expression levels (Gochman et al., 
2012, Keshavarzian et al., 2003). In line with these studies our results show an increased 
fold change of iNOS concentration in the colitis model Winnie and CAC model Winnie x 
Nlrp3-/- when compared to WT mice. 
Another inflammatory marker associated with CAC and abundantly found in colorectal 
tumours in human patients is myeloperoxidase (MPO) (Roncucci et al., 2008). MPO is an 
enzyme contained in lysosomes of neutrophils, monocytes and macrophages, active 
immune cells which infiltrate and accumulate in inflamed colonic mucosa (Krawisz et al., 
1984). MPO is released upon activation of these immune cells converting hydrogen 
peroxide to generate cytotoxic oxidants increasing ROS in inflamed tissue. The results 
show a significant increase in MPO in the colonic tissue of Winnie and Winnie x Nlrp3-/- 
in comparison to WT. The increase in fold change observed in the spontaneous colitis 
model Winnie is consistent with other studies where they show an elevated expression of 
MPO pointing to enhanced neutrophil activity in UC (Krawisz et al., 1984, Raab et al., 
1992). In agreement with the results in CAC model Winnie x Nlrp3-/- and other studies have 
shown MPO elevation in colorectal carcinomas and linked with increase in DNA damage 
(Roncucci et al., 2008, Hirt et al., 2013). 
Reactive Oxygen and Nitrogen species (RONS) such as hydrogen peroxide, nitric oxide 
and superoxides leads to oxidative stress in inflamed tissues. These RONS interact with the 
DNA of resident cells and induce various forms of DNA damage including such as double-
strand breaks (Jackson and Loeb, 2001). Oxidative stress inactivates  mismatch repair 
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system, leading to the insertion of mutation into key oncogenes or tumour-suppressor genes 
contributing to tumour initiation (Colotta et al., 2009). Moreover, chronic inflammation 
induces higher rates of mitosis accelerating epithelial cell turnover in the colonic mucosa 
predisposing the mucosa to mutagenic assault resulting in DNA damage. 
One of the major oxidative DNA damage biomarkers is 8-Oxoguanine, which is a 
mutagenic oxidative damage product of guanine. Guanine is the main target for reactive 
oxygen species in DNA, with 8-oxoguanine being the most frequent base lesion. Formation 
of 8-oxoguanine is common in inflamed and dysplastic tissue, but not in healthy mucosa 
(D'Inca et al., 2004). Recognition and removal of 8-oxoguanine is mediated by OGG1 DNA 
glycosylase which is elevated in CRC patients however it is insufficient to counteract the 
production of DNA damage associated with oxidative stress (Obtułowicz et al., 2010). 
Agreeing with these studies a high expression of 8-oxoguanine was detected in the Winnie 
x Nlrp3-/- colonic tissue. 
DNA damage activates the  DNA damage response (DDR) mechanisms such as direct 
repair and  nucleotide excision repair (Curtin, 2012). One of the essential DDR to DNA 
double strand breaks (DSB) is the phosphorylated H2A.X (γH2A.X) which promotes 
recruitment of DNA repair proteins to sites of DSBs (Rogakou et al., 1998, Paull et al., 
2000). This leads to significant accumulation of γH2A.X molecules relative to the severity 
of the DNA damage. Thus, γH2A.X has been used as a sensitive marker for the presence 
of inflammation induced  DSBs in cells and tissues (Rogakou et al., 1998). Elevated 
expression of  γH2A.X have been reported in IBD (Risques et al., 2008, Sohn et al., 2012)  
and various human cancer cell lines including colon cancer (Sedelnikova and Bonner, 
2006). γH2A.X was highly elevated in the Winnie x Nlrp3-/- colonic tissue. 
Quinone oxidoreductase 1 (NQO1) function under normal conditions is to protect cells 
from oxidative stress (Li et al., 2015). Oxidative damage promotes transcription factor Nrf2 
and activates transcription of NQO1. Recent studies have reported high expression of 
NQO1 in several human solid tumours such as lung, bladder and colorectal cancer  (Mikami 
et al., 1998, Chao et al., 2006). Another study showed the high expression of NQO1 protein 
in CRC tissues compared with adjacent non-tumour tissues by immunohistochemistry 
staining (Ji et al., 2014). NQO1was highly expressed in the Winnie x Nlrp3-/- colonic tissue 
indicating a high level of oxidative stress in tumour associated tissue. 
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The conversion of tyrosine to 3-nitrotyrosine have been reported to be through the nitrating 
agent peroxynitrite a key component of the nitric oxide signalling pathway (Ischiropoulos 
et al., 1992). Analysis of human biopsies of colitis and colon cancer using 
immunohistochemistry revealed elevated iNOS and nitro tyrosine protein expression levels 
in these tissues (Gochman et al., 2012). Another study reported observation of nitro tyrosine 
in a number of human cancer tissue including colorectal carcinoma (Kondo et al., 2002). 
Winnie x Nlrp3-/- colonic tissue showed an elevated level of iNOS and high expression of 
3-nitrotyrosine indicating nitrosative stress due to CAC pathogenesis. 
CRP analysis in Winnie x Nlrp3-/- mice showed an increase as compared to WT indicating 
the severity of CAC. C-reactive protein (CRP) is an acute phase protein produced primarily 
in the liver and is mainly induced by the proinflammatory cytokines IL-6 (Castell et al., 
1990, Pepys and Hirschfield, 2003). Circulating serum value of CRP is a major clinical 
indicator of ongoing tissue inflammation and has been used as a reliable biomarker 
evaluating the disease activity and extent of inflamed tissue in UC patients (Solem et al., 
2005, Chouhan et al., 2006). The chronic inflammation associated with colon tumour tissue 
initiates a systemic inflammatory response that  can be measured by the circulating 
inflammatory marker CRP levels and has been used as a prognostic indicator for all stages 
of colorectal cancer (Roxburgh et al., 2009, Contu et al., 2009). Studies have reported that 
the risk of mortality among patients with colorectal cancer is positively associated with 
plasma CRP (Cooney et al., 2013, McMillan et al., 2003).  
Chronic intestinal inflammatory conditions such as IBD can lead to CAC (Rubin et al., 
2012). Once tumours are generated, they are tightly controlled by the tumour 
microenvironment which is regulated by proinflammatory cytokines and chemokines 
released from epithelial and tumour-infiltrating immune cells. These proinflammatory 
mediators act on epithelial and premalignant cells activates molecular mechanisms of cell 
proliferation, angiogenesis and inhibition of apoptosis (Grivennikov and Karin, 2010b, 
Grivennikov and Karin, 2010a).  
To elucidate the activated pathogenic molecular pathways in CAC, it is essential to identify 
and measure the proinflammatory cytokine levels in the diseased colon. Thus, multiple 
cytokines were assessed in colonic culture supernatants and the results were compared to 
WT control. The results showed that the Nlrp3-/- mice showed basal expression of cytokines 
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comparable to the WT control. This supports the idea that the NLRP3 inflammasome is 
redundant in a non-disease condition.  
The key downstream effector molecules associated with NLRP3 inflammasome activation, 
IL-1β, IL-18 and IL-17 showed an increase in Winnie as previously reported (Eri et al., 
2011). Winnie mice treated with the specific NLRP3 inhibitor MCC950 had a significantly 
low level of these  inflammatory mediators as compared to untreated Winnie mice (Perera 
et al., 2018). However, interestingly the expression of these cytokines showed a significant 
age dependent increase in the Winnie x Nlrp3-/- model (6 week and 12 week) even in the 
absence of a functional NLRP3 inflammasome. 
In CAC pathogenesis IL-1β acts as key protumorigenic factor by associating with massive 
infiltration of neutrophils and regulating proinflammatory cytokines and chemokines 
(Wang et al., 2014c). Over production of IL-1β in CAC, promotes differentiation of naive 
T cells in to Th17 cells that produces the proinflammatory cytokine IL-17 (Acosta-
Rodriguez et al., 2007). IL-1β is not only linked to the induction of the tumour 
microenvironment but also initiates tumour invasiveness (Voronov et al., 2003, Krelin et 
al., 2007). It is now believed that NLRP3 and IL-1β are selectively expressed in the LPMCs 
while IL-18 is only expressed in intestinal epithelial cells (Zhu et al., 2017, Yao et al., 
2017b). In line with this finding a recent study has shown the functional role of NLRP3 
activation is carried out by elevated production of IL-1β and not IL-18 (Yao et al., 2017b). 
Thus, the high expression of IL-1β seen in Winnie x Nlrp3-/- colon could be the driving 
factor of CAC seen in this model. 
Initial investigations on the role of NLRP3 in colitis and CAC models showed a reduced 
expression of IL-18 in NLRP3 deficient mice (Zaki et al., 2011b, Allen et al., 2010). During 
DSS-induced colitis in Nlrp3-/- mice, IL-18 was essential for the intestinal tissue repair of 
the ulcerated epithelium during the acute inflammatory phase and injecting recombinant 
IL-18 reduced the severity of colitis (Zaki et al., 2010b). In DSS/AOM induced CAC, IL-
18 was found to be protective against colitis associated tumorigenesis by the activation of 
tumor suppressors STAT1 and IFN- (Zaki et al., 2010b). These results established IL-18, 
but not IL-1β, as the critical player for NLRP3 inflammasome-mediated resistance to colitis 
and CAC.  
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In contrast to the previously published studies the results of the spontaneous colorectal 
cancer model Winnie x Nlrp3-/- deficient in NLRP3 showed an increased expression of IL-
18. This unexpected result could be explained by recent studies where it is  shown that  the 
epithelium caspase-1 activation and IL-18 secretion were found to be independent of 
NLRP3 (Yao et al., 2017b, Song-Zhao et al., 2013). Moreover, the Winnie x Nlrp3-/- model 
is not chemically induced CAC and compared to AOM/DSS model it has a more intact 
epithelium with better ability to produce IL-18 as compared to the chemically eroded 
epithelium in DSS model. Additionally, during colitis and associated colorectal cancer  
infiltrating macrophage cells will also contribute to IL-18 production (Zaki et al., 2010b). 
It is reported that higher concentration of IL-18 promotes tumorigenesis (Siegmund, 
2010a). Finally, IL-18 was shown to induce Fas ligand production and the generation of 
multiple secondary proinflammatory cytokines, chemokines, cell adhesion molecules, and 
NO species (Maxwell et al., 2006, Horwood et al., 1998). Thus, in the Winnie x Nlrp3-/- 
colon IL-18 plays a pro-tumorigenic role. 
In a hypoxic tumour microenvironment undergoing high tissue damage and inflammation 
caspase-1 activation by inflammasomes leads to GSDMD-induced pyroptosis allowing the 
release of high doses of the alarmin IL-1α (Voronov et al., 2013, Gross et al., 2012). The 
bioactive extracellular IL-1α  is mainly generated by the epithelial cells and is associated 
with driving inflammation at mucosal barrier surfaces (Malik et al., 2016). In recent years, 
IL-1α has also emerged as an important driver of colon inflammation and cancer 
(Bersudsky et al., 2014). Studies have shown that IL-1α deficient mice are protected from 
DSS induced acute colitis (Bersudsky et al., 2014, Malik et al., 2016). A study has shown  
carcinoma-derived IL-1α and IL-1β activates mesenchymal stem cells to produce 
Prostaglandin E2 and cytokines, such as IL-6, IL-8 and RANTES, which in turn, induce 
activation of β-catenin in the malignant cells and their transition into Cancer Stem Cells 
leading to tumour initiation (Li et al., 2012). Similarly, IL-1α is highly expressed in the 
Winnie x Nlrp3-/- colon and exacerbates colitis towards CAC. 
Numerous studies have reported increased levels of IL-6 trans signalling play a crucial 
pathogenic role in IBD patients and is positively correlated with the severity of 
inflammation (Atreya and Neurath, 2008, Atreya and Neurath, 2005). In the Winnie x 
Nlrp3-/- model IL-6 peaked at week 12 with the appearance of intestinal tumours. Other 
studies also found elevated IL-6 in CAC patient serum and in the  tumour 
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microenvironment and correlated with tumour size and disease status in various clinical 
and experimental studies (Komoda et al., 1998, Chung and Chang, 2003, Grivennikov and 
Karin, 2010a). In addition, IL-6 has been associated with liver metastases and reduced 
survival (Heikkila et al., 2008, Olsen et al., 2015). This can be attributed to LPMC ability 
to generate IL-6, to enhance proliferation of tumour progenitor cells and the protection of 
normal and premalignant intestinal epithelial cells from apoptosis by the signal transducer 
and activator of transcription 3 (STAT3) signalling (Becker et al., 2005, Huber et al., 2012). 
Recent studies have demonstrated that the IL-6/STAT3 axis as a crucial tumour promoter 
in colitis-associated cancer (Grivennikov et al., 2009, Bollrath et al., 2009). Prolonged 
STAT3 activation enhances the sustained expression of IL-6 induced proteins that play 
important roles in inflammation and carcinogenesis (Wang et al., 2013). Due to the 
correlation of IL-6 expression with CRC prognosis and the increased expression of IL-6 in 
patients with IBD, IL-6 could be the tipping point of chronic inflammation pathogenesis to 
tumour development in the Winnie x Nlrp3-/- model. Another key proinflammatory role of 
IL-6 is the differentiation of Th1 to Th17 cells, which is the major source of IL-17 (Bettelli 
et al., 2006, Atreya et al., 2000).  
An increased level of IL-17 is observed in Winnie x Nlrp3-/- model and has been associated 
in active IBD (Fujino et al., 2003) as well as CAC pathogenesis (Wang et al., 2014a). The 
proinflammatory role of IL-17 in the pathogenesis of CAC was also confirmed in animal 
models. Blocking IL-17A attenuated colitis and reduced tumour burden in APCmin/+ mice 
and AOM/DSS treated mice (Hyun et al., 2012, Chae et al., 2010). Additionally, It is 
suggested that IL-17 facilitates angiogenesis and promotes CRC development by inducing 
the production of VEGF (Liu et al., 2011). 
GM-CSF promotes CAC in AOM/DSS-challenged mice as treatment with a neutralizing 
anti-GM-CSF antibody decreased tumour development and colitis score in this model 
(Wang et al., 2014b). GM-CSF is produced by IECs and even more by neoplastic colonic 
epithelial cells (Nebiker et al., 2014, Wang et al., 2014b). Commensal microbiota derived 
LPS triggers GM-CSF expression in IECs (Wang et al., 2014b) which would explain the 
increase of GM-CSF observed in Winnie PC and DC. Stromal fibroblasts and lymphocytes 
adjacent to the CRC tumour have also been found to be positive for GM-CSF (Trutmann 
et al., 1998). Cancerous epithelial cells, monocytes, and antigen-presenting cells all express 
the GM-CSF receptor in the CRC microenvironment (Urdinguio et al., 2013, Nebiker et 
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al., 2014, Wang et al., 2014b). GM-CSF induces autocrine or paracrine VEGF release by 
IECs (Wang et al., 2014b), thereby promoting angiogenesis; yet, it does not have a direct 
proliferative effect on these cells (Trutmann et al., 1998). GM-CSF binding to its receptor 
activates the JAK-STAT, the MAPK, and the PI3K pathways, which results in cell survival 
and proliferation (Hercus et al., 2009). The high level of GM-CSF observed in Winnie x 
Nlrp3-/- could be driving colitis to CAC through its association with VEGF and PI3K 
pathway. 
CAC progression is determined not only on pro-tumour mediators discussed so far but also 
with the anti-tumour factors activated by the immune response of the host. The clinical 
outcome of CAC patients depends on the balance between the pro-tumour and anti-tumour 
mediators at the invasive site of colorectal cancer. 
IL-12 is crucial for the induction and the expansion of Th1 responses as well as the 
activation of cytotoxic immune effectors, such as NK and CD8+ T cells (Engel and 
Neurath, 2010). IL-12 exerts its anti-tumour effect by activating the IFN-γ production in 
these cells and subsequent generation of IFN-γ  initiates antiproliferative, antiangiogenic, 
and cytotoxic effects that limits tumour growth (Nardin and Abastado, 2008, Hayes et al., 
1995). In the Winnie x Nlrp3-/- we see an age dependent increase of IL-12 as observed in 
other CAC models. 
IL-10 is an anti-inflammatory cytokine which suppresses IBD and CAC mouse models. IL-
10 deficient mice are highly susceptible to UC and CAC due to uncontrolled inflammation 
in the colon and develop spontaneous adenocarcinoma of the colon by 6 months of age 
(Berg et al., 1996, Dennis et al., 2015, Sturlan et al., 2001).  IL-10 deficient mice showed 
a marked increase CD4+ cells and macrophages in the lamina propria, along with 
associated elevated levels of TNFα, IL-6 and nitric oxide (Davidson et al., 1996). The anti-
tumorigenic effect of IL-10 could be attributed to it limiting a pathogenic Th17 
inflammatory response (Chaudhry et al., 2011). In agreement with these studies the IL-10 
expression in Winnie x Nlrp3-/- age dependently decreases with progression of CAC. 
IFN-γ is known to be  produced by Th17 cells to induce pathogenic responses (McGovern 
and Powrie, 2007) however IL-18 has been shown to play the major role in the induction 
of IFN-γ production (Wong et al., 2013, Chaix et al., 2008, Takeda et al., 1998). IFN-γ 
subsequently activates several intrinsic cellular pathways such as Janus kinase (JAK)-
STAT signalling (Zaki et al., 2011a). Activation of JAK-STAT signalling leads to nuclear 
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translocation of the STAT1 protein and increases the transcription regulation of IFN-γ 
induced genes, which are responsible for proliferation, differentiation, and cell death. In 
addition, IL-18-INF--STAT1 axis activation is involved in colon carcinogenesis (Zaki et 
al., 2011b). Mechanistically, IFN-γ acts on CRC cells by inducing STAT1 phosphorylation 
and inhibiting the EGFR/Erk1/2 and Wnt/βcatenin signalling pathways, thereby restraining 
cell proliferation (Wang et al., 2015a). In line with these studies I observed an age 
dependent increase of IFN-γ in Winnie x Nlrp3-/-. 
Winnie x Nlrp3-/- mice showed poor survival with 50% survival rate at 16 weeks. Winnie 
x Nlrp3-/- mice colonic tissue and serum analysis showed an elevation of proinflammatory 
cytokines, MPO, iNOS, CRP and ROS levels. These molecules activated proinflammatory 
pathways aggravating colitis to CAC leading to a decrease in survival rate.  
A decrease in most of the proinflammatory cytokine levels were observed in the Winnie x 
Nlrp3 -/- at week 16. Macroscopic analysis at this age showed solid colonic tumours. These 
established tumours create a local environment with low levels of inflammation which can 
be immunosuppressive and is therefore favourable for tumour growth, angiogenesis, and 
metastasis.  
5.5 Conclusion 
The clinical assessment of the novel mouse model Winnie x Nlrp3-/- colon displayed 
aggravated inflammation and spontaneous tumorigenesis. Histopathological assessment of 
Winnie and Winnie x Nlrp3-/- mice revealed all the features of the classical pathway of CAC 
starting with high inflammation to hyperplasia, dysplasia and invasive carcinoma. The 
biochemical analysis quantified the excessive production of ROS resulting in elevated 
oxidative stress in Winnie x Nlrp3-/- mice colonic tumours. The immunohistochemical 
analysis showed high levels of oxidative stress markers present in the colorectal tumours 
and the inactivation of the DNA repair system by oxidative stress leading to genomic 
mutations in oncogenes and tumour suppressor genes initiating and promoting 
tumorigenesis in the colon.  
The cytokine profile of Winnie x Nlrp3-/- mice was analysed to understand the underlying 
immunopathology. The colons of Winnie x Nlrp3-/- are highly inflamed by the generation 
of significantly elevated levels of cytokines and chemokines associated with CAC in the 
local tumour microenvironment as well as in serum. Moreover, even with deficiency of 
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NLRP3 inflammasome over production of IL-1β, IL-18 and IL-1α and subsequent 
activation of the adaptive immune system promotes an enhanced pro-inflammatory 
environment locally in Winnie x Nlrp3-/- initiating tumorigenesis in colonic tissue.  
Taken together, Winnie x Nlrp3-/- represents human CAC, where the progress from chronic 
inflammation in UC to the morphological features of CAC initiates with constant 
production of pro-inflammatory cytokines, chemokines and reactive oxygen and nitrogen 
species promoting aberrant intestinal epithelial cell proliferation, survival and angiogenesis 
leading to epithelial dysplasia of low grade to high grade and progression to invasive 
carcinoma over time. 
In summary, these data demonstrate ablating the Nlrp3 gene in the spontaneous colitis 
Winnie mutant mouse leads to severe colorectal cancer. To our knowledge, this is the first 
study to identify such a mechanism for NLRP3 inflammasome in a spontaneous colitis 
mouse model similar to human UC. The findings thus emphasize the critical contribution 
of the NLRP3 inflammasome as a negative regulator of CAC.  
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Chapter 6 
Molecular, Microbiota and metabolomic analysis of        
Winnie x Nlrp3-/- mouse colon          
6.1 Introduction 
Cancer cells are characterized by abnormal signalling pathways involving cell 
proliferation, apoptosis, and angiogenesis. These pathways have also been linked to 
chronic inflammation, a major mediator of tumour progression in several cancers. I 
analysed these pathways in the Winnie x Nlrp3-/- model to reveal the mechanism of colitis 
in to CAC. 
In colitis associated carcinogenesis it is speculated that inflammation results in neoplastic 
transformation by enhancing abnormal proliferation of the crypt epithelium. The 
monoclonal antibody Ki-67 recognises an antigen present in the nuclei of cells in the 
proliferative phases of the cell cycle and is used as a marker of prognosis in colorectal 
cancer (Li et al., 2015).  
Tumour cells also need to acquire the ability to escape from programmed cell death 
mediated by apoptosis (Strasser et al., 2011). Abnormalities in apoptotic function is an 
essential for the pathogenesis of colorectal cancer. Survivin (Birc5) is a member of the 
inhibitor of apoptosis protein (IAP) family and is highly upregulated in colon cancer 
(Hernandez et al., 2011, Adamkov et al., 2015). We decided to probe the protein Survivin 
in the colonic tumours to evaluate the upregulation of IAP proteins. 
The increased distance between the tumour cell and blood vessels reduces the chance of 
getting oxygen and thus, decreases the survival of tumour cells. Therefore, neoangiogenesis 
in tumour microenvironment is vital to provide sufficient oxygen and nutrients to tumour 
cell survival and growth and positively correlates with advanced tumour stage (Cao et al., 
2009). Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that 
contributes to the new blood vessel network.  Therefore, we looked at the expression of Ki-
67, VEGF and Survivin biomarkers to investigate cell proliferation, angiogenesis, and anti-
apoptotic activity of the Winnie x Nlrp3-/-. 
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To investigate potential mechanisms resulting in tumorigenesis in Winnie x Nlrp3-/-, we 
quantified transcription of a panel of genes associated with colorectal neoplasms. A 
limitation of the use of RNA from total tissues in microarray gene expression analysis is 
that the results are reflective of the whole colon tissue and does not specify exact cellular 
types. However, it avoids the modification of gene expression taking place during cell 
purification procedure, and it has been shown to be able to provide important information 
regarding the main molecular pathways affected in different experimental or pathological 
conditions. 
To analyse the molecular mechanism involved in Winnie x Nlrp3-/- tumorigenesis we 
investigated prominent pathways upregulated in CAC. The phosphatidylinositol 3-kinase 
(PI3K)–Akt pathway and its downstream factors were examined first, as they are directly 
involved in proliferation and growth in epithelial cells and is associated in colitis associated 
colorectal cancer (Sheng et al., 2003, Danielsen et al., 2015). Activation of PI3K/Akt 
signalling has been shown to inhibit Glycogen synthase 3 kinase β (GSK3β) through 
phosphorylation at Ser9 (Huber et al., 2005). 
Another major pathway involved with proliferation and differentiation in colon cancer is 
the over activated Wnt/β-catenin signalling pathway (Pandurangan et al., 2018, Lapham et 
al., 2009). GSK3β is an important negative regulator of Wnt/β-catenin signalling pathway. 
In the absence of Wnt signalling, Axin, GSK3β and APC assemble as a complex to 
phosphorylate β-catenin for ubiquitin mediated degradation (Wu and Pan, 2010). In the 
presence of Wnt signalling, the inactivated form P-GSK3β protects β-catenin from 
degradation and the stabilized  β-catenin in the cytoplasm translocates into the nucleus and 
activates transcription factors TCF/ lymphocyte enhancer factor (TCF/LEF), and stimulates 
the expression of target genes such as c-Myc, c-Jun, CD44 and Cyclin-D1 (Lapham et al., 
2009, Van der Flier et al., 2007, Dang, 2012, Shtutman et al., 1999). 
The protooncogene c-Myc regulates the expression of genes involved in cell proliferation, 
DNA repair, apoptosis and angiogenesis (Luscher, 2012, Gabay et al., 2014). High 
expression of c-myc is seen in colon tissue of colon cancer patients (Lee et al., 2016). c-
myc is required for the transcription of many cell cycle related proto-oncogenes such as 
Cyclin D1 (Obaya et al., 1999) which is overexpressed in colon cancer (Wang et al., 1998).  
Several studies have established that breakdown of the homeostasis by dysbiosis of gut 
microbiota results in the development of various pathological conditions such as IBD and 
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CAC (Nistal et al., 2015, Tjalsma et al., 2012, Xavier and Podolsky, 2007). Concomitantly 
other studies have shown association of pro-carcinogenic microbiota with tumour tissues 
(Kostic et al., 2012, Sanapareddy et al., 2012). Tjalsma et al proposed a model where 
bacteria with the tumorigenic potential act as drivers and induce inflammation, which 
facilitates the expansion of tumorigenic bacterial strains. Another study showed that that 
intestinal inflammation in the IL-10 knock out mouse model modifies gut microbial 
communities and promotes the growth of genotoxic bacteria (Arthur et al., 2012).  
Another way that gut microorganisms contribute to IBD and CAC development is by their 
role in inducing pro-inflammatory responses, such as the induction of IL-17 or IFNγ pro-
inflammatory responses (Ivanov et al., 2009, Kim et al., 2007, Kullberg et al., 1998) or 
specifically activate suppressive IL-10 cytokine response (Mazmanian et al., 2008, Round 
and Mazmanian, 2009). 
The NLRP3 inflammasome is a well characterised gut innate immune sensor belonging to 
the NLR family that are critical for modulating microbial ecology to protect against tumour 
development (Kamada et al., 2013, Allen et al., 2010). In the study we have generated a 
CAC mouse model in the absence of NLRP3 and the analysis of the microbiota will define 
the protective role of NLRP3 inflammasome in CAC penetrance. 
One of the mechanisms by which gut microbiota contributes to tumorigenesis is by 
changing the production of metabolite levels. Gut microbiota produces short-chain fatty 
acids (SCFAs) acetate, propionate, and butyrate by fermentation of dietary fibre (den 
Besten et al., 2013). Specifically, the phylum Bacteroidetes members mainly produce 
acetate and propionate, whereas the phylum Firmicutes produce butyrate as its primary 
metabolic end product (Koh et al., 2016). Among SCFAs, butyrate has received most 
attention for its effects on colonic health (Hamer et al., 2008). Butyrate has been suggested 
to be protective against colon cancer due to its antiproliferative effects in most human colon 
cancer cell lines and its ability to increase apoptosis and differentiation (Hague et al., 1993, 
Heerdt et al., 1994). 
From the studies mentioned above, to understand the pathogenesis of CAC it is vital to 
identify the involvement of unique microbiota and metabolomic composition in colon 
cancer. Therefore, in the study, we have performed an in-depth analysis of the microbiota 
and its metabolomics in Winnie x Nlrp3-/- CAC model. We analysed Winnie x Nlrp3-/- at 
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two age groups, 12 and 16 weeks to identify dynamic changes in the composition of 
microbiota and metabolomics during disease progression. 
6.2 Methodology 
Confocal Immunofluorescence Microscopy 
Sections were deparaffinized and subjected to 0.01 mol/L citrate buffer (C9999, Sigma-
Aldrich) at pH 6.0 antigen retrieval at 1210C for 4 minutes in a decloaking chamber 
(DC2012, Biocare Medical). Nonspecific binding was blocked by a 1-hour incubation in 
blocking buffer (0.1 mol/L phosphate-buffered saline/5% normal goat serum/0.05% 
Tween-20) at room temperature in the dark. Immunofluorescence staining was performed 
using specific antibodies against VEGF using Anti-VEGF antibody (ab2350, Abcam) and 
Ki67 with anti-Ki67 antibody (ab15580, Abcam) in the dark, at room temperature overnight 
at 40C. Sections then were incubated for 1 hour in the dark with appropriate Alexa Fluor–
conjugated secondary antibody (ab150077, Abcam). Section were incubated with Hoechst 
33342 (62249, Thermo Fisher Scientific) diluted in PBS (P3813, Sigma-Aldrich) and 
mounted with ProLong Gold Antifade (P36930, ThermoFisher Scientific). Slides were 
examined using a Laser Scanning Confocal Inverted Microscope (FV1200, Olympus). 
RNA extraction and RT-PCR 
Colonic tissue was homogenised using an Omni Mixer Homogenizer (3410B05, Thomas 
Scientific) and RNA extracted using the RNeasy Mini spin column kit (74104, Qiagen) 
according to the manufacturer’s instructions. Integrity and concentration of extracted RNA 
was assessed using Eppendorf Biophotometer (D30, Eppendorf). Complementary DNA 
(cDNA) was synthesised from RNA samples using the iScript gDNA clear cDNA synthesis 
kit (1725034, Bio-Rad) using reaction conditions suggested by the manufacturer. 100 ng 
of cDNA from each sample was added to a PCR reaction including TaqMan Fast Advanced 
Master Mix (4444557, Applied Biosystems) and a single gene-specific TaqMan 
probe/primer set. Aim2 (Assay ID: Mm01295719_m1, Thermo Fisher Scientific), Nlrc3 
(Assay ID: Mm00615968_m1, Thermo Fisher Scientific), Nlrc4 (Assay ID: 
Mm01239561_m1, Thermo Fisher Scientific), Nlrp6 (Assay ID: Mm00460229_m1, 
Thermo Fisher Scientific), Bcl2 (Assay ID: Mm00437796_m1, Thermo Fisher Scientific) 
and Sod2 (Assay ID: Mm01313000_m1, Thermo Fisher Scientific), Ppar (Assay ID: 
Mm00440940_m1, Thermo Fisher Scientific), Myc (Assay ID: Mm00487804_m1, Thermo 
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Fisher Scientific), Survivin (Assay ID: Mm00599749_m1, Thermo Fisher Scientific) and 
Cdk2 (Assay ID: Mm00486279_m1, Thermo Fisher Scientific). Thermal cycling was 
performed using a StepOnePlus Real-Time PCR Systems (4376600, Applied Biosystems). 
Gene expression was quantified using the comparative (ΔΔCT) method where the threshold 
cycle (CT) for each gene was normalised to reference gene Gapdh (Assay ID: 
Mm99999915_g1, Thermo Fisher Scientific). Relative gene expression was presented as 
2−ΔCT. 
Colorectal neoplasms PrimerPCR assay 
Colonic tissue was homogenised using Omni Mixer Homogenizer (3410B05, Thomas 
Scientific) and RNA extracted using the RNeasy Mini spin column kit (74104, Qiagen) 
according to the manufacturer’s instructions. Integrity and concentration of extracted RNA 
was assessed using Eppendorf Biophotometer (D30, Eppendorf). Complementary DNA 
(cDNA) was synthesised from RNA samples using the iScript gDNA clear cDNA synthesis 
kit (1725034, Bio-Rad) using reaction conditions suggested by the manufacturer. 20 ng of 
cDNA of samples were loaded into the Colorectal neoplasms Tier 1 M96 plate (10035050, 
Bio-Rad). The mRNA levels of 88 genes involved in Colorectal neoplasms were detected 
at the same time using SYBR Green Supermix (1708880, Bio-Rad) on StepOnePlus Real-
Time PCR Systems (4376600, Applied Biosystems). The data were analyzed by using Bio-
Rad PrimePCR Analysis software. 
Western blotting 
Proteins from the colon were extracted using RIPA lysis buffer (R0278 Sigma) 
supplemented with proteinase and phosphatase inhibitors (4693116001, Sigma-Aldrich). 
The protein samples were resolved on 4-20% mini-protean precast SDS-PAGE gels 
(4561093, Biorad) and transferred onto polyvinylidene difluoride membrane (1620177, 
Biorad) using transfer buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol, pH 8.3) 
in a wet-transfer system. Membranes were blocked in 5% (wt/vol) dried milk in TBS-T (50 
mM Tris/HCL, pH 7.6, 150 mM NaCl and 0.1% (vol/vol) Tween-20) for 1 hour at room 
temperature. Membranes were incubated with primary antibody diluted in 5% (wt/vol) 
dried milk in TBS-T and then with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody diluted in 5% (wt/vol) dried milk in TBS-T for 1 hour. 
Membranes were developed using SuperSignal West Pico chemiluminescent substrate 
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(34580, Thermo Fisher Scientific). Membranes were stripped using Restore PLUS Western 
blot stripping buffer (46430, Thermo Fisher Scientific) before being re-probed. 
Primary antibodies used were Rabbit GSK-3β (12456, Cell Signalling Technology), 
Phospho Anti-beta Catenin (9561T, Cell Signalling Technology), CD44 Mouse mAb 
(3570, Cell Signalling Technology) Cyclin D1 Rabbit (2978, Cell Signalling Technology) 
LEF1 Rabbit mAb  (2230, Cell Signalling Technology) c-Myc Rabbit mAb (5605, Cell 
Signalling Technology) TCF1/TCF7 Rabbit mAb (2203, Cell Signalling Technology) at a 
concentration of 1 in 1,000; Anti-Ki67 antibody (ab16667, Abcam), Anti-VEGF antibody 
(ab2350, Abcam), Anti-PI 3 Kinase (Ab182651, Abcam), Anti-AKT1 antibody (ab81283, 
Abcam), IL-1β (NB600-633, Novus Biologicals), β-actin (4967, Cell Signalling 
Technology)  at 1:500. Secondary HRP-conjugated antibodies used were, anti-rabbit IgG 
(7076, Cell Signalling Technology) and Anti-mouse IgG (7076, Cell Signalling 
Technology) at 1:2000. 
Faecal and Mucosal Sample Collection and Preparation  
Faecal samples were collected from separately housed mice in a manner similar to Langille 
et al. (Langille et al., 2014). To minimize contamination, the mice were on the day of 
sampling mice had no access to food and water, and sterile forceps were used for faecal 
sample collection. At least 2 pellets (100–150 mg of the sample) were collected from each 
mouse and immediately transferred into a sterile microcentrifuge tube, stored at -80°C for 
16S rRNA gene sequencing.  
Mucosal samples were collected on the exact age after the mice were euthanized by CO2 
asphyxiation. Colon was excised, and luminal contents of colonic-mucosa were carefully 
collected with sterile forceps immediately transferred into a sterile microcentrifuge tube. 
These samples were immediately stored at -80°C for subsequent metabolomic analysis. 
Microbiota analysis using 16s rRNA High-Throughput sequencing 
The total DNA was extracted from faecal samples using the QIAamp DNA Stool Mini Kit 
(51504, Qiagen). The samples underwent high-throughput sequencing on the Illumina 
MiSeq platform at the Australian Genome Research Facility (University of Queensland, 
Brisbane, QLD, Australia). PCR amplicons spanning the 16S rRNA V3-V4 hypervariable 
region with 27F forward Primer (5’-AGAGTTTGATCMTGGCTCAG-3’) and 519R 
reverse Primer (5’-GWATTACCGCGGCKGCTG-3’) were sequenced. Paired-end reads 
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were assembled by aligning the forward and reverse reads using PEAR1 (version 0.9.5). 
Primers were identified and trimmed. Trimmed sequences were processed using 
Quantitative Insights into Microbial Ecology (QIIME 1.8) 4 USEARCH 2.3 (version 
8.0.1623) and UPARSE software (Edgar, 2013). Using USEARCH tools, sequences were 
quality filtered; full-length duplicate sequences were removed and sorted by abundance. 
Singletons or unique reads in the data set were discarded. Sequences were clustered 
followed by chimera filtering using "rdp_gold" database as a reference (Edgar et al., 2011). 
To obtain several reads in each Operational taxonomic units (OTUs), reads were mapped 
back to OTUs with a minimum identity of 97%. Using QIIME, taxonomy was assigned 
using Greengenes database5 (Version 13_8, Aug 2013) (Kuczynski et al., 2012). Image 
analysis was performed in real time by the MiSeq Control Software (MCS) v2.6.2.1 and 
Real-Time Analysis (RTA) v1.18.54, running on the instrument computer. RTA performs 
real-time base calling on the MiSeq instrument computer. Then the Illumina bcl2fastq 
2.20.0.422 pipeline was used to generate the sequence data (Edgar et al., 2011, Kuczynski 
et al., 2012). 16S rRNA gene sequences were analysed using MEGAN6 (Community 
edition version) (Huson and Mitra, 2012), Microbiome analyst (Dhariwal et al., 2017) and 
QIIME. Statistical analysis of Brady-Curtis dissimilarities was calculated using the relative 
abundances of bacterial genera was conducted using Adonis function in R (version 3.2). 
Metabolomics analysis for SCFA 
All samples were prepared and derivatised following the protocol developed by Furuhashi 
et al., (2018) (Furuhashi et al., 2018), with some modifications. Briefly, mucosal samples 
(stored at -80°C) were weighed to ±0.1 mg accuracy. These samples (100 – 150 mg fresh 
weight) were added to a sterile 1.5 mL bead-beating tube (NAVYR5, Next Advance). 
Isobutanol (78-83-1, Merck) (10% in water, volume = 1.0 mL) was added to each sample, 
followed by two 30 second, 4,000 rpm homogenization pulses sandwiched between a 20-
second pause interval with a Precellys Evolution Homogenizer (Bertin Instruments). The 
samples were subsequently centrifuged at 15,700 g for 6 minutes. 
The supernatant (675 µL) was transferred to a clean round bottomed 2 mL centrifuge tube 
(0030120094, Eppendorf,) and 20 mM, 125 µL of NaOH (30620, Merck) and 400 µL of 
chloroform (102445, Merck) were added. The samples were briefly vortexed and 
centrifuged at 15,700 rpm for 3 minutes. The aqueous phase (upper layer, 400 µL) was 
transferred to a new clean round bottomed 2 ml centrifuge tube (0030120094, Eppendorf) 
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containing a boiling chip (1.07913, Sigma-Aldrich). 100µL Pyridine (109728, Merck), 80 
µL isobutanol (78-83-1, Merck) and 70 µL milliQ water were added and the samples were 
subjected to gentle vortexing followed by addition of 50 µL isobutyl chloroformate 
(177989, Sigma-Aldrich). The tube was then opened to release any generated gases and 
was allowed to stand for about 1 minute. 150 µL Hexane (675393, Sigma-Aldrich) was 
then added to each tube, which was capped and vortexed prior to centrifugation at 15,700 
g for 4 minutes. The upper phase (100 µL) was subsequently transferred to GC autosampler 
vials fitted with salinized glass inserts; Malathion (36143, Sigma-Aldrich) (1 µL, 
equivalent to 2.5 µg/mL) was added as an internal standard. 
The GC-MS analysis was performed on an Agilent 6890B gas chromatograph (GC) oven 
coupled to a 5977B mass spectrometer (MS) detector (Agilent Technologies, Mulgrave, 
VIC, Australia) fitted with an MPS autosampler (Gerstel GmbH & Co.KG, Deutschland, 
Germany). The GC oven was fitted with two 15 m HP‐5MS columns (0.25 mm ID and 
0.25 µm film thickness; 19091S-431 UI, Agilent Technologies, Mulgrave, VIC, Australia) 
coupled to each other through a purged ultimate union (PUU) for the use of post-run 
backflushing.  The sample (1.0 µL) was introduced via a multimode inlet (MMI) operated 
in split mode (1:20). The column was maintained at 40°C for 5 min, followed by an increase 
to 250°C at a rate of 10°C/min. This was followed by a second increment to 310°C at a rate 
of 60°C/min. The column was held at 310°C for 1 min. The mass spectrometer was kept in 
Extractor ion mode (EI mode) at 70 eV. The GC-MS ion source temperature and transfer 
line were kept at 250°C and 280°C, respectively. Detector voltage was kept at 1054 V. The 
MS detector was turned off for the first 3 min and, at 4.0 – 4.8 min and 12.5 – 13.2-min 
time windows until the excess derivatization reagent and chloroformate/hexane solvents 
were eluted from the column. This ensured that the source filament was not saturated and 
damaged. The scan range was kept in the range of m/z 35 – 350 (35 – 350 Daltons). Data 
acquisition and spectral analysis were performed as described previously (Vemuri et al., 
2018) and qualitative identification of metabolites was performed according to the 
Metabolomics Standard Initiative (MSI) chemical analysis workgroup (Sansone et al., 
2007) using standard GC-MS reference metabolite libraries (NIST 17, Agilent Fiehn RTL 
Library [G166766A, Agilent Technologies] with the use of Kovats retention indices based 
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Faecal Metabolomics 
The samples were subjected to derivatisation to increase volatility before subjecting to GC-
MS analysis. Briefly, faecal samples (n = 5, weight = 40 mg) were freeze-dried and 
suspended in 1 mL methanol (322415, Sigma-Aldrich), supplemented with 10 µg/mL 
adonitol (A5502, Sigma-Aldrich) as an internal standard in sterile 2 mL bead-beating tube. 
The samples were homogenized by bead beating for 30 s and then centrifuged at 570 g/ 
4°C for 15 minutes. The supernatant (50 µL) was transferred to a fresh centrifuge tube (1.5 
mL) and dried in a vacuum evaporator centrifuge (LabGear, Brisbane, QLD, Australia) at 
35°C. Methoxyamine-HCl (20 mg/mL in Pyridine) (226904, Sigma-Aldrich) was added 
(40 µL) and samples were incubated at 30°C/ 1400 rpm (ThermoMixer C, Eppendorf) for 
90 minutes. This was followed by slylation with 70 µL BSTFA (33027, Sigma-Aldrich) at 
37°C/ 1400 rpm for 30 minutes. Pre-derivatized 13C-Stearic acid (10 µg/mL) was added 
(1 µL) as the QA/QC internal standard. The mixture was briefly vortexed and centrifuged 
at 15,700 g for 5 min. The aliquot was transferred to vials for GC-MS analysis.  
The GC-MS analysis was performed on an Agilent 6890B gas chromatograph (GC) oven 
coupled to a 5977B mass spectrometer (MS) detector (Agilent Technologies, Mulgrave, 
VIC, Australia) fitted with an MPS autosampler (Gerstel GmbH & Co.KG, Deutschland, 
Germany). The GC-MS conditions were as stated previously (Beale et al., 2013, Karpe et 
al., 2015, Beale et al., 2014). Data acquisition and spectral analysis were performed using 
the Qualitative Analysis software (Version B.08.00) of MassHunter workstation. 
Qualitative identification of the compounds was performed according to the Metabolomics 
Standard Initiative (MSI) chemical analysis workgroup (Members et al., 2007) using 
standard GC-MS reference metabolite libraries (NIST 17, Fiehn Metabolomics RTL 
Library [G166766A, Agilent Technologies] and the Golm database) and with the use of 
Kovats retention indices based on a reference n-alkane standard (C8-C40 Alkanes 
Calibration Standard, Sigma-Aldrich). For peak integration, a 5- point detection filtering 
(default settings) was set with a start threshold of 0.2 and a stop threshold of 0.0 for 10 
scans per sample. Procedural blanks (n = 7) were analyzed randomly throughout the 
sequence batch. The obtained data was processed on Quantitative analysis platform of 
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Data Analysis and Multivariate Analysis 
GC-MS data imported to Microsoft Excel platform was normalized with respect to the 
internal standard adonitol (relative standard deviation = 11.257%). The normalized data 
was further log-transformed and auto-scaled (mean-centered) before statistical analysis 
(French et al., 2018). To determine overall microbial variation in four groups, we used a 
principal coordinate analysis (PCoA), Unweighted Pair Group Method with Arithmetic 
Mean (UPGMA) dendrogram, Neighbour-Net (a distance-based method for constructing 
phylogenetic networks) hierarchical clustering with Brady-Curtis ecological indexing and 
Euclidean distances as the similarity measure and Ward’s linkage as clustering algorithm 
(Yu et al., 2017, French et al., 2018). For analysis of metabolome variations, Principal 
component analysis (PCA), partial least squares-discriminant analysis (PLS-DA) and 
orthogonal (O) PLS-DA were used. Because PLS-DA can overfit data, we used 1000 
permutations to validate these models. The OPLS-DA was used to identify discrimination 
between metabolites contributing to classification.  
Statistical Analysis 
Graph Pad Prism version 7.0 for Windows was used for the statistical analysis. The data 
were analyzed using the Wilcoxon Mann–Whitney Test (multiple comparisons), with p < 
0.05 set as the level of statistical significance. For microbial comparative analysis, a linear 
discriminant effect size (LEfSe) analysis was performed (α = 0.05), logarithmic Linear 
Discriminant Analysis (LDA) score threshold = 1.0. A MetaboAnalyst (Version 4.0) data 
annotation approach and Kyoto Encyclopaedia of Genes and Genomes (KEGG) Pathway 
Database were used for the hierarchical clustering analysis, significance analysis for 
microarrays (SAM) along with the variable importance of projection (VIP) (Sun et al., 
2013). The SAM and VIP methods are a well-established statistical method for metabolites, 
was used to select the most discriminant and interesting biomarkers (Hayakawa et al., 
2016). 
6.3 Results 
6.3.1 Analysis of proliferation, apoptosis and angiogenesis in colonic tissue 
Since colonic tumorigenesis is associated with abnormal proliferation of the crypt 
epithelium, we assessed the localisation of the Ki-67 marker of proliferating cells. We 
observed that colonic mucosal epithelial cell proliferation, as indicated by Ki-67 staining, 
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was decreased in Winnie mice compared with Winnie x Nlrp3-/- (Figure 6.1a). In contrast, 
the proliferative signal intensity of the colonic crypt of Winnie x Nlrp3-/- at week 16 was 
more intense than Winnie x Nlrp3-/- at week 12 suggesting increased proliferation of the 
colonic epithelium. 
Tumour cells develop mechanisms to avoid programmed cell death mediated by apoptosis 
by upregulating IAPs such as Survivin. We looked in to the expression of Survivin in 
colonic tissue of Winnie and Winnie x Nlrp3-/-. We found an elevated expression of VEGF 
in Winnie x Nlrp3-/- when compare to Winnie mice (Figure 6.1b).  
Since neoangiogenesis is essential for the tumour growth, we evaluated the expression of 
potent angiogenic factor VEGF in colonic tissue of Winnie and Winnie x Nlrp3-/-. We found 
an elevated expression of VEGF in Winnie x Nlrp3-/- when compare to Winnie mice (Figure 
6.1c). 
Figure 6.1: Expression of Ki67, Survivin and VEGF. Representative immunofluorescence confocal 
images showing expression of Ki-67 in colonic tissue in Winnie (W), Winnie x Nlrp3-/- 12-week 
(WxN 12wk) and Winnie x Nlrp3-/- 16-week (WxN 16wk) mice proximal and distal colon tissue. 
Western blotting showing expression levels of (b) Survivin (c) VEGF (the loading control used was 
β-actin) in Winnie (W), Winnie x Nlrp3-/- 12-week (WxN 12wk) and Winnie x Nlrp3-/- 16-week 
(WxN 16wk) mice proximal and distal colon tissue. Data are from one experiment representative 
of three independent experiments.  
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6.3.2 Analysis of Inflammasome mRNA expression profile in colonic tissue  
Quantitative reverse-transcriptase PCR analysis revealed a significant reduction in the 
expression of the gene encoding NLRP6 in Winnie x Nlrp3-/- at week 12 tumour tissue of 
the proximal colon when compared with non-tumour-associated tissue in the proximal 
colon of C57BL/6 (Figure 6.5a). In the distal colon tissue of Winnie x Nlrp3-/- week 12 a 
significant reduction of the expression of AIM2, NLRC4 and NLRP6 were observed 
(Figure 6.5b). In Winnie x Nlrp3-/- week 16 proximal and distal colon tissue expressed a 
significantly increased expression of AIM2, NLRC3, NLRC4 and NLRP6 when compare 
to C57BL/6 expression (Figure 6.5b). 
6.3.3 Analysis of colorectal cancer biomarker array in colonic tissue 
In this study, we used Bio-Rad PrimePCRTM microarray gene expression platform for 
analysis of altered molecular signatures of colorectal neoplasia in the mouse colon of 
Winnie x Nlrp3-/- 12 week and 16 weeks relative to Winnie. We have presented the 
dysregulated biomarkers significant in relative expression as cluster gram and tabled the 
relative P-values in Figure 6.3. 
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Figure 6.2: The mRNA expressions of AIM2, NLRC3, NLRC4 and NLRP6 in (a) proximal and 
(b) distal colon tissue were determined by real time PCR. Nlrp3-/-, Winnie, Winnie x Nlrp3-/- data 
was normalised to the C57BL/6 samples. Data are expressed as the mean±SEM (n=6 per group) *P 
< 0.05, **P < 0.01, ***P < 0.001 (one sample t test).
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Figure 6.3: The expression of mRNA of Colorectal neoplasm biomarkers in Winnie and Winnie x Nlrp3-/- at 12 week and 16week (a) proximal and (b) distal 
colon tissue were determined by Bio-Rad PrimePCRTM. The cluster gram and relative normal expression of Winnie x Nlrp3-/- at 12 week and 16-week data was 
normalised to the C57BL/6 samples by the Bio-Rad PrimePCR Analysis software. Data are expressed as the mean±SEM (n=2 per group) P values obtained by 
one sample t test.
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The data shows significant upregulation of Bcl2, Birc5 (Survivin), Cav1, Cd44, Hif1a, Myc, 
Ppar, Stat3, Ptgs2 (Cox2), Sod2, Vegfa and Zwint in Winnie x Nlrp3-/- when compared to 
Winnie. We observed a significant down regulation of the genes Pten and Vdr in Winnie x 
Nlrp3-/- when compared to Winnie. These dysregulated biomarkers could hint at molecular 
pathways in colonic carcinogenesis in Winnie x Nlrp3-/-. 
  
Figure 6.4: The mRNA expressions of Bcl2, Sod2, Ppar,Myc, Survivin and Cdk2 in distal colon 
tissue were determined by real time PCR. Winnie x Nlrp3-/- 12-week (WxN wk12) and Winnie x 
Nlrp3-/- 16-week (WxN wk16) were normalised to the C57BL/6 samples. Data are expressed as the 
mean±SEM (n=6 per group) *P < 0.05, **P < 0.01, ***P < 0.001 (one sample t test). 
 
Using RT-PCR, we validated the upregulated expression of six genes significantly involved 
in many biologic processes relevant to cancer such as apoptosis, cell proliferation, and cell 
cycle arrest. All these genes showed a significant upregulation in relative expression in the 
distal colon of Winnie x Nlrp3-/- 12-week and Winnie x Nlrp3-/- 16-week compared to 
Winnie (Figure 6.4). 
6.3.4 Analysis of upregulated molecular signalling pathways  
To examine whether PI3k/AKT pathway is upregulated in the Winnie x Nlrp3-/-, we first 
investigated the activity of PI3K and saw that PI3K phosphorylation increased in Winnie x 
Nlrp3-/- in comparison to Winnie colon tissue (Figure 6.5j). Then we analysed the 
phosphorylation of Akt at Ser473, which is strongly dependent upon PI3K activity. Figure 
6.5i shows that Winnie x Nlrp3-/- clearly resulted in a progressive and significant increase 
in Akt phosphorylation. 
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We analysed the protein expression profile of the Wnt/β-catenin signalling pathway in the 
novel model Winnie x Nlrp3-/- colonic tissue. Firstly, we analysed the phosphorylation 
status of GSK-3β and observed upregulation in Winnie x Nlrp3-/- colonic tissue (Figure 
6.5g). We then monitored the status of phosphorylated β-catenin, the downstream substrate 
of GSK-3β, and showed a significant decrease in this protein (Figure 6.5f). Next, we 
monitored the expression status of LEF1 and TCF and observed an increased expression in 
Winnie x Nlrp3-/- colonic tissue (Figure 6.5 d and e). We then analysed c-myc (Figure 6.5 
c), Cyclin D1(Figure 6.5b) and CD44 (Figure 6.5c) the chief genes upregulated by 
transcription factor TCF/LEF. CD44 showed an increased expression in Winnie x Nlrp3-/- 
12 week and 16week (Figure 6.5a) while c-myc and were only expressed in the Winnie x 
Nlrp3-/- distal colonic tissue at 16 weeks. We analysed the IL-1β expression and found it 











Figure 6.5: Western blotting of upregulated upstream signaling molecules within the PI3K/Akt and 
Wnt/β-catenin pathway in Winnie, Winnie x Nlrp3-/- 12-week (WN 12wk) and Winnie x Nlrp3-/- 
16-week (WN 16wk) mice Proximal and Distal colon tissue. Data are from one experiment 
representative of three independent experiments.  
 
Proximal Colon Distal Colon 
 
 
Agampodi Promoda Perera 
ROLE OF NLRP3 IN COLITIS AND COLITIS ASSOCIATED COLORECTAL CANCER   125 
 
6.3.5 Analysis of Microbiota  
 
Figure 6.6: C57BL/6, Nlrp3-/-, Winnie, Winnie x Nlrp3-/- 12-week (WN 12wk) and Winnie x Nlrp3-
/- 16-week (WN 16wk) mice faecal bacteria 16S rRNA V3-V4 region was sequenced with Miseq 
technology (Illumina) and Shannon-Weaver index (a) and Simpson Diversity index (b) were 
compared between the mouse groups. Data are shown as means ± SEM (n=3).  
To investigate whether an altered gut microbiota directly underlies the pathogenesis of 
colorectal cancer, we analysed the levels of major bacterial species of gut microbiota in 
stool samples of separately housed (single housed) C57BL/6, Nlrp3-/-, Winnie and Winnie 
x Nlrp3-/- mouse groups in three independent experiments. Faecal microbiota profiling was 
performed using 16S rRNA gene sequencing-based method. 
We calculated the Shannon and Simpsons index which are diversity indexes encompassing 
comprehensive OTU richness and OTU evenness, and the larger the index, the more 
abundant the species in the samples. We found that the richness and diversity of the 
intestinal microbiota do not differ among the groups as seen by the Shannon-Weaver and 
Simpsons indexes (Figure 6.6).  
Interestingly in our study, the PCoA plots of phylogeny with Brady-Curtis ecological 
indexing using ward clustering showed a clear separation of each group with four distinct 
clusters at the OTU level among 4 groups (Figure 6.7a). Interestingly, PCoA plot showed 
the control groups (C57BL/6, Nlrp3-/-) were concentrated in one quadrant, while the 
remaining diseased groups (Winnie x Nlrp3-/-, Winnie) were concentrated in another 
quadrant, this indicates that the overall structure of the gut microbiota shows a striking 
difference in the composition of microbial communities between the control and diseased 
models.   
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Figure 6.7: The gut microbiota changes observed in C57BL/6, Nlrp3-/-, Winnie, Winnie x Nlrp3-/- 
12 week (WN 12wk) and Winnie x Nlrp3-/- 16 week (WN 16wk) were differentiated by principle 
coordinate analysis (PCoA) using Brady Curtis ecological index distance method (a). The gut 
microbiota composition profiles at phylum (b), genus levels (C) and species level (d) in all 5 groups 
revealed by 16S rRNA gene sequencing. 
We classified around 99% of the total microbial abundance into nine major phyla in all 
groups, the rest were allocated as unknown (Figure 6.7b). At the phylum level, the 
abundance of dominant intestinal bacteria such as Bacteroidetes becomes significantly 
reduced (P < 0.05) in the Winnie and Winnie x Nlrp3-/- genotypes while the Firmicutes 
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have increased when compared to C57BL/6. In line with the findings a study has shown a 
decrease in overall abundance of Bacteroidetes in IBD (Blumberg and Powrie, 2012). We 
found a significantly higher (P < 0.05) abundance in Verrucomicrobia in Winnie and 
Winnie x Nlrp3-/- genotypes when compare to C57BL/6.  
At the genus level, the distribution of microbial populations of Winnie and Winnie x Nlrp3-
/- was markedly different when compared to C57BL/6 group. The experimental genotypes 
were enriched with higher populations of colitogenic Akkermansia and Bacteroides while 
reducing the abundances of beneficial Prevotella and Lactobacillus as shown in Figure 6.7 
c.  
At the species level, there was a significant increase (p < 0.05) in Akkermansia munciphilia 
levels, and significant decrease (p < 0.05) in Desulfovibrio C21_c20, Ruminococcus gnavus 
and Bacteroides acidifaciences levels in the Winnie and Winnie x Nlrp3-/-, when compared 
to C57BL/6 group (Figure 6.7 d). 
6.3.6 Analysis of Metabolomics and SCFA  
To gain an untargeted overview of CAC related changes in dominant gut metabolites, we 
analysed mucosal samples using a GC-MS platform. A total of 68 metabolites of different 
functional groups such as sugars, amino acids and biogenic amines were detected. An 
unsupervised PCA was used to obtain an overview of the samples, and all samples were 
clearly discriminated, as shown in Figure 6.8a. PCA analysis showed four distinct 
clustering of the four genotypes. The samples from control groups (C57BL/6 and Nlrp3-/-) 
were different from Winnie and Winnie x Nlrp3-/- disease groups. The control and disease 
groups formed two clusters that were different and showed great divergence compared to 
the control groups. Similarly, the Nlrp3-/- group formed a cluster which was different from 
the Winnie group and more closely related to the WT group. The biplot for PC1 and PC2 
showed the compounds with the greatest impact on the division among the samples, as 
shown in Figure 6.8b. In order to provide a better visualization and to carry out the class 
information of each variable, a supervised PLS-DA approach was used to evaluate the 
metabolic patterns of Winnie group and Winnie x Nlrp3-/- group (Figure 6.8C). The 
accuracy, R2X, R2Y and Q2 of PLS-DA score analysis was 0.875, 0.821, and 0.517, 
respectively (Figure 6.8C), indicating the classification was well suited for the models, and 
the genotypes were classified clearly. This analysis indicated the clear differences in the 
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Figure 6.8: a. Principle component analysis (PCA) plot of mucosal collected from C57BL/6, Nlrp3-
/-, Winnie, Winnie x Nlrp3-/- 12 week (WN 12wk) and Winnie x Nlrp3-/- 16 week (WN 16wk) 
showing divergence. b. Key compounds separating all four groups based on variable importance in 
projection (VIP) score plot.  
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metabolic profiles of mice in Winnie group and Winnie x Nlrp3-/- group, which suggests 
that CAC induced significant biochemical changes. 
 
Figure 6.9: Short chain fatty acid (SCFA) distribution observed in C57BL/6, Nlrp3-/-, Winnie, 
Winnie x Nlrp3-/- 12 week (WN 12wk) and Winnie x Nlrp3-/- 16 week (WN 16wk). The 
concentrations of butyrate (a), propionate (b) and acetate (c) were measured by GC-MS analysis 
from mucosal contents. *P < 0.05, **P<0.01, ***P<0.001 (One-way ANOVA with Tukey’s post-
hoc test and data are expressed as the mean ± SEM).  
A total of 15 volatile compounds were identified in the untargeted metabolomics from 
mucosal samples in all four groups Table 6.1. These 15 metabolites included the three 
major SCFA of butyrate, propionate, and acetate. C57BL/6 and Nlrp3-/- did not show any 
difference in the production of butyrate, propionate, and acetate in the mucosal samples. 
Notably, in the mucosal samples, butyrate, propionate, and acetate levels were significantly 
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Table 6.1: List of volatile fatty acids (VFA) identified in C57BL/6, Nlrp3-/-, Winnie, Winnie x 
Nlrp3-/- 12wk, Winnie x Nlrp3-/- 16wk n=3. The concentrations of VFA in the mucosal content 
(samples were measured by GC-MS analysis from mucosal contents at the end of the study. 
*P < 0.05 (One-way ANOVA with Tukey’s post-hoc test and data are expressed as the mean ± 
SEM). 
Volatile fatty acids C57BL/6 Nlrp3-/-  Winnie WN 12wk WN 16wk 









0.18 ± 0.05 
*** 
0.33 ± 0.11 
*** 
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0.19 ± 0.04 
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0.31 ± 0.06 
2-Propen-1-ol, 2-
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1.6 ± 0.35 
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6.4 Discussion 
Initiation of CAC occurs when activated inflammatory signalling pathways (Grivennikov, 
2013) lead to aberrant intestinal epithelial and disruption of homeostasis. The epithelial 
cells undergo abnormal proliferation with decreased differentiation and apoptosis leading 
to early dysplasia and adenomatous polyps. High expression of Ki-67, a cell proliferation 
marker, is considered an independent  prognostic marker in colorectal cancer (Melling et 
al., 2016). The results revealed a significant increase in numbers of both Ki-67+ cells in 
intestinal crypt of Winnie x Nlrp3-/- compared to Winnie mice confirming colitis associated 
carcinogenesis in colonic tissue. 
Survivin is a member of the inhibitor of apoptosis (IAP) family that counteracts cell death 
and controls mitotic progression and is overexpressed in colorectal cancer (Li et al., 1999, 
Altieri, 2003). Evidence from cDNA microarray demonstrated that Survivin also plays an 
important role in the pathogenesis of CRC (Williams et al., 2003, Huang et al., 2013). 
Similarly, the results demonstrated an upregulation at the protein and the gene level for 
Survivin in the colonic tissue of Winnie x Nlrp3-/- compared to Winnie mice. 
Kim et al has shown that Survivin is a new target gene of the TCF/ catenin signalling axis, 
coupling increased cell proliferation to enhanced cell survival in intestinal crypt cells (Kim 
et al., 2003). Similarly, other studies have shown compelling evidence that the presence of 
Survivin in CRC is strongly associated with the expression of Bcl2 and ki-67 demonstrating 
that Survivin expression is related to CRC proliferation (Danilewicz et al., 2015, Cai et al., 
2015). Likewise, the results show a significant correlation between the increased expression 
of Survivin, Bcl2 and ki-67. 
In colon cancer VEGF expression is elevated in tumour tissue and positively correlates with 
advanced tumour stage as well as reduced life expectancy (Cao et al., 2009, Bendardaf et 
al., 2008). CAC mouse model (AOM/DSS-treated) has shown elevated expression of  
VEGF with anti-VEGF treatment reducing the tumour growth (Waldner et al., 2010a). In 
another study inhibition of VEGF dramatically reduced the tumour development, 
angiogenesis and cell proliferation (Waldner et al., 2010b). Moreover, it has been shown 
that β-catenin/Wnt signalling regulates VEGF expression in CRC (Easwaran et al., 2003). 
In addition to tumorigenesis, angiogenesis and VEGF is associated in the pathogenesis of 
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inflammatory bowel disease (Costa et al., 2007). In line with these studies the results show 
VEGF expression in both Winnie and Winnie x Nlrp3-/- mouse models. 
Absent in melanoma 2 (AIM2) is a pyrin-HIN protein that binds cytosolic double-stranded 
DNA and forms the active inflammasome complex with the common inflammasome 
adaptor ASC (Hornung et al., 2009, Fernandes-Alnemri et al., 2009). A previous study 
showed that AIM2 gene reduction or absence is observed in several cancer types (Patsos et 
al., 2010).  
A study has shown that AIM2 physically interacted with and limited activation of DNA-
dependent protein kinase (DNA-PK) (Merkle et al., 2002). DNA-PK is a PI3K-related 
family member that promotes Akt phosphorylation (Feng et al., 2004, Li et al., 2013, Lu et 
al., 2006). A recent study has shown AIM2 reduced Akt activation and tumor burden in 
CAC mouse models. The same study showed the effects of AIM2 on CAC were 
independent of inflammasome activation and IL-1β and were primarily mediated by a non–
bone marrow source of AIM2 (Wilson et al., 2015). Similarly, in the study we have 
observed a significant reduction of AIM2 in the tumour tissue of the distal colon of the 
Winnie x Nlrp3-/- mice at 12 weeks while the expression of IL-1β cytokine was significantly 
high. 
However, we observed a significant increase in expression of the inflammasomes AIM2, 
NLRC3, NLRC4 and NLRP6 in Winnie x Nlrp3-/- week 16 mouse colons. At 16 weeks 
Winnie x Nlrp3-/- mice have solid tumours with invasive carcinomas with high expression 
of ROS and DNA damage markers. Overproduction of these DAMPS could lead to the over 
activation of inflammasomes and could explain the upregulation of inflammasomes genes 
seen in Winnie x Nlrp3-/- week 16.  
The results of the quantified transcription of genes associated with colorectal neoplasms 
revealed significant upregulation of many genes related to multiple signalling pathways. 
These target genes are involved in tumour cell survival (e.g. Bcl2, Survivin), proliferation 
(e.g. cdk2, Myc, cd44, jun), angiogenesis (e.g. Hif1alpha, Vegfa), inflammation (e.g. IL-6, 
Sod2, Cox2) and epithelial mesenchymal transition (EMT) (e.g. zwint). 
Bcl2 overexpression is known to suppress caspase-1 mediated cell death (Miura et 
al.,1993). Similarly, we saw a significant upregulation of Bcl2 in Winnie x Nlrp3-/- colon 
which could lead to the survival of malignant cells initiating tumorigenesis.  
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Cdk2 is cyclin-dependent kinase 2 is a promoter of cell cycle and mitosis and is associated 
with colon cancer (Yamamoto et al., 1998). qPCR analysis showed a significant increase 
of Cdk2 in Winnie x Nlrp3-/- colon which could aid in the aberrant cell proliferation 
observed in the colonic epithelium of Winnie x Nlrp3-/-.  
Myc plays a fundamental role in several cellular functions, including regulation of cell 
growth, proliferation, metabolism, differentiation, apoptosis, and angiogenesis (Gabay et 
al., 2014). We found an increase in Myc expression in the Winnie x Nlrp3-/- distal colon at 
the protein and gene level indicating Myc plays a prominent role in tumorigenesis in the 
CAC model. 
Ptgs2 (Cox-2) plays an important role in invasion, angiogenesis and metastasis of colorectal 
carcinogenesis. Elevated expression of Ptgs2 is found to be exhibited in 85% of colorectal 
tumours (Gupta and Dubois, 2001) and later upregulated with the advance stages 
(Castellone et al., 2005). It is expressed early by IECs in response to growth factors and 
proinflammatory cytokines during inflammation (Ishikawa and Herschman, 2010) and 
plays a very crucial role in prognosis of CRC at an early stage (Umar et al., 2004). Cox-2 
may promote tumour development through its ability to induce the expression of 
antiapoptotic proteins such as Bcl-2 and result in resistance to apoptosis. In addition, 
overexpression of Cox-2 is associated with elevated levels of MMPs and increased 
migration of malignant cells (Gupta and Dubois, 2001). Similarly, we observed a 
significant upregulation of Cox-2 gene expression in Winnie x Nlrp3-/- colon indicating this 
molecule plays an essential role in the tumorigenesis of the novel mouse model. 
Interestingly, the results showed a significant decrease in the gene expression of Vdr 
(vitamin D receptor) in the Winnie x Nlrp3-/- colon. Vdr mediates the active metabolite of 
Vitamin D to produce varieties of biological effects (Baker et al., 1988). Some studies have 
shown that Vdr mRNA and protein levels are reduced in the early stages of colon cancer 
(Giardina et al., 2015, Anderson et al., 2006). Vitamin D has been proposed as a 
chemotherapeutic agent against cancer but the loss of Vdr reduce the beneficial effects of 
high vitamin D status on cancer progression  (Fleet et al., 2012). The above studies 
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Ppar is a metabolic regulator of lipid anabolism. Activation of Pparδ can induce Cox-2 
expression via a self-amplifying loop contributing to colorectal carcinogenesis(Oshio 
et al., 2008). Likewise, the Winnie x Nlrp3-/- colon revealed a significant upregulation of 
Ppar. 
We observed an upregulation of Stat3 in the Winnie x Nlrp3-/- colon. Activation of Stat3, 
by proinflammatory cytokines leads to the regulation of anti-apoptotic genes such as Bcl-
2, cell cycle regulators, like Cyclin D1 or c-Myc and angiogenic factors, such as and VEGF 
(Grivennikov and Karin, 2010a, Yu et al., 2009). Indeed, inactivation of Stat3 in intestinal 
epithelium affects both cell survival and cell proliferation during acute or chronic colitis 
(Bollrath et al., 2009, Grivennikov et al., 2009, Pickert et al., 2009) and in cancer model 
decreases CAC tumor multiplicity and diminishes tumor growth (Bollrath et al., 2009, 
Grivennikov et al., 2009).  
In addition, we observed a significant increase in the gene expression of Hif1a in the Winnie 
x Nlrp3-/- colon. Hif1a is a master regulator of cell response to hypoxia by activating genes 
involved in angiogenesis, apoptosis, and energy metabolism (Bakker et al., 2007, Shi et al., 
2013). 
Interestingly, we observed a high expression of EMT-associated transcription factor Zwint 
in the Winnie x Nlrp3-/- colon. Zwint is upregulated in the early event of invasion and 
metastasis and is regulated by the Wnt/ β -catenin signalling pathway (Rodriguez-Salas et 
al., 2017, Abbas and Dutta, 2009). 
Several inflammatory pathways, including of NF-κB, PI3K/Akt pathways can drive β-
catenin nuclear accumulation thereby increasing Wnt/β-catenin signalling (Lee et al., 2010, 
Kaler et al., 2009b, Brown et al., 2010). Similarly, the Western blot results showed 
upregulation of apical molecules of the PI3K/Akt and the Wnt/β-catenin. The results 
suggest that colitis associated activation of PI3K/Akt signalling activates the Wnt/β-catenin 
pathway by increasing p-GSK3β and directing β-catenin to the nucleus to upregulate 
transcription factors that induce cell proliferation and cell differentiation signalling.  
A recent study  demonstrated that colon cancer cells stimulate normal human monocytes 
and THP1 macrophages to release IL-1β, and showed that IL-1β is sufficient to induce 
canonical Wnt signalling and to promote growth of colon cancer cells through inactivation 
of GSK3β in the epithelial cells, establishing a previously unknown link among 
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inflammation, IL-1β and Wnt signalling and growth of colon cancer cells (Kaler et al., 
2009a). Another study from the same group has shown that IL-1β secreted by tumour 
associated macrophages activate NF-κB dependent PDK1/AKT signalling which mediate 
phosphorylation of GSK3β and enhance activation of Wnt signalling, and promote c-myc. 
(Kaler et al., 2009b). Activation of NF-κB family of transcription factors in tumour cells 
appears to be a critical molecular link between inflammation and cancer (Karin and Greten, 
2005). Activation of NF-κB can stimulate tumour progression and invasion through the 
expression of VEGF, Cox-2, and IL-8 to promote angiogenesis (Wang et al., 2009). 
Specific inactivation of NF-κB signalling in intestinal cells dramatically decreased the 
incidence of intestinal tumours in a mouse model of colitis associated cancer (Greten et al., 
2004). Analysis of Winnie x Nlrp3-/- at the gene and protein level shows an over expression 
of IL-1β in the tumour associated colonic tissue. The above observations establish 
increased production of IL-1β and subsequent over activation of NF-κB leading to the 
aberrant activation of Wnt signalling as a novel molecular link between inflammation and 
tumor growth which is very relevant mechanism to the tumorigenesis of Winnie x Nlrp3-/-
. 
Pten (Phosphatase and tensin), acts as a tumor suppressor gene, has been found damaged 
or deficient in many cancer (Lin et al., 2011, Garcia et al., 1999). One major function of 
PTEN is to negatively regulate PI3K signalling (Stambolic et al., 1998). The abnormal 
activation of Wnt/β-catenin signalling is one of the major causes of cancer, which can be 
regulated by PTEN/PI3K/Akt signalling through the phosphorylation of GSK-3β. The 
decreased expression of Pten gene could be responsible for the cell proliferation effect in 
Winnie x Nlrp3-/- colon cancer cells 
The results suggest the deficiency of NLRP3 inflammasome stimulates NF-κB, 
PTEN/PI3K/Akt and Wnt/β-catenin signalling mechanisms which play central role in CAC 
seen in Winnie x Nlrp3-/- mouse model. However, the exact mechanism by which the 
NLRP3 inflammasome negatively regulates these pathways remains to be defined. 
Therefore, this model could be used to further study major pathways initiating colon cancer 
and could reveal potential therapeutic target for treatment for CAC. 
Analysis of the gut microbiota composition shows Winnie x Nlrp3-/- mice promotes the 
development of a proinflammatory microbiota. The study found that the genus Prevotella, 
which have been shown to be colitogenic (Elinav et al., 2011) is significantly increased 
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whereas Lactobacillus a low risk associated with CAC (Reddy et al., 1985)  is significantly 
decreased in the Winnie x Nlrp3-/-. At the species level Akkermansia muciniphila is 
significantly increased in Winnie and Winnie x Nlrp3-/- mice microbiota. A recent study 
has shown the abundance of mucin-degrading microbe, pathobiont Akkermansia 
muciniphila was sufficient for promoting intestinal inflammation in spontaneous colitis in 
Il10-/- mice (Seregin et al., 2017). From these findings, it can be concluded that the overall 
nature of Winnie x Nlrp3-/- mice microbiota is intrinsically more pathogenic. 
A healthy intestinal barrier is very important for intestinal homeostasis. This is underscored 
by the fact that any interference with the quality of mucus layer or with tight junctions leads 
to increased susceptibility to intestinal inflammation (Johansson et al., 2008, Petersson et 
al., 2010). Similarly, in Winnie mice, a missense mutation in the Muc2 gene results in 
aberrant Muc2 biosynthesis leading to depleted mucus barrier increasing vulnerability to 
luminal bacteria, antigens and to inflammation-inducing toxins. 
Furthermore, CAC is also associated with impaired barrier function, facilitating bacterial 
translocation and the induction of cytokines that maintain an inflammatory environment 
within the tumour (Jobin, 2012). Another study has detailed barrier deterioration induced 
during colon cancer results in adenoma invasion by microbial products, thereby promoting 
tumour-elicited inflammatory cytokines, including IL-17 and IL-23. These cytokines, in 
turn, lead to enhanced tumour growth (Grivennikov et al., 2012).   
Consistent with these studies ablation of Muc2, a major component of mucus layer in the 
colon, in the Muc2-/- mice, causes spontaneous intestinal inflammation (Van der Sluis et 
al., 2006) that progresses to CAC even without introduction of additional mutations or 
carcinogens (Velcich et al., 2002) and also accelerates adenoma growth when introduced 
into ApcMin mice (Yang et al., 2008). 
From the studies mentioned above, we can conclude that a possible mechanism of 
pathogenesis of CAC observed in Winnie x Nlrp3-/- could be due to a depleted mucosal 
barrier exposing the intestinal epithelium to the tumorigenic bacteria identified in the 
Winnie x Nlrp3-/- microbiota in the absence of the protective innate immune modulator the 
NLRP3 Inflammasome. 
The gut microbiota produces SCFA, which promote colonic health and ameliorate 
inflammation (Smith et al., 2013). The functions of butyrate in promoting colonic health 
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range from being energy source for colonocytes and by playing a role in the prevention and 
treatment of distal ulcerative colitis, Crohn’s disease, and cancer (Canani et al., 2011). Gut 
microbiome analysis has revealed a significant decrease in the number of butyrate-
producing bacteria in colon of patients with ulcerative colitis and colon cancer (Frank et 
al., 2007, Wang et al., 2012). Furthermore, colonic irrigation with butyrate suppresses 
inflammation during ulcerative colitis (Hamer et al., 2008). From the studies mentioned 
above we can conclude that the significant decrease in SCFAs particularly butyrate seen in 
the disease genotypes Winnie and Winnie x Nlrp3-/- contributes to the ulcerative colitis and 
colitis associated cancer phenotypes, respectively. 
6.5 Conclusion 
The data generated in this study showed that in Winnie x Nlrp3-/-, molecules related to cell 
proliferation, angiogenesis, and anti-apoptotic activity were upregulated at the gene and 
protein level while down regulated molecules were negatively associated with colitis 
associated colon cancer. Altogether the results validate Winnie x Nlrp3-/- as a CAC model. 
These dysregulated biomarkers points to a potential mechanism where NF-κB, 
PTEN/PI3K/Akt and Wnt/β-catenin signalling pathways play a central role in CAC seen in 
Winnie x Nlrp3-/- mouse model (Figure 6.10). Winnie x Nlrp3-/- has shown an association 
between colitogenic microbiota and CAC susceptibility and introduces a novel therapeutic 
marker for diagnosis or treatment of CAC in future. Furthermore, the Winnie x Nlrp3-/- 
mouse model introduced in the study represent a promising animal model for colitis 
associated colorectal cancer, caused by dysregulation in innate immune signalling, 
providing a new option for future studies in therapeutic agents for CAC. 
In summary, the results of this study and those by others demonstrated that NLRP3 
contributes to the negative regulation of tumorigenesis in CAC (Zaki et al., 2010b, Allen 
et al., 2010, Yao et al., 2016). Future studies unravelling the exact functional mechanism 
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Figure 6.10: Proposed mechanism of colitis associated colon cancer in Winnie x Nlrp3−/− mouse 
model. The three signaling pathways controlling the tumorigenesis of the intestinal epithelium are 
Wnt, PI3K and NF-kB. 3-phosphinostitide dependent protein kinase-1 (PDK1), Casein Kinase 1 
(CK1), Dishevelled protein (DVI), Glycogen synthase kinase- 3β (GSK3β),IκB kinase (IKK), 
Nuclear facto kB (NF-KB), Phosphate and tensin homolog deleted on chromosome 10 (PTEN), 
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Chapter 7 
General Discussion  
7.1 Final Discussion 
The inflammasome was first discovered by Martinon et al. (Martinon et al., 2002) and 
during the prevailing 17 years has been an intense area of research in immunology. NLRP3 
inflammasome has been the most characterised among the inflammasomes and is closely 
associated with intestinal inflammatory diseases such as colitis. A major complication of 
colitis is the development of colitis-associated colorectal cancer (CAC). However, specific 
underlying mechanisms through which colitis regulates CAC initiation and progression are 
not understood. 
Three main studies were conducted in this thesis; 1) investigate the efficacy of specific 
NLRP3 inhibitor MCC950 to ameliorate colitis (Chapter 4), 2) Evaluate the effect of 
NLRP3 on the severity of colitis, by the generation and study of Winnie mice deficient in 
Nlrp3 (Chapter 5), 3) investigate the influence of NLRP3 inflammasome on gut 
microbiome and metabolomics in colitis (Chapter 6). 
The reasons for conducting these studies were, that despite over 10 years of intensive 
research, the suggested role of NLRP3 in the gut remains multifaceted and controversial. 
Some studies using artificially induced models of colitis (Dextran Sodium Sulphate) and 
colorectal cancer (carcinogen Azoxymethane) indicate that Nlrp3-/- mice exhibit severe gut 
inflammation while others have reported protection from colitis and improved gut barrier 
integrity. The reason for the discrepancies observed in the Nlrp3-/- chemically induced 
colitis and CAC model phenotype is not clear but could be due to differences in length and 
concentration of chemical treatment or baseline differences in the composition of the 
intestinal microbiota in experimental mice. 
To settle these conflicting data and as a novel solution to previous experimental errors, I 
conducted all investigations in the spontaneous colitis mouse model Winnie. Winnie mice 
have a single missense mutation in the Muc2 mucin gene resulting in a depleted intestinal 
mucus barrier and develop spontaneous distal intestinal inflammation displaying symptoms 
of pain, diarrhoea and rectal bleeding at different stages of colitis like human ulcerative 
colitis (UC).  
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Currently, treatment for colitis is not curative; with patients commonly, enduring relapsing 
illness for the remainder of their lives. Thus, there is an urgent need to develop potent drugs 
with novel mechanisms of action. Given the evidence that aberrant NLRP3 activation is 
involved in the progression of colitis, targeting the activation pathway is a promising 
strategy for the development of novel effective therapeutics for colitis. Many chemical 
NLPR3 inhibitors tested in experimental colitis mouse models have shown reduced disease 
severity however these inhibitors were not specific to the NLRP3 inflammasome. MCC950 
is a potent, highly specific small molecule inhibitor of both canonical and noncanonical 
activation of NLRP3 inflammasome and has been evaluated in a multitude of NLRP3 
driven inflammatory diseases.  
I investigated the therapeutic effect of MCC950 in the spontaneous chronic colitis mouse 
model Winnie. This study is significant, and, to my knowledge, it is the first to examine the 
efficacy of a specific NLRP3 inhibitor in a naturally occurring spontaneous colitis murine 
model.  Application of a specific inhibitor enabled me to quantify the contribution of anti-
inflammatory effects resulting exclusively from inhibition of both the canonical and non-
canonical NLRP3 inflammasome activation in colitis. This primary finding supports the 
use of specific NLRP3 inhibitors as therapeutic option in colitis. 
MCC950 treatment significantly ameliorated colitis with improved body weight gain, colon 
length, ratio of colon weight to body weight, and disease activity index. Histopathological 
scores of MCC950 treated Winnie mice were significantly reduced suggesting not only 
attenuation of ongoing colitis but also delay of disease onset. MCC950 significantly 
suppressed IL-1β and IL-18 cytokine expression at both mRNA and protein levels in 
Winnie colons. Additionally, MCC950 also effectively suppressed the release of 
proinflammatory cytokines and chemokines in mucosal explants. Furthermore, MCC950 
treatment resulted in a significant decrease of IL-1β release and activation of caspase-1 in 
Winnie explants and in vitro macrophage cells isolated from Winnie mice. Collectively, 
our results illustrate the efficacy of MCC950 in the treatment of murine ulcerative colitis 
and has clinically relevant implications as a novel therapeutic agent for human 
inflammatory intestinal diseases.  
Moreover, I investigated the possibility of MCC950 and Glyburide target to be the NEK7-
NLRP3 interaction.  Shi et al has shown that NEK7 phosphorylation enhances its binding to 
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NLRP3 and promotes inflammasome activation (Shi et al., 2016). Our results showed no difference 
in the level of phosphorylated NEK7 between the untreated and MCC950 or glyburide treated 
samples. This result suggest that the inhibitory target is not NEK7-NLRP3 but is downstream of 
this interaction. This finding will significantly add to the current understanding of the 
inhibitory mechanism of MCC950.  
With the success in chemically inhibiting NLRP3 and ameliorating colitis I hypothesized 
that genetic ablation of Nlrp3 gene will cure the colonic inflammation in Winnie mice. 
Thus, to take the research a step further, a novel mouse model was generated by knocking 
out the Nlrp3 gene in the spontaneous colitis mouse model Winnie, within a defined 
microbiota. Extensive studies done in Winnie has proven it to be a suitable murine model 
to study colitis and its pathogenesis. The inflammatory pathology of Winnie mice has been 
analysed up to one year of age and a spontaneous development of CAC has not been 
observed. To my knowledge, this study is the first to examine the role of NLRP3 in 
inflammation, associated with a naturally occurring spontaneous colitis without the need 
for carcinogen treatment, similar to CAC pathogenesis in humans. 
The detailed phenotypical analysis of Winnie x Nlrp3-/- colon at 12 and 16 weeks showed 
spontaneous multiple colonic tumours. Winnie x Nlrp3-/- mice had significantly shorter 
colons, and a higher ratio of colon weight to length and poorer survival rate than the control 
groups indicating the severity of colitis and tumorigenesis. Histopathology of Winnie x 
Nlrp3-/- colon shows biological features like colitis associated colorectal dysplasia–
invasive carcinoma sequence observed in human CAC and in future will be a useful 
experimental model for anti CAC therapeutic agents. 
The study analysed the expression of bio-markers Bcl2, Sod2, Pparγ, Myc, Birc5 and Cdk2 
and their upregulation was positively related to colonic tumorigenesis. These findings could 
be potentially useful in identifying early prognostic bio-markers in CAC. 
Winnie x Nlrp3-/- mice colonic tissue and serum analysis showed an elevation of 
proinflammatory cytokines, MPO, iNOS, CRP, ROS and DNA damage biomarkers. These 
biomarkers are positively associated with decreased survival of CAC patients and explains 
the poor survival rate of Winnie x Nlrp3-/- mice. 
Immunofluorescence data generated in this study showed that in Winnie x Nlrp3-/-, 
molecules related to cell proliferation, angiogenesis, and anti-apoptotic activity were 
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upregulated at the gene and protein level while down regulated molecules were negatively 
associated with colitis associated colon cancer. The molecular mechanism of tumorigenesis 
was revealed by protein analysis of colonic tumours and Western blot results showed 
upregulation of PI3K/ AKT and Wnt/β-catenin pathways. Collectively, these results 
validate Winnie x Nlrp3-/- as a suitable CAC murine model. 
The thesis reports novel findings from the analysis of the microbiota and metabolites in 
Winnie x Nlrp3-/- mice colon to define the role of NLRP3 inflammasome in CAC 
penetrance. Faecal microbiota analysis revealed significant increase in colitogenic 
members in the phylogenetic architecture in Winnie x Nlrp3-/- mice while metabolomics 
profiling revealed upregulation of key metabolites and short chain fatty acids. These results 
confirmed the role of NLRP3 as a negative regulator of tumorigenesis during CAC.  
The primary result of this study has provided the first evaluation of a specific NLRP3 
inhibitor in colitis and will allow potentially new therapeutic approaches to emerge. 
Altogether, results of this thesis will significantly add to the current understanding of the 
importance of NLRP3 in pathogenesis and pathophysiology of colitis and CAC. 
The main limitation of these studies was that all experiments were performed in mouse 
models and cannot be directly translated to clinical utility. Fortunately, there is a striking 
concordance in the human and mouse inflammasome complexes. However, recent research 
showed that there are changes in types of receptors, caspases and regulatory mechanisms 
which clearly warrants further studies in patient samples. 
7.2 Future directions  
The above discussion highlights the crucial importance of using human macrophage and 
colonic tissue samples from individuals with active ulcerative colitis to validate the 
therapeutic effect of MCC950 observed in the experimental mouse model. A positive 
outcome will benefit to optimize the current therapeutic regime in IBD. 
The earliest time point the Winnie x Nlrp3-/- colon was examined was at week 12 and the 
results highlight key mechanisms in advanced stage of CAC rather than the early stages of 
inflammation driven tumorigenesis. Therefore, there is a need for in depth studies at an 
early age to delineate the critical underlying mucosal and immune cell mediated 
mechanisms involved in the tipping point from IBD to CAC. To this end, a future study 
can employ advanced cell culture techniques such as three-dimensional (3D) organoid 
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cultures derived from stem cell-containing colon or tumoroid. These organoid cultures are 
far superior to 2D cell culture and can be used to evaluate specific mechanisms ex vivo as 
well as inflammatory pathways on cell survival and proliferation. Additionally, patient-
derived organoid cultures will allow for characterization and therapeutic evaluation for 
personalized care.   
Another exciting innovation that can be incorporated to organoid culture is the genome 
editing novel technique CRISPR-Cas9. We propose to investigate the upregulated 
signalling pathways involved in the transformation of colitis to colorectal cancer using 
CRISPR-Cas9 genome editing in primary organoid cultures generated from CAC patient 
biopsies. 
7.3 Concluding remarks 
Colitis is a lifelong disease with no current cure. The investigations of this thesis show 
specific chemical inhibition of an over active NLRP3 inflammasome in chronic colitis 
attenuated severity of the disease. This indicates a harmful effect of an overactive NLRP3 
inflammasome in colitis and the potential therapeutic intervention of NLRP3 inhibitors. 
The success MCC950 attenuating symptoms of IBD is an exciting therapeutic development 
with significant clinical translational value and should be acknowledged as such. 
However, the genetic ablation of NLRP3 gene in a spontaneous chronic colitis model lead 
to a phenotype of colitis associated colorectal cancer. This highlights the critical function 
of NLRP3 inflammasome as a negative regulator of tumorigenesis in CAC. The novel 
model Winnie x Nlrp3-/- shows biological features like CAC dysplasia–invasive carcinoma 
sequence observed in human CAC and represent a promising mouse model for studying 
the molecular mechanism of CAC. Moreover, the Winnie x Nlrp3-/- model will also provide 
an experimental model to investigate the efficacy of therapeutic interventions by novel 
agents at different stages of colon cancer. The study introduces possible microbial and 
molecular interventions for CAC, giving this study a significant clinical relevance.  
All together the results have generated new data and knowledge that defines the NLRP3 
inflammasome as a double-edged sword in colitis and CAC. The results of this thesis 
highlight the complex roles of NLRP3 and stresses the importance of evaluating the dosage 
and long-term effect of novel NLRP3 inhibitors designed for chronic colitis in clinically 
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relevant experimental models before progressing to human clinical trials. In conclusion, as 
far as the gut is concerned NLRP3 activation should not be too hot or too cold but just rite!  
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